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Abstract
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy and the most common
subtype of non-Hodgkin’s lymphoma in adults, with one of the highest mortality rates in most developed areas of
the world. More than half of DLBLC patients can be cured with standard R-CHOP regimens, however approximately
30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and
mortality due to the limited therapeutic options.
Recent advances in gene expression profiling have led to the identification of at least three distinct molecular
subtypes of DLBCL: a germinal center B cell-like subtype, an activated B cell-like subtype, and a primary mediastinal
B-cell lymphoma subtype. Moreover, recent findings have not only increased our understanding of the molecular
basis of chemotherapy resistance but have also helped identify molecular subsets of DLBCL and rational targets
for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and
personalized combinations to both prevent and treat relapsed/refractory DLBCL. Novel agents such as lenalidomide,
ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as single-agent or in combination with
(rituximab-based) chemotherapy have already demonstrated promising activity in patients with relapsed/
refractory DLBCL. Several novel potential drug targets have been recently identified such as the BET
bromodomain protein (BRD)-4, phosphoribosyl-pyrophosphate synthetase (PRPS)-2, macrodomain-containing
mono-ADP-ribosyltransferase (ARTD)-9 (also known as PARP9), deltex-3-like E3 ubiquitin ligase (DTX3L) (also
known as BBAP), NF-kappaB inducing kinase (NIK) and transforming growth factor beta receptor (TGFβR).
This review highlights the new insights into the molecular basis of relapsed/refractory DLBCL and summarizes
the most promising drug targets and experimental treatments for relapsed/refractory DLBCL, including the use
of novel agents such as lenalidomide, ibrutinib, bortezomib, pidilizumab, epratuzumab, brentuximab-vedotin or
CAR T cells, dual inhibitors, as well as mechanism-based combinatorial experimental therapies. We also provide a
comprehensive and updated list of current drugs, drug targets and preclinical and clinical experimental studies in
DLBCL. A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 (also known as PARP14) as novel potential drug
targets in distinct molecular subsets of DLBCL.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is a clinically
and genetically heterogeneous lymphoid malignancy
with molecular subtypes and subsets defined by distinct
molecular signatures and clinical outcomes. Many sub-
types and subsets are at high-risk for treatment failure
with standard immuno-chemotherapy [1–4]. DLBCL is
by far the most common category and disease entity of
B-cell non-Hodgkin lymphoma (NHL) in adults, with
one of the highest mortality rates of B-cell NHL in most
developed areas of the world [1–3]. In Europe and USA,
the current annual incidence of NHL is estimated to be
15–20 cases/100,000 [5]. DLBCL accounts for approxi-
mately 30–40 % of all newly diagnosed B-cell NHL cases
in Western countries, and for an even higher percentage
in developing countries [6–9]. The median age of
DLBCL at diagnosis falls between the sixth and seventh
decade [1, 9]. DLBCL corresponds to a group of lymph-
oid malignancies composed of large cells with vesicular
nuclei, prominent nucleoli, basophilic cytoplasm and a
high proliferation rate [9]. DLBCL is usually aggressive,
characterized by the appearance of rapidly growing
tumors in lymph nodes, spleen, liver, bone marrow or
other organs [10]. Nearly 90 % of aggressive mature B-
cell NHL tumors in the Western world are identified as
DLBCL [6, 7]. More than half of DLBLC patients can be
cured with current multi-agent chemo-, radio- and/or
immunotherapeutic regimes, combined with or without
autologous stem cell transplantation, representing one of
the successes of modern cancer therapy. However, ap-
proximately 30 to 40 % of patients will develop relapsed
or refractory disease that remains a major cause of mor-
bidity and mortality in most developed areas of the
world [2, 3, 6, 7].
Gene expression and genome sequencing analyses have
not only increased our understanding of DLBCL subtypes
and the molecular basis of chemotherapy resistance but
also led to the identification of novel molecular DLBCL
subsets and rational targets for drug interventions that
may allow for subtype/subset-specific molecularly tar-
geted precision medicine and personalized combina-
tions to both prevent and treat relapsed/refractory
DLBCL. Recent studies identified several novel poten-
tial drug targets such as, the BET bromodomain pro-
tein 4, phosphoribosyl-pyrophosphate synthetase 2,
macrodomain-containing mono-ADP-ribosyltransferase 9,
deltex-3-like E3 ubiquitin ligase, NF-kappaB inducing
kinase, programmed cell death 1 and transforming growth
factor beta receptor.
In the present review we give a systematic overview of
the current drug targets and experimental treatments for
newly diagnosed and relapsed/refractory DLBCL. We
also provide comprehensive and updated lists of current
drug targets and preclinical and clinical experimental
studies in DLBCL, including mechanism based combina-
torial studies. The use of novel approaches for relapsed/
refractory DLBCL, such as antibody drug conjugates
and chimeric antigen receptor-modified autologous T
cells will also be discussed. A special focus is given
on STAT1, ARTD9, DTX3L and ARTD8 as novel poten-
tial drug targets in distinct molecular subsets of DLBCL,
respectively.
Oncogenic pathways in DLBCL
The majority of DLBCLs are thought to arise from
normal antigen-exposed B cells that are at separate
stages of differentiation and are undergoing clonal ex-
pansion in the germinal center (GCs) of peripheral
lymphoid organs [1–3]. DLBCLs are considered clonal
malignancies that evolve and progress through a range
of multistep transformation processes, i.e., chromo-
somal translocations through errors in the Ig gene re-
modeling processes during normal B cell differentiation
[11–13].
Progression of DLBCLs to a more aggressive state ei-
ther evolves slowly over time as a consequence of clonal
evolution (selective growth and survival benefits of
subclones) or alternatively, through the rapid outgrowth
after catastrophic intracellular events that result in sub-
clones characterized by extensive DNA rearrangements
that have occurred simultaneously and that confer a
significant survival advantage [3, 11, 12, 14]. Consistent
with their clinical and genetic (clonal) heterogeneity, several
diverse genetic abnormalities have been identified in
DLBCL including aberrant somatic hypermutations,
nonrandom chromosomal deletions, balanced reciprocal
translocations deregulating the expression of proto-
oncogene products such as BCL6, REL, BCL2 or c-MYC,
and often associated with dysregulated apoptosis or
defective DNA repair [2, 3, 12, 13, 15–17].
Several recent whole-genome/exome sequencing studies
identified over 300 DLBCL cancer genes that are recur-
rently mutated in primary DLBCLs [12, 13, 15–22]. These
recurrent mutations are located both in genes that are well
known to be functionally relevant in DLBCL and in genes
for which a functional role in DLBCL has not been previ-
ously suspected [12, 16, 17, 22]. It is thought that the
primary or early oncogenic events are chromosomal
translocations involving oncogenes such as BCL6,
BCL2, REL or c-MYC whereas the secondary or late
oncogenic events consist of clonally represented recur-
rent mutations/gene alterations including BCL2, PRDM1,
CARD11, MyD88, TNFAIP3, CREBBP, TP53, EZH2,
MLL2, MYOM2, PIM1, LYN, CD36, B2M, CD79B,
MEF2B, ANKLE2, KDM2B, HNF1B, NOTCH1/2, DTX1
and MYCCD58 [12, 13, 15–22]. Moreover, alterations in a
variety of DNA repair and DNA damage signaling genes,
such as ARTEMIS, DNA-PKS, KU80, KU70, CHECK2 or
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ARTD1/PARP1 that affect the MMR and/or NHEJ DNA
repair pathways have been recently identified in DLBCL
tumors and most likely also constitute intermediate cancer
driver events in lymphomagenesis [23, 24]. Overexpres-
sion of proto-oncogene products through mutation or
translocation of BCL6, BCL2, REL, or c-MYC, constitutive
activation of canonical and/or non-canonical nuclear fac-
tor kappa B (NF-κB) pathways through genetic lesions
and mutations in TNFAIP3, CARD11, CD79A/B, MyD88
or TRAF2 and TRAF3 genes, respectively [15–18, 25–27],
and/or epigenetic reprogramming, triggered by mutations
in genes such as TET1, MLL2, EZH2, MEF2B, EP300 and
CREBBP [15–17, 19, 20, 28–30], account for some of the
most frequent cancer driver events in DLBCL [2]. The
alterations in gene expression of proto-oncogene products
and/or tumor suppressors provide tumor cells with
gene expression plasticity, escape from apoptosis and
enhanced growth through constitutive survival and
proliferative signals. See next sections. For a detailed
description of oncogenic pathways in DLBCL, the readers
are referred to the recent excellent reviews [2, 3, 31–36].
Distinct disease entities and molecular subtypes of DLBCL
Based on the morphological, biological pathological,
and/or clinical grounds, DLBCL has been subdivided
into four distinct categories and disease entities within
the 4th. Edition of the World Health Organization
(WHO) Classification of Tumors of Hematopoietic and
Lymphoid Tissues (2008) [1, 9, 37, 38]: 1.) DLBCL with a
predominant extranodal location, including primary
mediastinal (thymic) large B-cell lymphoma (PMLBCL),
2.) Large cell lymphomas of terminally differentiated B-
cells, 3.) B-cell neoplasms with features intermediate
between DLBCL and other lymphoid tumors, including
B-cell neoplasm with features intermediate between
DLBCL and Burkitt lymphoma (DLBCL/BL) and 4.)
The biologically and clinically heterogeneous and there-
fore collectively termed DLBCL, not otherwise specified
(DLBCL-NOS) [37, 39–41].
Gene-expression profiling (GEP) and cell-of-origin
(COO) studies (cell-of-origin signatures) have con-
firmed the physiological heterogeneity of the disease
and defined at least three molecular subtypes of DLBCL:
Primary mediastinal (thymic) large B-cell lymphoma
(PMLBCL), belonging to the WHO category DLBCL
with a predominant extranodal location [37] and two
subtypes, belonging to the WHO category DLBCL-NOS
[9]. The DLBCL-NOS category has been subdivided
based on the origin and gene expression signature
(COO signature) into at least two/(three) molecular,
biologically and clinically distinct subtypes: the two
fully classified subtypes germinal center B-cell-like
(GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL,
the not yet fully classified T cell/histiocyte-rich large
B-cell lymphoma (T/HRLBCL) and cases, that remain
non-classified, termed type-3 or NC-DLBLCL [35, 39, 40,
42–44]. These DLBCL-NOS subtypes originate from B
cells at different stages of development and have distinct-
ive mechanisms of oncogenic activation and different clin-
ical outcomes (Fig. 1) [2, 3, 9, 35, 39, 40, 42, 43]. A
summary of clinical, pathological, and molecular charac-
teristics of the molecular subtypes of DLBCL is shown in
Table 1. GCB and ABC subgroups represent up to 45 %
and 35 %, respectively, of DLBCL-NOS cases [1, 35]. The
not yet fully classified T/HRLBCLs account for roughly
1–5 % of all DLBCL cases [1, 45–47] whereas the residual
15–20 % of DLBCL are unclassifiable DLBCLs, including
type-3-DLBCL [1, 35].
Primary mediastinal (thymic) large B-cell lymphoma
(PMLBCL)
PMLBCL constitutes roughly 2–4 % of B-cell NHL and
8 % of DLBCLs, respectively [1, 48]. It shares morpho-
logic features with DLBCL and some features of classical
Hodgkin’s lymphoma (cHL) [1, 9, 35, 48–50]. PMLBCL
is characterized by a diffuse proliferation of medium-to-
large B cells associated with sclerosis [51]. The presence
of somatic hypermutations suggests a germinal or post-
germinal center origin for PMLBCL [1, 48, 49, 52]. The
similar pattern of mutations of IGVH and BCL6 genes
found in thymic B cells and PMLBCLs further supports
the theory that PMLBCL originates from thymic B cells
[52]. Thus, PMLBCLs is a distinct entity and thought to
stem from thymic asteroid medulla B cells of the thymus
[51]. PMLBCL normally affects young women with the
mediastinum being the predominant site of lymphoma
manifestation [48]. PMLBCLs have a gene expression
signature that is distinct from other forms of DLBCL
but closely resemble that of cHL [53–55]. Over 30 % of
all PMLBCL signature genes were also more highly
expressed in cHL [53–55]. This is characterized by
constitutive activation of the NF-κB signaling pathway
[53–55], which in part, acts through c-REL containing
NF-κB transcriptional complexes [56]. The SOCS1 gene,
a suppressor of Janus kinase (JAK)-2 signaling is recur-
rently deleted in PMLBCL [57, 58].
The expression of interleukin (IL)-13-receptor and
downstream effectors JAK2 and signal transducer and
activator of transcription (STAT)-1 as well as their activ-
ities are both up-regulated in PMLBCL [53–55]. Prolifer-
ation and survival of PMLBCL cells relies on JAK/STAT
and NF-κB signaling [59, 60]. Like cHL, PMLBCLs show
low levels of expression of multiple components of the B
cell (antigen) receptor (BCR)-signaling cascade [53–55].
Moreover, constitutive STAT6 activation has been
identified as a characteristic feature of PMLBCL com-
pared with other DLBCL subgroups [3, 53–55, 61]. A
summary of the characteristic molecular features of
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PMLBCL is shown in Table 2. For a detailed description
of the biology and pathology of PMLBCL as well as diag-
nosis and treatment options, the readers are referred to
the recent excellent reviews [1, 48, 50, 51, 62–64].
Germinal center B cell-like (GCB)-DLBCL-NOS
GCB-DLBCLs are thought to arise from normal
germinal center B cells [65] and show features that are
consistent with germinal center B cell derivation [13,
66–70]. GCB-DLBCLs largely express gene products,
such as BCL6, HGAL and LMO2 [13, 65–69] that
define normal germinal center B cells within the
germinal center light zone [71]. Malignant GCB-
DLBCL clones continue to undergo somatic hyper-
mutation of their variable immunoglobulin heavy
chain gene and have often switched IgH classes that
are mediated by AID, an enzyme that is characteris-
tically expressed at high levels in germinal center B
cells [72–74]. The GCB-DLBCL subtype is character-
ized by low level of NF-κB activation and its survival
is not dependent on NF-κB [13, 18]. Various oncogenic
pathways are deregulated in GCB-DLBCL and contrib-
ute to its molecular pathogenesis. Oncogenic (deregu-
lated) intracellular signaling pathways in GCB-DLBCL
are summarized in Fig. 2.
Translocations of BCL2 and/or c-MYC genes are
commonly observed in GCB-DLBCLs [13, 66, 75].
These translocations lead to constitutive activation of
c-MYC and the anti-apoptotic BCL2 protein [76] and
to a malignant transformation by preventing terminal
differentiation or blocking apoptosis [2, 3]. 20 % have
gain of function mutations of the histone methyltrans-
ferase EZH2, which is a master regulator of the GCB
phenotype and cooperates, at least partly, with BCL2
and BCL6 to mediate lymphomagenesis in GCB-
DLBCL [20, 29, 77–79]. GCB-DLBCL is furthermore
characterized by downregulation of the phosphatase
and tensin homologue (PTEN) and concomitant upreg-
ulation of phosphatidylinositol-3-kinase (PI3K) signal-
ing pathway (Fig. 2) [13]. Upon loss of the PTEN gene
or repression of the PTEN promoter through the
mir-17-92 microRNA cluster, phosphatidylinositol-3
phosphate accumulates and AKT and mTORC1 are
activated, further promoting cell survival, proliferation,
and growth [13, 80–83]. GCB-DLBCL is also associated
with loss of sphingosine-1-phosphate receptor-2 (S1PR2) -
G-protein alpha 13 (Gα13) signaling, which negatively
modulates GC B-cell migration and PI3K signaling
[15–17, 84].
The GCB-DLBCL subtype also frequently carries
additional mutations affecting epigenetic modification
such as mutations in genes encoding the histone
acetyltransferases CREB-binding protein (CREBBP) and
E1A-binding protein p300 (EP300) as well as the histone-
lysine N-methyltransferase and myeloid/lymphoid or
mixed-lineage leukemia protein 2 (MLL2) [15, 19, 20, 29].
Other characteristic features of GCB-DLBCLs are
the amplification of MDM2, a negative regulator of
Fig. 1 Origins of germinal center (GC)-derived and non-GC derived molecular subtypes of DLBCL. Germinal center (GC)-derived molecular subtypes
of B-cell lymphoma originate from GC B cells that are blocked at different stages of development and have distinctive mechanisms of oncogenic
activation and different clinical outcomes. T cell/histiocyte-rich large B-cell lymphoma. (T/HRLBCL) is thought to originate from a progenitor cell of
germinal center origin. T/HRLBCLs are characterized by scattered large B cells immersed in a T-cell rich background with frequent presence of
histiocytes. GC B cell (GCB)-like diffuse large B-cell lymphoma (DLBCL) originate from light zone B cells. Activated B cell-like (ABC) DLBCL shows
characteristics of the late post–germinal center plasmablasts, a normally transient state that is committed to terminal plasmacytic differentiation.
Primary mediastinal (thymic) large B-cell lymphomas (PMLBCL) shows characteristics of late post-germinal center thymic B cells and are thought to
originate from thymic asteroid medulla B cells. Adapted from REF [3, 70, 86]. Information for this figure was gleaned from the following references:
references: T/HRLBCL [37, 38, 42, 43, 45–47, 111, 112, 116], GCB-DLBCL [2, 3, 13, 35, 39, 40, 42, 43, 65–74, 86], ABC-DLBCL [2, 3, 13, 35, 39, 40, 42, 43, 65,
66, 70, 86, 87, 96] and PMLBCL [1, 3, 9, 35, 48, 49, 51, 52, 62, 63, 70, 86]. Abbreviations: FDC follicular dendritic cell, Ag antigen
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the tumor suppressor TP53, as well as deletions of the
tumor suppressor gene TP73 [13]. A summary of the
characteristic molecular features of GCB-DLBCL is
shown in Table 3. The GCB subtype has a cure rate of
about 70 to 80 % with currently available therapies
[13, 85]. For a more detailed description of the biology
and pathology of GCB-DLBCL, the readers are referred
to the recent excellent reviews [2, 35, 39, 70, 86].
Activated B cell-like (ABC)-DLBCL-NOS
The second subtype, ABC-DLBCL has experienced the
germinal center and is thought to arise from post-
germinal center B cells that are arrested during plas-
macytic differentiation [13, 65, 70, 87]. ABC-DLBCLs
have a COO signature that is reminiscent of the
plasmablast stage of B cell development [65]. ABC-
DLBCLs largely express genes normally induced during
in vitro activation of peripheral blood B cells, including
genes that define the end stage memory B cells or
plasma cells, such as the transcription factors IRF4 and
XBP1 [13, 65, 66, 87]. IRF4 is transiently expressed during
normal lymphocyte activation and is essential for the pro-
liferation of B cells in response to signals from the acti-
vated B cell (antigen) receptor [88, 89]. Thus, constitutive
expression of interferon response factor (IRF)-4 in ABC-
DLBCLs contributes to unchecked proliferation of DLBCL
tumors [90, 91]. X-box binding protein 1 (XBP1) is the
master regulator of immunoglobulin secretion [35, 92].
On the other hand, ABC-DLBCLs acquire genetic alter-
ations that repress BLIMP1 expression and function,
Table 1 Summary of clinical, pathological, and molecular characteristics of the molecular subtypes of DLBCL
Molecular
subtype





Etiology Frequencya Clinical features








Unknown ~1–4 % Median age: 30–50
Gender dominance: male
Extranodal (vague nodularity is rare)
BOB1, PU.1+/—, CT2, PAX5, (BCL2),
BCL6, IRF4—
Diffuse pattern with predominance of
reactive T cells
Bone marrow involvement: ~ 30 %
Survival ~ 50 % at 5 years
Curable ~ 45 %
GCB- CD20, CD10, CD22, (CD30), (BCL2),
(MYC), BCL6, GCET, HGAL, LMO2,






Unknown ~17 % Median age 61
DLBCL Gender dominance: male≥ female
Nodal and extranodal
Bone marrow involvement: ~ 15 %
Survival ~ 60 % at 5 years
Curable ~ 50 %
ABC- CD20, CD22, (CD30), (CD79A/B),







Unknown ~15 % Median age: 66
DLBCL Gender dominance: male≥ female
Nodal and extranodal
Bone marrow involvement: ~ 15 %
Survival ~ 40 % at 5 years
Curable ~30 %
PMLBCL CD19, CD20, CD22, CD30, CD45, CD79A,
CD3—, CD10—, CD21— BOB1, PU.1,






Unknown ~6 % Median age: 33
Gender dominance: female Mediastinal,
thoracic > nodal Bone marrow
involvement: rare Survival: > 60 %
at 5 years
Curable: > 60 %
The PMLBCL, GCB and ABC subtypes are histologically indistinguishable and require gene expression profiling (GEP) to be discerned. T/HRLBCL also shows
overlapping histological features of other distinct entities and may appear similar to other lymphoid diseases, such as nodular lymphocyte-predominant
Hodgkin lymphoma, classical Hodgkin lymphoma, and peripheral T-cell lymphoma. Diagnosis of this entity is occasionally difficult and requires careful
immunohistochemical analysis of the tumor cells. GEP can greatly help to classify T/HRLBCL.
aApproximate percentage of the particular DLBCL subtype among all patients with B-cell lymphoma. Adapted from REF: [3, 70, 86]. Information for this table was
gleaned from the following references: [1–3, 15, 19, 20, 29, 35, 37–40, 45–48, 50, 51, 56, 62, 63, 65–70, 75, 86, 87, 107, 108, 111, 112, 116].
DLBCL diffuse large B cell lymphoma, T/HRLBCL T cell/histiocyte-rich large B-cell lymphoma, GCB Germinal center B cell-like, ABC Activated B cell-like, PMLBCL
primary mediastinal (thymic) large B-cell lymphomas
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thereby blocking the differentiation into end stage plasma
cells [92–94]. ABC-DLBCL is characterized by genetic ab-
normalities that play an important role in its pathogenesis.
For instance, the p16INK4A/p14ARF tumor suppressor
locus is deleted in approximately 30 % of ABC-DLBCLs
and is associated with inferior outcome within this sub-
type [13, 95]. A summary of characteristic molecular fea-
tures of ABC-DLBCL is shown in Table 4.
ABC-DLBCLs express genes that are upregulated in
B cells with activated BCR signaling [13, 96] see also
next sections. BCR-mediated NF-κB-dependent survival
signaling plays important roles in certain B-cell malig-
nancies [97–99]. Similar to PMLBCL, a key feature of
the more aggressive ABC-DLBCL subtype is the con-
stitutive activation of NF-κB-dependent gene expres-
sion and its dependency on the activity of NF-κB
family members for proliferation and survival [18, 54,
66, 76, 100]. NF-κB is a family of inducible transcrip-
tion factors consisting of five members, REL-A (p65),
REL-B, c-REL, NF-κB1 (p50 and its precursor p105),
and NF-κB2 (p52 and its precursor p100) [101]. Inhib-
ition of this pathway using either a dominant active
form of NF-κB inhibitory protein inhibitor of kappa B
(IκB)-α or a specific IκB kinase inhibitor is toxic to
ABC- but not to GCB-DLBCL cell lines [59, 100]. The
NF-κB family members REL-A, REL-B and c-REL have
the capacity to regulate transcription of various subsets
of genes involved in cell proliferation and resistance to
apoptosis [102]. ABC-DLBCLs shows a more restricted,
potentially developmentally regulated NF-κB target gene
signature [54, 76, 100]. Activation of NF-κB has been
identified as a key driver in apoptosis resistance in ABC-
DLBCL and PMLBCL leading to poor outcomes in pa-
tients with ABC-DLBCL [18, 54, 100]. In 39 % of ABC-
DLBCL cases, constitutive activation of NF-κB-dependent
gene expression is activated by somatic, gain-of-function
mutations in the myeloid differentiation primary response
gene (88) (MyD88) [103]. The most common MyD88 mu-
tant, L265P, spontaneously coordinates a signaling com-
plex in which interleukin-1 receptor-associated kinase
(IRAK)-4 phosphorylates IRAK1, leading to inhibitor
of kappa B (IκB) kinase (IKK) and NF-κB activation
[103]. In addition, 10 % of ABC-DLBCL patients har-
bor activating mutations in the gene encoding caspase
recruitment domain-containing protein 11 (CARD11)
leading to constitutively active NF-κB family members
[104]. CARD11 is a key signaling adaptor that coordi-
nates a BCR and CD40-mediated signaling complex that
activates NF-κB pathways [105, 106]. ABC-DLBCLs
with wild-type CARD11 depend on constitutively active
BCR signaling [104]. Both wild-type and mutant
CARD11 are essential for chronic active BCR signaling and
survival in ABC-DLBCL [103]. Approximately, 20 % of
ABC-DLBCLs have mutations in the BCR signaling mole-
cules CD79B and CD79A [66, 96, 104], which lead to con-
stitutively active BCR signaling [66, 96]. Oncogenic
(deregulated) intracellular signaling pathways in ABC-
DLBCL are summarized in Fig. 3. Translocations of both
BCL2 and c-MYC genes also occur in ABC-DLBCLs and
contribute to the inferior survival of the ABC subtype of
DLBCL [107]. Both GCB-DLBCL and ABC-DLBCL share
genetic lesions that lead to inactivation of chromatin modi-
fiers, owing to mutations in CREBBP, EP300 and MLL2
[15, 19, 20, 29], as well as to immune escape, owing to
inactivation of β2 microglobulin (B2M), CD58 and genes
encoding human leukocyte antigens (HLA-A, HLA-B and
HLA-C) [15, 19, 20, 29, 108]. The ABC subtype has a cure
rate of about 40 to 50 % with currently available therapies
Table 2 Summary of the major characteristic molecular features of PMLBCL
Genetic Aberration: Gain of function Genetic Aberration: Loss of function Pathways: Upregulated/Gain Pathways: Inhibited/
Loss
Study
JAK2 (9p24.1 Ampl) SOCS1 (Mut) JAK/STAT (STAT1, STAT3, STAT6)
c-MYC PD-1/PD-L1/2
[57, 60, 603–605]
STAT6 (Mut) PTPN1 (Mut) STAT6 PTPN1 [558, 606]
JMJD2C (9p24.1 Ampl) c-MYC [603]
CD274 (PD-L1) (Tx/ 9p24.1Ampl)
PDCD1LG2 (PD-L2) (Tx/Ampl)
PD-1 [607, 608]
TNFAIP3 (A20) (Mut) NF-κB (c-REL), TRAF1 A20 [56, 609]
CIITA (Tx) PD-1 HLA II complex [64, 610]
TP53 (Mut) TP53 [611]
Overlapping molecular features of PMLBCL and ABC-DLBCL are marked as italic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are
marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype.
DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del
deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, PRDM1/BLIMP1 B lymphocyte-induced maturation protein 1, PD-L1/L2
programmed cell death ligand 1/2, JMJD2C jumonji domain containing 2c, PTPN1 phosphotyrosine phosphatase N1, SOCS1 suppressor of cytokine signaling 1,
TNFAIP3 tumor necrosis factor, alpha-induced protein, 3, NF-κB nuclear factor-kappa B, TRAF TNF receptor-associated factor, STAT signal transducer and activator of
transcription, HLA human leukocyte antigens
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[13, 85]. For a detailed description of the biology and
pathology of ABC-DLBCL, the readers are referred to the
recent excellent reviews [2, 3, 35, 39, 70, 86, 102, 109, 110].
T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)
T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)
is an aggressive DLBCL with a poor clinical outcome,
similar to ABC-DLBCL [45, 47]. T/HRLBCL accounts for
approximately 5 % of DLBCL [111, 112]. Many T/HRLBCL
tumors, especially cases containing numerous histiocytes
behave aggressively and show resistance to current therap-
ies for DLBCL [45]. T/HRLBCL occurs in younger patients,
predominantly affects men, and involves liver, spleen, and
bone marrow with greater frequency than classical
DLBCL [45, 111]. T/HRLBCL is thought to stem from
a progenitor cell of germinal center origin [111].
T/HRLBCL is an uncommon morphologic subtype
characterized by a minor population of scattered large
neoplastic B cells existing in a background of predomin-
ant reactive T-lymphocytes with frequent presence of
histiocytes [37, 45, 111]. No recurrent genetic rear-
rangements and/or mutations directly affecting the biol-
ogy and pathology of T/HRLBCL have been identified
yet [111–115]. According to the WHO classification
2008, T/HRLBCL is considered a separate clinically het-
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Fig. 2 Oncogenic (deregulated) intracellular signaling pathways in germinal center B cell-like (GCB) diffuse large B-cell lymphoma
(DLBCL). Germinal center B cell-like diffuse large B-cell lymphoma (GCB-DLBCL) are characterized by the inactivation or loss of the
phosphatase and tensin homologue (PTEN) and S1PR2-Gα13-ARHGEF1 signaling pathways, which both negatively modulate GC B cell migration
and phosphatidylinositol-3-kinase (PI3K) signaling [13, 82–84, 324, 593]. In addition, activating mutations of the histone methyltransferase EZH2
(enhancer of zeste homologue 2) and master regulator of the GCB phenotype promote epigenetic changes that, at least partly, cooperate with the
B-cell lymphoma 2 (BCL2) and BCL6 to mediate lymphomagenesis in GCB-DLBCL [77, 79]. A subset of GCB-DLBCL is characterized by translocations
affecting the c-MYC and/or the BCL2 loci [80, 81, 87]. These translocations lead to constitutive activation of c-MYC and the anti-apoptotic BCL2 protein
and to a malignant transformation by preventing terminal differentiation or blocking apoptosis. The different colors that are used in the figure indicate
molecules that belong to a specific pathway and/or lead to a specific outcome. Adapted from REF: [3, 70, 86, 109]. Information for this figure was
gleaned from the following references: [2, 3, 13, 15–18, 20, 29, 39, 66, 75–84, 86, 87, 93, 109, 123, 148, 247–251, 259, 324, 325, 352, 354–356, 360–365,
367, 374, 375, 377, 380–382, 384–386, 593, 612]. Abbreviations: S1PR2 sphingosine-1-phosphate receptor-2, Gα13 (GNA13) heterotrimeric G protein
alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR)
complex 1, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2, EZH2 enhancer of zeste homologue 2
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However, several recent morphological and GEP studies
[42, 43, 46, 116] indicate that T/HRLBCL and the
T/HRLBCL-like variant nodular lymphocyte predomin-
ant Hodgkin lymphoma (NLPHL), initially defined as
distinct entities, may represent a spectrum of the same
disease [42, 43]. T/HRLBCL and NLPHL were found to
share rare imbalances on chromosomes 4q and 19p sug-
gesting a similar precursor for both disorders [113, 114].
The different clinical behavior of these lymphomas may
be strongly influenced by differences in the lymphoma
microenvironment [42].
The T/HRLBCL associated diffuse T cell- and histiocyte-
rich infiltrates are important for a tolerogenic host immune
response and for escaping the T cell-mediated immune
surveillance [45, 46]. Genes found to be upregulated in T/
HRLBCL overlapped significantly with genes found to be
related to an unfavorable immune response in a subset of
follicular lymphomas and DLBCL [85, 117], particularly
with genes found to be related to host inflammatory re-
sponse in the host response subtype DLBCL, HR-DLBCL
(see next sections) [116]. T/HRLBCL and subsets of
NLPHL have therefore been suggested to represent to-
gether a distinct clinical and molecular subtype of DLBCL-
NOS [42, 43]. The gene expression signature of T/HRLBCL
is dominated by interferon gamma (IFNγ) and STAT1-
dependent pathways and suggests a macrophage/histio-
cyte-activated status that is required for the tolerogenic
host immune response [45, 46, 116, 118]. For a detailed
description of the biology and pathology of T/HRLBCL,
as well as diagnosis and treatment options, the readers are
referred to the recent excellent reviews [45, 47, 111].
In the following sections we will mainly focus on the
two molecular subtypes of DLBCL-NOS; GCB- and
ABC-DLBCL.
Table 3 Summary of the major characteristic molecular features of GCB-DLBCL-NOS





BCL2 (Tx/Ampl/Methyl) BCL2 Pro-apoptotic signaling [75, 362, 365]
EZH2 (Mut) EZH, BCL2, BCL6 BLIMP1, CREBBP; EP300 [16, 17, 77–79]
BCL6 (Tx/Ampl/Methyl) BCL6 BLIMP1, CREBBP; EP300 [87, 93, 148, 386, 612]
MEF2B/(MEF2C) (Mut) BCL6 BLIMP1, CREBBP; EP300 [16, 17, 28]
MDM2 (Ampl) TP53 (Del/Mut), TP73 (Del) TP53 and TP73
Pro-apoptotic signaling
[16, 17, 155, 613, 614]
c-MYC (Tx/Ampl/Methyl) c-MYC, miR-17-92, BCR,
PI3K/AKT/mTORC1
ISGs/IFITs, PTEN [80, 81, 87]
miR-17-92 BCR, PI3K/AKT/mTORC1 ISGs/IFITs, PTEN [13, 80, 81]
P2RY8 (Mut) PI3K/AKT/mTORC1 (Mut) [15–17, 84]
S1PR2 (Mut) PI3K/AKT/mTORC1 (Mut) [15–17, 84]
GNA13 (Mut) PI3K/AKT/mTORC1 Gα13 [15–17, 84]
ARHGEF1 (Del/Mut) PI3K/AKT/mTORC1 ARHGEF1 [15–17, 84]
PTEN (Del/Methyl/miR) PI3K/AKT/mTORC1 PTEN [13, 82, 83, 593]
B2M (Del/Mut) B2M, HLA-I complex [16, 17, 615, 616]
CD58 (Del/Mut) CD58, HLA-I complex [16, 17, 615, 616]
MLL2, MLL3 (Mut) BCL6 MLL2/3, CREBBP; EP300 [12, 16, 17, 20]
CREBBP; EP300 (Del/Mut) BCL6, HSP90, CREBBP; EP300, BLIMP1, TP53 [16, 17, 19, 386, 388]
TNFRSF14 (Mut) HVEM/FAS [16, 17, 617]
FAS (Mut) FAS/ Pro-apoptotic signaling [16, 618]
TRAF3 (Del/Mut) Non-canonical NF-κB
signaling (p52/RELB),
?? [26, 27]
?? ?? STAT1 [470]
Overlapping molecular features of GCB- and ABC-DLBCL are marked as bold italic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are
marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype.
DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas,
Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6,
CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, NF-κB nuclear factor- kappa B, PRDM1/BLIMP1 B-
lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/lymphoid or
mixed-lineage leukemia, TNFRSF14 tumor necrosis factor receptor superfamily, member 14, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT signal
transducer and activator of transcription, P2RY8 purinergic receptor P2Y, G-protein coupled 8, S1PR2 sphingosine-1-phosphate receptor 2, MEF2B myocyte
enhancer factor 2B, PTEN phosphatase and tensin homolog, FAS TNF receptor superfamily, member 6, HLA human leukocyte antigens, ISGs/IFITs interferon
stimulated genes/interferon inducible transcription factors
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Molecular signatures associated with poor prognosis
More recent GEP studies using multiple clustering methods
revealed the existence of at least seven distinct DLBCL-
NOS subsets with poor prognosis. The first study identified
three discrete DLBCL-NOS subsets defined by their unique
transcriptional profiles (consensus cluster (CC) signature):
Oxidative phosphorylation (OxPhos)-DLBCL, B-cell recep-
tor (BCR)/proliferation (BCR)-DLBCL, and host-response
(HR)-DLBCL [116]. Several other recent studies provided
evidence for at least four additional molecular subsets asso-
ciated with poor prognosis: c-MYC-driven (MD)-DLBCL
[119], stromal-II signature-subtype DLBCL [85], CDKN2A/
2B (9p21)-deletion signature subtype DLBCL [120] and
RCOR1-(TRAF3)-deletion signature subtype DLBCL [121].
An overview of molecular signatures in DLBCL-NOS
associated with poor prognosis is presented in Table 5.
OxPhos-signature-subtype DLBCLs
The first signature identified by Monti S. et al., termed
oxidative phosphorylation (OxPhos) signature, is charac-
terized by overexpression of genes that regulate oxida-
tive phosphorylation, mitochondrial function and the
electron transport chain, such as the nicotinamide aden-
ine dinucleotide dehydrogenase (NADH) complex and






















CARD11 (Mut) NF-κB, IRF4 IRF7/IFNβ
(Type 1 interferon)
[16–18]
TRAF3 (Del/Mut) Canonical NF-κB (p65/p50)
and non-canonical
NF-κB (p52/RELB) signaling, IRF4
IRF7/IFNβ
(Type 1 interferon)
[16–18, 26, 27, 160]
TRAF2 (Del/Mut)
SPIB (Tx/Mut) CARD11/NF-κB, IRF4 IRF7/IFNβ
(Type 1 interferon)
[13, 16, 17, 87, 90]
REL (Ampl) _ _ [619]
BCL2 (Tx/Ampl/Methyl) BCL2 Pro-apoptotic signaling [362]
MYC (Tx/Ampl/Methyl) c-MYC [87, 107]
BCL6 (Tx/Ampl/Methyl) BCL6 BLIMP1, CREBBP; EP300 [87, 93, 148, 386, 612, 620]
MEF2B (Mut) BCL6 BLIMP1, CREBBP; EP300 [13, 16, 17, 28]
STAT3 (Mut) IL6/10, JAK/STAT3 [307, 316]
?? ?? STAT1 [470]
FOXP1 (Ampl) Wnt/β-catenin TP53/Pro-apoptotic signaling [13, 621, 622]
TP53 (Del/Mut) TP53 and TP73
Pro-apoptotic signaling
[16, 17, 155, 614
TP73 (Del)
B2M (Del/Mut) B2M, HLA-I complex [16, 17, 615, 616]
CD58 (Del/Mut) CD58, HLA-I complex [16, 17, 615, 616]
MLL2, MLL3 (Mut) MLL2, CREBBP; EP300 [12, 16, 17, 20]
CREBBP; EP300 (Del/Mut) BCL6, STAT3, HSP90 CREBBP; EP300, BLIMP1, TP53 [17–19, 386, 388, 392]
CDKN2A/B (Del/Methyl) P16INK4a/pRB p14ARF/TP53 [13, 120]
TNFAIP3 (Del/Mut) NF-κB, IRF4 A20 [13, 16–18]
PRDM1 (Del/Mut) BLIMP1 [13, 16, 17]
Overlapping molecular features of ABC-DLBCL and PMLBCL are marked as italic and those of GCB- and ABC-DLBCL are marked as bolditalic. Overlapping molecular
features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless
of subtype.
DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas,
Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6,
NF-κB nuclear factor-kappa B, TLR Toll like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11,
IRF4 interferon-regulatory factor 4, CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, PRDM1/ BLIMP1
B-lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/
lymphoid or mixed-lineage leukemia, CDKN1A cyclin-dependent kinase inhibitor 1A, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT
signal transducer and activator of transcription, FOXP1 forkhead box P1, IRF7 interferon-regulatory factor 7, IFNβ interferon beta, MEF2B myocyte enhancer
factor 2B, FAS TNF receptor superfamily, member 6, HLA Histocompatibility antigen, domains alpha
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cytochrome c/cytochrome c oxidase (COX) complex as
well as adenosine triphosphate (ATP) synthase compo-
nents [40, 116, 122]. OxPhos-DLBCL tumors have also
higher levels of the antiapoptotic BCL2 related family
member, BFL-1/A1 and exhibit genetic lesions affecting the
intrinsic and extrinsic apoptotic pathways [40, 116, 122].
The OxPhos-DLBCL subset does not display any chronic
or active/functional BCR signaling [97] and is insensitive to
inhibition of BCR survival signaling [122, 123]. OxPhos-
DLBCL display enhanced mitochondrial energy transduc-
tion, greater incorporation of nutrient-derived carbons into
the tricarboxylic acid cycle, and increased glutathione levels
[122]. Although the exact nature of survival pathways in
this group of tumors is not known, - based on findings in
other cancer models- it has been suggested that the in-
creased fatty acid metabolism observed in OxPhos-DLBCL
may serve as an alternative survival pathway that is
triggered by glucose deprivation or lack of glucose uptake
[122]. Indeed, disturbing the fatty acid oxidation program
and glutathione synthesis is selectively toxic to the
OxPhos-DLBCL tumor subset [122]. 46 % of OxPhos-
DLBCL tumors analyzed in theses studies were classi-
fied as GCB-, 18 % as ABC- and the remainder 36 %
were designated type-3-DLBCL-NOS [116].
BCR/proliferation-signature-subtype DLBCLs
The second subtype signature identified by Monti S.
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Fig. 3 Oncogenic (deregulated) intracellular signaling pathways in activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). The oncogenic
constitutive activation of canonical nuclear factor-kappa B (NF-κB) family members in activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL),
together with a blockade in terminal B cell differentiation, which is in part mediated by BCL6, represent the hallmarks of ABC-DLBCL pathogenesis
[13, 16–18, 102]. The different colors that are used in the figure indicate molecules that belong to a specific pathway and/or lead to a specific outcome.
Adapted from REF: [3, 70, 86, 109]. Information for this figure was gleaned from the following references: [2, 3, 12, 13, 15–20, 27, 29, 54, 60, 70, 75–81,
86, 87, 90, 91, 93, 96–100, 103, 104, 107, 109, 123, 133, 148, 160, 161, 171, 232, 233, 247–251, 254–257, 259, 271, 285, 286, 307–311, 313–317, 360–365,
367, 374, 375, 377, 380–382, 384–386, 572, 612, 620]. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine kinase, SYK spleen tyrosine kinase, PI3K
phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, CD40L CD40 ligand, JAK Janus kinase, IRF4 interferon-
regulatory factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1, BCL10 B cell lymphoma protein 10, TLR Toll-like re-
ceptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein kinase Cβ, STAT3
signal transducer and activator of transcription 3, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2
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levels of many components of the BCR signaling cascade
(CD19, Ig, CD79A, BLK, SYK, PLCγ2, and MAPK4) and
enhanced BCR signaling activity [97, 98, 116]. BCR/prolif-
eration-DLBCL tumors also show increased expression
levels of cell-cycle regulatory factors, (including CDK2 and
MCM family members), DNA damage response signaling
factors (such as PMS2 family members, H2AX, PTIP, and
TP53) as well as higher levels of various essential B cell-
specific transcription factors (such as BCL6, MYC, STAT6,
PAX5, OBF1 and E2A). 53.2 % of BCR-DLBCL tumors
analyzed in theses studies were classified as ABC-, 23.4 %
as GCB- and 23.4 % as type-3-DLBCL-NOS [116].
In normal untransformed B cells, BCR signaling is
activated in an active antigen-dependent manner that initi-
ates the germinal center response [96, 124–128]. Antigen-
induced aggregation of the BCR activates BCR signaling
through receptor oligomerization and phosphorylation
of immunoreceptor tyrosine-based activation motifs
(ITAMS) by SRC family kinases, including FYN and B
lymphocyte kinase (BLK) [129, 130]. Following ITAM
phosphorylation, the spleen tyrosine kinase (SYK) is
then recruited to the dually phosphorylated ITAMs
through its tandem SRC homology 2 (SH2) domains,
resulting in SYK phosphorylation and recruitment of
additional adaptor proteins and initiating downstream
signaling through phosphatidylinositol-3-kinase (PI3K)
[124], Brutons’s tyrosine kinase (BTK) and finally the
activation of protein kinase C (PKC)-β, which in turn
phosphorylates many substrates including CARD11
[105, 106]. Active antigen-dependent BCR signaling en-
gages multiple downstream pathways, [105, 106, 129, 130].
Normal untransformed B cells also exhibit tonic,
ligand (antigen)-independent, ITAM-transmitted BCR
signaling, that promotes subsequent development and
survival of mature B cells in the periphery [96, 124–128].
Tonic active BCR signaling engages the phosphoinositide
Table 5 Overview of molecular signatures in DLBCL-NOS associated with poor prognosis
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NF-κB, NIK [27, 121, 160]
DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, n.c.i. not completely investigated, TCA tricarboxylic acid, PPARγ
peroxisome proliferators activated receptor-gamma, BCR B cell receptor, NF-κB nuclear factor-kappa B, STAT signal transducer and activator of transcription, BCL2
B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, PI3K phosphoinositide 3-kinase, BTK Bruton’s tyrosine kinase, NIK NF-κB inducing kinase, RB1 Retina
blastoma protein 1, mTORC1/2, mammalian target of rapamycin (mTOR) complex 1 and 2, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, ARTD9 ADP- ribosyltransferase-9
diphteria toxin like, PRPS2 phosphoribosyl-pyrophosphate synthetase 2, BRD2 and 4 bromodomain and extra terminal (BET) protein-2 and 4, CXCL12 CXC chemokine
ligand 12 (also called stromal-cell-derived factor 1, or SDF-1), CXCR4 CXCL12 receptor, VEGFR2 vascular endothelial growth factor receptor 2; RCOR1 REST corepressor 1,
HDAC histone deacetylase
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3-kinase (PI3K) pathway only and is also relevant to B-cell
malignancies [96, 124–128, 131]. A role for tonic BCR sig-
naling has been postulated for GCB-DLBCL based on the
sensitivity of certain cell lines of this lymphoma subtype
to R406, a broad range small molecule inhibitor of SYK
[97]. However, genetic knockdown of proximal BCR sub-
units (IgM, Ig-kappa, CD79A and CD79B) killed only
ABC-DLBCL with wild-type CARD11 but did not kill
other lymphomas including various GCB-DLBCL cell
lines [96]. Moreover, GCB-DLBCL tumors do not acquire
highly recurrent mutations in the BCR signaling or canon-
ical NF-κB pathways [96]. Thus it remains to be elucidated
whether SYK is indeed essential in GCB-DLBCL or other
receptors might be required for activation of the observed
BCR-like signaling in GCB-DLBCL [31].
A third type of BCR signaling, termed chronic active
BCR signaling, have been characterized in B-cell malig-
nancies, which can involve mutations of BCR pathway
components or be triggered by (auto-) antigens present
in the tissue microenvironment [96, 124–128, 131].
Similar to the antigen-activated active BCR signaling in
normal B cells chronic active BCR signaling, which
typifies ABC-DLBCL, engages multiple downstream path-
ways, including PI3K/AKT/mTORC1 and canonical NF-
κB signaling pathways [31, 96, 105, 106, 110, 124–131].
Chronic active BCR signaling is distinct from tonic BCR
signaling, which stimulates the PI3K pathway but not the
NF-κB signaling pathways [31]. Up to 20 % of ABC-
DLBCLs have somatic gain of function mutations in the
immunoreceptor tyrosine-based activation motifs (ITAM)
of the BCR subunits CD79B and CD79A, which lead to
chronic BCR signaling [66, 96, 104]. However, CD79A/B
mutants do not initiate BCR signaling de novo when in-
troduced into heterologous cells, but rather increase the
amplitude of ongoing BCR signaling through increased
BCR surface expression and attenuation of LYN kinase ac-
tivity, a negative regulator of BCR signaling [66, 96]. LYN
functions as a feedback inhibitor of BCR-stimulated sig-
naling [132]. LYN is frequently mutated and inactivated in
ABC-DLBCL [21]. This new pathogenetic mechanism in
ABC-DLBCL was therefore termed chronic active BCR
signaling [96]. Certain BCR-dependent ABC-DLBCLs
also exhibit constitutive PI3K activation, which modu-
lates downstream NF-κB signaling [98, 133].
HR-signature-subtype DLBCLs
Several studies have shown that differences in the tumor
microenvironment of DLBCL affect survival after
treatment with rituximab-based chemotherapeutic
regimens [85, 116, 134, 135]. HR-DLBCL was identi-
fied by a microenvironment gene expression signature
and is associated with increased expression of inflam-
matory mediators, such as multiple components of the
T-cell receptor (TCR), molecules associated with T/NK-
cell activation and the complement cascade, downstream
targets of IFNγ and/or IFNγ/STAT1 signaling and upregu-
lation of NF-κB pathways [116, 134]. The robust NF-κB
target gene signature of HR-DLBCL partially overlaps with
that of PMLBCLs, implicating the NF-κB survival pathway
in this subtype [40, 54, 116]. HR-DLBCL lack most of the
common cytogenetic abnormalities seen in OxPhos-
DLBCL or BCR-DLBCL and occur in younger patients
who often have splenomegaly and bone marrow involve-
ment [116]. The molecular profiles and clinicopathologic
features of HR-DLBCL tumors resemble those of T/
HRLBCL [46, 116]. In contrast to OxPhos-DLBCL and
BCR-DLBCLs, HR-DLBCL tumors are associated with a
brisk, but ineffective host immune/inflammatory response
and with a prominent T-cell/dendritic cell infiltrate as pre-
viously described for T/HRLBCL [46, 47, 116, 134]. 30.6 %
of HR-DLBCL tumors analyzed in theses studies were
classified as GCB- and 16.8 % as ABC-DLBCL. However
the large majority (53 %) was sub-classified as type-3-
DLBCL-NOS [116]. Remarkably, the clinical outcome of
HR-DLBCLs upon R-CHOP treatment is not improved
despite their increased host immune/inflammatory re-
sponse [116, 134]. Thus, it has been suggested that simi-
lar to T/HRLBCL, either their immune responses are
inhibited by counter-regulatory mechanisms or HR-
DLBCL tumors were resistant towards R-CHOP-based
chemotherapy, or a combination of both [116, 134].
The clinical outcome of tumor microenvironment/host
inflammatory HR-DLBCL is quite similar to those of
BCR/proliferation-DLBCL and OxPhos-DLBCL, with a
5-year survival of 54 to 60 % [40, 116, 134].
MD-subtype DLBCLs
The c-MYC overexpressing subsets of DLBCL-NOS have
been recently suggested to be sub-classified as c-MYC-
driven (MD) subtype of GCB-, ABC and type-3-DLBCL-
NOS [119]. C-MYC is overexpressed in up to 15 % of
DLBCL-NOS and in up to 58 % of DLBCL, unclassifi-
able, with features intermediate between DLBCL and
Burkitt lymphoma (DLBCL/BL) as a result of the t(8,14)
translocation (5–14 %), gain/amplification (8q24) (21–
38 %) or other, epigenetic mechanisms (28–41 %)
[136, 137]. In accordance with the concept of c–MYC
translocations arising in the GC microenvironment,
most of the DLBCL-NOS cases harboring a c-MYC
gene translocation show a GCB-type gene expression
profile and/or a GCB phenotype [107, 138–147]. Large
fractions of DLBCL (58–83 %) with the t(8,14) trans-
location contain concurrent rearrangements of the
anti-apoptotic BCL2 oncogene and are referred to as
double-hit lymphomas [107, 137, 144]. Double-hit
cases harboring a c-MYC gene translocation and BCL6
rearrangements have also been reported, although at a
much lower frequency than with BCL2 [148]. In
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addition, in some cases with the t(8,14) translocation,
there is a concurrent rearrangement of both anti-
apoptotic BCL2 and BCL6 oncogene(s), which are
referred to as triple-hit lymphomas [107, 144]. A re-
cently published comprehensive study of double-hit
and triple-hit lymphomas showed that 62 % of double
hit lymphomas involve BCL2 and 18 % involved BCL6,
the remaining cases were triple-hit lymphomas [149].
DLBCLs with high co-expression of c-MYC and BCL2
proteins have an aggressive clinical course and an
inferior overall survival when treated with R-CHOP
[143, 144, 150]. The aggressive nature of double-hit and
triple-hit lymphomas is likely due to the concurrent re-
arrangement of both the pro-proliferative c-MYC onco-
gene and the anti-apoptotic BCL2 oncogene [107, 144].
C-MYC/BCL2 co-overexpression in DLBCL is more
common in the ABC subtype and contributes to the
overall inferior prognosis of patients with ABC-DLBCL
[107, 144]. Several studies indicate that the overexpres-
sion of the c-MYC protein might be a prognostic marker
for poor survival in DLBCL, independent of BCL2
[138–142]. Thus, MD-DLBCLs, composed of the c-
MYC-driven subsets of DLBCL-NOS and DLBCL/BL,
including subsets of the newly defined categories of
double-hit and triple-hit DLBCL have been suggested
to represent an independent clinically highly relevant
diagnostic molecular subtype [119]. However, it is still
controversial whether the high expression of c-MYC
has prognostic significance as a sole marker, inde-
pendent of BCL2 co-overexpression [107, 144–147].
Indeed, it has been recently suggested that only high
co-expression of both c-MYC and BCL2 proteins may
serve as an independent predictor of very poor sur-
vival in DLBCL [107, 144–147]. The significantly
worse outcome in patients with double-hit and triple-
hit DLBCL may include both synergistic action of
c-MYC and BCL2/BCL6 as well as other molecular
features originating from the more numerous genetic
aberrations in double-hit and triple-hit DLBCL [151, 152].
For instance, TP53 inactivating mutations/deletions have
been detected in a large number of high-risk subgroup
of relapsed/refractory double-hit DLBCLs with c-MYC
and BCL2 [152–154] but not c-MYC and BCL6 gene
translocations [152]. TP53 mutations constitute an early
recurrent event in lymphomagenesis of c-MYC/BCL2
double-hit DLBCLs, leading to BCL2 driven evasion of
apoptosis free from TP53-mediated control and contrib-
ute to the highly aggressive morphological and clinical
phenotype of this entity [152–157].
Stromal-II signature-subtype DLBCL
A large GEP study performed by Lenz G. et al. identified
an additional microenvironment (stromal) gene expres-
sion signatures associated with superior or inferior
outcomes, respectively after treatment with rituximab-
based chemotherapeutic regimens [85]. Three gene-
expression signatures, - termed germinal-center B cell,
stromal-I and stromal-II signatures - were identified that
predicted survival in patients who received CHOP or R-
CHOP, respectively [85]. The stromal-I-signature, related
to extracellular matrix deposition and histiocytic infiltra-
tion was associated with a good outcome [85, 158]. By
contrast the angiogenesis-related stromal-II signature
reflected tumor blood-vessel density and was found to
be highly associated with a poor outcome [85]. This
stromal-II signature includes genes encoding key regula-
tors of angiogenesis such as vascular endothelial growth
factor (VEGF) receptor 2, growth factor receptor-bound
protein (GRB)-10, which mediates VGFR2 signaling;
integrin alpha 9, which enhances VEGF signaling and
the endothelial receptor tyrosine kinase TEK, the receptor
kinase for angiopoietin signaling [85]. DLBCLs with overex-
pression of the stromal-II gene expression are associated
with increased tumor blood-vessel density [85]. The
stromal-II gene expression signature has been there-
fore suggested to represent an angiogenic switch in
which the progression of a hyperplastic lesion to a
fully malignant tumor is accompanied by new blood-
vessel formation [85].
CDKN2A/2B (9p21) deletion signature-subtype DLBCL
Jardin F. et al. recently defined an additional signature-
subtype of DLBCL characterized by deletions of the
cyclin-dependent kinase inhibitor genes CDKN2A and/
or CDKN2B [120]. DLBCL with CDKN2A/2B (9p21)
deletions have a specific gene expression profile and
a poor prognosis under R-CHOP treatment [120].
The CDKN2A/2B locus encodes 2 different proteins:
p16INK4A and p14ARF. Analysis of the 9p21 genomic
region indicated that transcripts encoding p14ARF
and p16INK4A were both disrupted in most patients
with CDKN2A/2B deletion [120]. CDKN2A/2B dele-
tion impairs both p14ARF/p53 and p16INK4A/pRB
pathways. Loss of CDKN2A/2B is observed in up to
35 % of DLBCL-NOS patients and is significantly asso-
ciated with a poor prognosis after R-CHOP treatment,
independently of the international prognostic index
(IPI) and COO [120].
CDKN2A/2B deletion is predominantly observed in
ABC-DLBCL [13, 120]. CDKN2A/2B is deleted in up to
30 % of ABC-DLBCL and in up to 4 % of GCB-DLBCL
[13, 120]. Patients with CDKN2A/2B deletion predomin-
antly show an activated B cell profile and a specific gene
expression signature that combines direct and indirect ef-
fects of the deletion, characterized by dysregulation of the
RB/E2F pathway, activation of cellular metabolism, increase
of anti-apoptotic mechanisms and decreased immune
and inflammatory responses, including downregulation
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of FAS (TNFRSF6), IL1R1, AIM1, ARTD12 (PARP12)
and TNFRSF1A [120].
RCOR1-(TRAF3)-deletion signature-subtype DLBCL
A systematic integrative study of high-resolution genotyp-
ing arrays and RNA sequencing data of two independent
large cohorts of homogenously R-CHOP-treated DLBCL
patients identified novel focal and recurrent deletions in
the chromatin regulator and transcriptional corepressor
gene RCOR1 (encoding CoREST1) that are associated
with a novel prognostically significant risk-associated
gene expression signature [121]. RCOR1 deletions de-
fine a subgroup of DLBCL patients with unfavorable
progression-free survival [121]. The chromatin regula-
tor and transcriptional corepressor RCoR1/CoREST1
has been linked biochemically to hematopoiesis and is
part of the BRAF35-histone deacetylase/LSD1-CoR-
EST histone demethylase and chromatin remodeling
complex, where it associates with the C-terminal
domain of REST, the histone deacetylases 1 and 2
(HDAC1/2), and the histone demethylase LSD1/KDM1A
[159]. The established Rcor1 loss-associated prognostic
gene signature was independent of the cell of origin classi-
fication [121]. This risk-associated gene expression signa-
ture comprises 233 genes and is enriched for biological
processes that includes upregulation of the prote-
asome, processing of capped intron-containing pre-
mRNA as well as downregulation of signaling events
mediated by HDAC class II [121]. Interestingly, loss of
RCOR1 was associated with deletions of the TRAF3
gene, which is located in close vicinity. TRAF3 is a
negative regulator of the alternative non-canonical NF-
κB signaling pathways in DLBCL, acting as a negative
regulator of NF-κB-inducing kinase NIK [27, 160, 161].
Thus, it is very likely that the combination of tran-
scriptional pattern changes mediated by RCOR1 loss
and the downstream effects on constitutive NF-κB sig-
naling may cooperate and contribute to the malignant
phenotype of this subgroup of DLBCL [121].
Chemotherapeutical strategies and clinical outcome
Until 1997, the standard treatment for DLBCL was the
anthracycline-based chemotherapy regimen of cyclophos-
phamide, hydroxyldaunorubicin, vincristine, and prednis-
one (CHOP). The majority of DLBCL patients initially
respond favorably when treated with CHOP alone, but
around 60 % eventually relapse [1, 109, 162]. Relapsed
CHOP-resistant lymphomas disseminate and are highly
lethal without autologous stem cell transplantation [1,
109, 162]. DLBCL subtypes differently respond to the
standard CHOP chemotherapy. The ABC-DLBCL subtype
is associated with a very poor prognosis when treated with
CHOP only, the majority of ABC-DLBCL patients treated
with CHOP alone will succumb to their disease [1, 109,
162]. In contrast, CHOP only treated patients with GCB-
DLBCL and PMLBCL have a significantly better outcome
with relatively favorable 5-year overall survival rates [1,
109, 162]. The constitutive activation of the NF-κB and
BCR pathways has been suggested to be required for the
anti-apoptotic phenotype and chemotherapy-resistance in
ABC-DLBCL [35, 109, 163].
Since 1997 the co-administration of the chimeric anti-
CD20 monoclonal antibody rituximab and CHOP chemo-
therapy significantly improved the survival of DLBCL
patients, with a cure rate of 60 to 70 % [1, 109, 162]. The
humanized chimeric anti-CD20 monoclonal antibody
rituximab binds to the CD20 antigen on B-lymphoma
cells and leads to the inhibition of five main pathways
NF-κB, PI3K/AKT/mTORC1, STAT3, MEK/ERK and
p38-MAPK pathways, resulting in downregulation of the
expression of BCL2 family members and direct activation
of FAS-mediated apoptosis [164–173]. This benefit is ob-
served in both ABC- and GCB-DLBCL patients, though
GCB-DLBCL is still associated with a much higher overall
survival [40, 85, 163] and a relapse rate of only ∼15 % to
20 % [85, 174]. The 3-year progression free survival (PFS)
rate and overall survival (OS) rate for R-CHOP treated
patients with ABC-DLBCL are approximately 40 % and
45 %, respectively, while the corresponding PFS and OS
rate for R-CHOP treated patients with GCB-DLBCL are
approximately 74 % and 80 %, respectively [85, 163].
Approximately 15 to 30 % of relapsing GCB- and ABC-
DLBCL patients have c-MYC/BCL2 or c-MYC/BCL6
double-hit DLBCLs with high co-expression of c-MYC
and BCL2 or BCL6 proteins [85, 174]. These groups of
patients pose a particular urgent clinical need because of a
very aggressive clinical course, high chemorefractoriness
and inferior overall survival when treated with R-CHOP
[143, 144, 150].
The combination of rituximab with R-CHOP [175–
177] or dose dense CHOP chemotherapy, every 14 or
21 days [178, 179], is now the current standard treat-
ment for most patients with newly diagnosed DLBCL
and improves the outcome of DLBCL patients of all ages
and risk groups [1]. The complete remission (CR) rate of
newly diagnosed DLBCL is approximately 65–75 % with
R-CHOP [175]. An alternative standard regimen for
first-line treatments is DA-EPOCH-R (dose-adjusted
etoposide, prednisone, vincristine, cyclophosphamide,
doxorubicin, rituximab) [180, 181]. Preliminary data
from ongoing clinical studies suggest that DA-EPOCH-R
therapy might have a superior outcome in some sub-
types of DLBCL when compared to R-CHOP therapy
[180, 182, 183]. For a detailed description of chemother-
apeutic regimens used for the first-line treatment of
DLBCL, the readers are referred to the recent excellent
reviews [1, 109, 184–186]. Unfortunately, specific mo-
lecular subsets of DLBCLs at high risk for treatment
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failure with rituximab and/or anthracycline-based
(immuno-)chemotherapy regimes are be coming more fre-
quent [187]. Even though more than half of DLBLC pa-
tients achieve and maintain complete remission after first-
line therapy with empiric combination multi-agent
chemo-, radio- and/or immunotherapeutic regimes; 30 to
40 % of patients with specific molecular subsets of
DLBCLs undergo relapse and approximately 10 to 15 %
have refractory disease [188, 189]. Relapsed or refractory
DLBCL is difficult to treat, with limited therapeutic op-
tions. Patients with relapsed/refractory DLBCL have a
poor prognosis, with only ~10 % ultimately achieving
complete cure [188].
After finding a significant improvement of survival
outcomes in an international randomized phase III
trial (PARMA study), high-dose chemotherapy (HDC)
followed by autologous stem cell transplantation (ASCT)
has been suggested as the standard therapy for patients
with relapsed or refractory DLBCL [1, 190]. In addition, a
recently performed prospective randomized trial by the
Dutch Belgian Hemato-Oncology Cooperative Group
established the benefits of rituximab combined with salvage
chemotherapy, demonstrating clear survival benefits of
combining rituximab with HDC prior to ASCT (HOVON-
44 study) [191]. Rituximab-based HDC/ASCT therapy
regimens have become the mainstay of therapy for
patients with chemotherapy-sensitive relapsed DLBCL,
still sensitive to conventional dose salvage chemother-
apy [1, 192]. On the other hand, rituximab mainten-
ance appears to have no defined role in relapsed DLBCL
after ASCT [193].
Various salvage regimens are available such as R-
DHAP (rituximab, dexamethasone, high-dose cytarabine,
and cisplatin) R-DHAP-VIM-DHAP (rituximab-
cisplatin, cytarabine, dexamethasone, etoposide - ifosfamide,
methotrexate - cisplatin, cytarabine, dexamethasone), R-
ESHAP (rituximab, etoposide, steroids, ara-C, and cis-
platin), R-DHAX (rituximab, dexamethasone, cytarabine,
and oxaliplatin), R-ICE (rituximab, ifosfamide, carboplatin,
etoposide), DA-EPOCH-R (etoposide, doxorubicin, and
cyclophosphamide with vincristine, prednisone, and rituxi-
mab), R-GIFOX (rituximab, gemcitabine, ifosfamide, oxali-
platin), R-GEMOX (rituximab emcitabine, oxaliplatin), R-
GDP (rituximab plus gemcitabine, cisplatin, and dexa-
methasone), R-MINE (rituximab mesna, ifosfamide,
mitoxantrone, etoposide) or R-BEAM (rituximab plus
carmustine, etoposide, cytarabine, and melphala) [191,
193–206]. However, salvage therapy and transplant condi-
tioning regimens are still suboptimal, as are therapeutic
options for patients who relapse following ASCT [1, 192].
Thus, the optimal salvage chemotherapy regimen still
needs to be determined. A summary of randomized, phase
III trial studies of rituximab combined chemotherapy regi-
mens in relapsed/refractory DLBCL is presented in Table 6.
R-ICE or R-DHAP followed by high-dose therapy and au-
tologous stem cell transplantation are the two most widely
used regimens worldwide for the treatment of patients with
relapsed/refractory DLBCL [1, 192, 193]. Recently, the re-
sults of the randomized collaborative trial, which com-
pared R-DHAP to R-ICE followed by HDC/ASCT in
relapsed aggressive B-cell lymphoma, including relapsed/
refractory DLBCL, have been reported (CORAL study)
[193]. There were no significant differences reported be-
tween R-ICE and R-DHAP for ORR, 3-year EFS, or OS
[193]. However, a subsequent subgroup analysis performed
on the CORAL database showed that salvage treatment
with R-DHAP was superior to R-ICE in the GCB subtype
and may improve outcome in patients with GCB-type
DLBCL [174, 207].
Unfortunately, not all patients are fit or eligible for the
HDC-ASCT. Patients with aggressive non-GCB-DLBCL
(ABC-subtype or c-MYC-driven type-3-DLBCL-NOS)
respond poorly to treatment with classical R-ICE or
R-DHAP based salvage therapy [207–209]. Relapsed
DLBCLs resistant to rituximab alone or R-CHOP treat-
ments are refractory to subsequent treatments with the
initial chemotherapy regimen and may even exhibit cross-
resistance to multiple chemotherapeutic anticancer drugs
[169, 210]. Many patients ultimately succumb to these
aggressive tumors despite second-line chemotherapy and
autologous stem cell transplantation, resulting in disap-
pointing 3-year overall survival rates of approximately
30 % [4, 188, 207]. Patients with relapsed/refractory
DLBCL who relapse after HDC-ASCT and develop refrac-
tory disease have an extremely poor prognosis with only a
few, if any, curative therapy options and a median survival
of approximately 3 to 4 months [188, 207]. The manage-
ment of patients ineligible for HDC-ASCT or with
relapsed/refractory DLBCL relapsing after HDC-ASCT is
very difficult and the only remaining treatment option for
these patients includes participation in phase 1/2 clinical
trials with novel experimental agents or palliative therapy
[188, 207]. Thus, for the remainder of these patients with
relapsed/refractory and high-risk biological subtypes of
DLBCL, further improvements in therapy and novel
therapeutic strategies are urgently needed. For a detailed
description of drug resistance pathways in DLBCL and
chemotherapeutic regimens used for the treatment of
relapsed/refractory DLBCL, the readers are referred to the
recent excellent reviews [187–189, 192, 211, 212].
Selected novel drug targets under study for relapsed/
chemo-refractory DLBCLS
Most patients with relapsed or refractory DLBCLs re-
sistant to rituximab and/or R-CHOP chemotherapy
are thought to have ABC-DLBCL or type 3-DLBCLs
[35]. Three different types of drug resistance have
been defined and are associated with adverse clinical
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outcomes: Drug resistance of DLBCLs can be inher-
ent from the beginning (innate, due to the genetic
heterogeneity of DLBCL tumor cells) [213, 214]. This
type is called intrinsic genetic resistance, which is as-
sociated with recurrent translocations and the pres-
ence of specific genetic abnormalities [12, 18, 213, 214].
Inherited genetic variations can contribute to the risk of
therapy-induced side effects [12, 18, 215]. A second type,
termed treatment acquired resistance, develops from prior
exposure to chemotherapy [33, 213, 214]. Acquisition of
chemotherapy resistance in DLBCL is due to the genetic and
epigenetic instability of DLBCL tumor cells and emergence
of subclonal populations of drug-resistant tumor clones,
which eventually leads to the failure of standard rituximab
and/or anthracycline-based chemotherapy regimens [33,
213, 214]. A third resistance mechanism, known as tumor
microenvironment (TME)/cell adhesion–mediated drug
resistance, arises from the interaction of DLBCL tumor
cells with the normal stromal tissue [216–219].
Due to the extensive heterogeneous genetic nature of
DLBCL, multiple drug-resistant molecular mechanisms are
required for the intrinsic genetic resistance and acquisition of
chemotherapy resistance in DLBCL. Only a small number of
high-risk subsets of DLBCL are associated with increased ex-
pression of multidrug pumps (i.e., P-glycoprotein; MDR1/
ABCB1) [189, 220, 221] and overexpression does not appear
to be consistently associated with chemoresistance in DLBCL
[221, 222]. Moreover, CD20 mutations involving the rituxi-
mab epitope are rare in both de novo and relapsed/
refractory DLBCL tumors, and do not represent a significant
cause of R-CHOP resistance [223]. CD20 protein-negative re-
lapses can occur in up to 20 % DLBCL cases after rituximab-
containing combination chemotherapies [223–226]. Down-
regulation of CD20 protein expression strongly correlates
with rituximab resistance in vitro [227]. However its clinical
relevance is not yet fully understood [223–226]. Chemother-
apy resistance has been mainly associated with down-
regulation of intrinsic apoptosis pathways and activation of
survival pathways in DLBCL [165, 166, 169–171, 189, 228].
For instance, repeated exposure to rituximab can generate a
therapy-resistant phenotype by the upregulation of the anti-
apoptotic BCL2 family proteins [169] or downregulation of
the pro-apoptotic BAK and BAX proteins [229]. A summary
of observed and postulated (immuno)-chemotherapy resist-
ance mechanisms in DLBCL is presented in Table 7.
Multiple driver mutations and aberrant signaling pathways
suggested to be required for drug resistance in DLBCL have
been recently identified in specific molecular subsets of
DLBCLs through gene expression profiling (GEP), transcrip-
tome sequencing, RNA interference screens, and DNA
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DLBCL diffuse large B cell lymphoma, BEAM carmustine, etoposide, cytarabine, and melphala, BEAM/ASCT carmustine, etoposide, cytarabine, and melphala with autologous
stem cell transplantation, PFS progression-free survival, FFS failure-free survival, OS overall survival, OS overall survival, HDC high-dose chemotherapy, HDC/ASCT high-dose
chemotherapy and autologous stem cell transplantation, R-DHAP rituximab plus dexamethasone, cytarabine, and cisplatinum, R-GDP rituximab plus gemcitabine, cisplatin,
and dexamethasone, DHAP-VIM-DHAP cisplatin-cytarabine-dexamethasone – etoposide-ifosfamide-methotrexate – cisplatin-cytarabine-dexamethasone, R-ICE
ifosfamide, carboplatin and etoposide, Bexxar iodine-131 tositumomab
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sequencing and have increased our understanding of
(chemotherapy-) resistance. A detailed list of novel potential
drug targets and agents in DLBCL-NOS, including relapsed/
refractory DLBCL is shown in Additional file 1: Table S1.
Numerous small molecule inhibitors acting as GCB- and
ABC-DLBCL subtype-specific pathway inhibitors are now in
various stages of investigation, including clinical trial phase
III studies. Only a few of them have been already approved
for the treatment of B-cell malignancies, none of them for
the treatment of DLBCL (Table 8). At least seven are cur-
rently evaluated in clinical phase III studies in patients with
newly diagnosed or relapsed/refractory DLBCL (Table 9).
These drugs are mainly targeting oncogenic factors regulat-
ing cell metabolism, proliferation, cell cycle, growth, migra-
tion, survival and angiogenesis in a subtype-specific manner.
A detailed list of novel single experimental agents in clinical
trials in relapsed/refractory DLBCL-NOS is shown in
Additional file 1: Table S2. Completed and ongoing experi-
mental clinical studies combining novel experimental agents
with conventional (immuno-)chemotherapy (i.e., R-CHOP,
DHAP) in first-line treatment of newly diagnosed DLBCL
and/or second-line treatment of relapsed/refractory DLBCL
are summarized in Additional file 1: Tables S3–S5.
Most of these drugs are targeting the DLBCL subtypes
according to their COO status (GCB- or ABC-specific) and
CC status (OxPhos-, BCR- or MD-specific). The most im-
portant of these novel drug targets currently under study
are discussed below.
Inhibition of BTK and SYK kinases in the BCR-subtype of
ABC-DLBCL
As mentioned above chronic active BCR-mediated signaling
was recently identified as a critically important pathway in
the pathogenesis of ABC-DLBCL [96, 116, 122, 230].
Chronic active BCR signaling in DLBCL is mainly
dependent on the BTK, SYK and PI3K kinases [231]. The
BTK, SYK and PI3K kinases have significant activities in
patients with relapsed/refractory ABC-DLBCL [96, 116,
230]. Thus, the BCR-associated kinases SYK and BTK
have emerged as promising therapeutic targets for re-
lapsed/refractory ABC-DLBCL. SiRNA-mediated deple-
tion of SYK or BTK as well as inhibition of SYK or BTK
by small molecule inhibitors selectively decreased BCR
signaling and induced apoptosis of BCR-dependent
DLBCL cell lines [90, 98, 232–234]. In a phase I/II clinical
trial study that involved 80 subjects with relapsed or re-
fractory DLBCL, ibrutinib (PCI-32765), a BTK inhibitor,
have shown a promising activity of ibrutinib as a single
agent in the BCR- subtype of ABC-DLBCL; a 37 % ORR
and a 16 % CR in relapsed/refractory DLBCL was
reported for patients with the ABC- subtype compared
with only 5 % of those with the germinal GCB subtype
[235–238]. Thus, ibrutinib efficacy is limited to ABC-
DLBCL patients with a constitutively active BCR signaling
pathway [235, 239, 240]. Consistent with the cooperation
between the BCR and MyD88 pathways observed in vitro,
ABC tumors with concomitant BCR and MyD88 muta-
tions responded to ibrutinib frequently [235]. However,
the highest number of responses occurred in ABC tumors
that lacked BCR mutations, as 67 % of ibrutinib re-
sponders had wild-type CD79A and CD79B [235]. Re-
markably, ibrutinib does not inhibit the growth and
survival of BCR wild-type tumors with MyD88- and/or
CARD11 mutations [235, 239, 240] indicating that ibruti-
nib specifically targets ABC-DLBCL tumors that rely on
chronic active BCR signaling [235].
Ibrutinib is a selective and irreversible BTK inhibitor that
binds covalently to a C481 residue in the BTK active site,
preventing Y223 phosphorylation required for activation
[241]. Ibrutinib is very well tolerable both as single agent
and in combination with R-CHOP [235–237, 242].
Ongoing clinical phase II studies and several randomized
clinical phase III studies are evaluating ibrutinib with
or without R-CHOP in patients with newly diagnosed
and relapsed/refractory DLBCL 30 (NCT01325701,
NCT01197560, NCT01804686, NCT01855750) [235, 236,
243–245] (Table 9 and Additional file 1: Tables S2–S5).
Fostamatinib (R406, FosD), a selective oral small molecule
inhibitor of SYK, also showed significant activity in
relapsed/refractory DLBCL in a phase I/II study [246]
(Additional file 1: Table S2). More than 20 % of the patients
with multiple relapsed/refractory DLBCL responded to
therapy with fostamatinib, though the CR was only 5 %
[246]. A multicenter phase II trial of fostamatinib has com-
pleted and is pending announcement of the results
(NCT01499303) (Additional file 1: Table S2). Additional
phase II trials have been proposed to determine whether
fostamatinib may improve the response to rituximab [246].
Inhibition of PKCβ in the BCR-subtype of ABC-DLBCL
Another potential therapeutic target in relapsed/refrac-
tory BCR-subtypes of ABC-DLBCL is the protein kinase
C (PKC) isoform PKCβ II. PKCβ II is a serine/threonine
kinase isoform amplified through the BCR signaling
pathway and is highly expressed in refractory DLBCL
[247–250]. PKCβ-II overexpression is an adverse prognos-
tic factor in DLBCL and associated with poor prognosis in
BCR-subtypes of ABC-DLBCL and GCB-DLBCL deficient
of phosphatase and tensin homolog (PTEN) [247–251].
Preclinical studies demonstrated that sotrastaurin
(AEB071) and enzastaurin, two adenosine triphosphate-
competitive selective inhibitors of PKCβ, induce apoptosis
and inhibit the proliferation of BCR-subtypes of ABC-
DLBCL in vitro and in vivo [252, 253].
Sotrastaurin selectively inhibited the growth of CD79
mutant BCR-subtypes of ABC-DLBCL in vitro and in
vivo whereas the presence of CARD11 mutations re-
sulted in resistance to the inhibitor [253]. Sotrastaurin
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is currently being tested in an international multi-
institutional phase I/II trial study in patients with
DLBCL that harbor either CD79A or CD79B mutations
(NCT01854606) [109]. Treatment with enzastaurin is
well tolerated in patients with newly diagnosed DLBCL
as well as in patients with relapsed/refractory DLBCL
[254–257]. However a recent clinical phase I/II trial
study showed that the improved outcome upon treat-
ment using enzastaurin alone was only modest in
relapsed/refractory DLBCL (NCT00042666, Additional
file 1: Table S2), indicating that enzastaurin is not very
effective as single-agent [254–256]. Moreover, a ran-
domized phase III study of enzastaurin as single-agent
in patients with newly diagnosed DLBCL did not meet
Table 7 Summary of observed mechanisms underlying drug resistance in DLBCL
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CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, DHAP cisplatin, cytarabine, dexamethasone, etoposide, VIM ifosfamide, methotrexate, ESHAP
etoposide, steroids, ara-C, and cisplatin, ICE ifosfamide, carboplatin, etoposide, GDP gemcitabine, cisplatin, and dexamethasone, BEAM carmustine, etoposide,
cytarabine, melphala, MDR multi drug resistance, BCR B cell receptor, NF-κB nuclear factor-kappa B, JAK Janus kinase, STAT signal transducer and activator of
transcription, PAK1 p21-activated kinase 1, CHK1/2 Chk1 protein kinase 1/2, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, ARTD9 ADP-ribosyltransferase-9 diphteria
toxin like, BCL B-cell lymphoma protein, MCL1 myeloid cell leukemia 1, HSPs heat shock proteins, HDAC histone deacetylase, CARD11 caspase recruitment domain
family, member 11, MyD88 myeloid differentiation primary response 88, 4EBP1 eukaryotic translation initiation factor 4E binding protein 1, mTORC1, mammalian target
of rapamycin (mTOR) complex 1, ALDH1A1 aldehyde dehydrogenase 1A1, GPX1 glutathione peroxidase 1, ABCG2 ATP-binding cassette, sub-family G, member 2, ABCB1
ATP-binding cassette, sub-family B (MDR/TAP), member 1, PLCγ2 phospholipase C gamma 2, BTK Bruton’s tyrosine kinase, TME tumor microenvironment
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its primary endpoint to improve progression-free survival
(NCT00332202) [258] (Table 9). Two clinical phase II
studies evaluating the efficacy and safety of enzastaurin in
combination with R-CHOP or R-Gemox have been
recently completed and are pending announcement of the
results (NCT00436280, NCT00451178) (Additional file 1:
Table S3).
Inhibition of canonical NF-κB signaling pathways in
ABC-DLBCL
As already discussed in previous sections recent studies
validated the NF-κB signaling pathways as an important
therapeutic target in ABC-DLBCL. Receptor-mediated
constitutive activation of NF-κB in B-cell malignancies
can occur through two distinct signaling pathways: the
canonical pathway or classical pathway mediated by the
action of RelA/p50 heterodimers and the non-canonical
or alternative pathway mediated by the action of p52/
p50, RelB/p50 or RelB/p52 heterodimers [26, 27, 160,
161]. The canonical pathway is the major NF-κB signal-
ing pathway in DLBCLs and activated through BCR,
CD40 and/or TLR signaling and by the inhibitor of κB
kinase complex (IKKα/β/γ), which in turn, phosphory-
lates IκB and causes its degradation [27, 160, 161].
The major fraction of oncogenic NF-κB activating mu-
tations in DLBCL is predominantly related to the canon-
ical NF-κB pathway [12, 16, 18, 19, 96, 104, 259]. The
less well-studied non-canonical NF-κB pathway is not
yet fully established as a drug target in DLBCL, see next
section. ABC-DLBCL and PMLBCL cell lines and pri-
mary tumors, including drug-resistant cases, can be sen-
sitized in vitro and in vivo to chemotherapy by
treatment with drugs, which can inhibit the canonical
NF-κB pathway. For instance, small molecule inhibitors
of the IKK complex were found to be selectively toxic
for ABC-DLBCL and PMLBCL cell lines, but had no ef-
fect on GCB-DLBCL cell lines [59]. Proteasome inhibi-
tors such as bortezomib or carfilzomib, block the
degradation of negative regulators of cell cycle progres-
sion as well as of NF-κB inhibitory protein IκBα thereby
inducing cell cycle arrest and mitochondrial dependent
apoptosis in ABC-DLBCL [260–262]. A preclinical/clin-
ical phase II study demonstrated that targeting the ca-
nonical NF-κB pathway through inhibition of the 26S
Table 8 Approved novel drugs for treatment of B-lymphoid malignancies that are currently in clinical evaluation for the treatment
of DLBCL
Drug name Target/Pathway Manufacturer Approved for the treatment of
Ofatumumab (Arzerra) Second-generation
anti-CD20 mAb
(↓) CD20-pro-survival signaling GSK Genmab B-cell chronic lymphocytic leukemia
Obinutuzumab (Gazyva/GA101) Third-
generation anti-CD20 mAb
(↓) CD20-pro-survival signaling Roche
Pharmaceuticals
B-cell chronic lymphocytic leukemia
Ibrutinib (Imbruvica/PCI-32765) BTK
inhibitor
(↓) BTK, BCR/NF-κB-pro-survival signaling Pharmacyclics/Janssen
Pharmaceutica




(↓) IRF4, BCR/NF-κB-pro-survival signaling
(↑) pro-apoptotic STAT2- IFNα/β axis




(↓) NF-κB-pro-survival signaling Millennium
Pharmaceuticals
Multiple myeloma
Carfilzomib (Kyprolis) Proteasome Inhibitor (↓) NF-κB-pro-survival signaling Multiple myeloma
Idelalisib (Zydelig/CAL-101, GS 1101) PI3Kδ
inhibitor
(↓) PI3Kδ PI3K/AKT/mTORC1 pathway Gilead Sciences Inc. B-cell chronic lymphocytic leukemia
Small lymphocytic lymphoma
Follicular lymphoma
Dasatinib SRC kinase inhibitor (↓) SRC family BCR/NF-κB-pro-survival
signaling








B and T-acute lymphoblastic leukemia
Antibody-drug conjugate (ADC) (anti-
CD30 mAb conjugated to cytotoxin
MMAE)









(↓) CD52-pro-survival signaling Sanofi B-cell chronic lymphocytic leukemia
mAB monoclonal antibody, BTK Bruton’s tyrosine kinase, BCR B cell receptor, NF-κB nuclear factor-kappa B, IRF4 interferon-regulatory factor 4, STAT2 signal trans-
ducer and activator of transcription 2, IFNα/β interferon alpha/beta, PI3K phosphoinositide 3-kinase, mTORC1, mammalian target of rapamycin (mTOR) complex 1,
HDAC histone deacetylase
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proteasome complex with bortezomib can selectively
sensitize patients with relapsed/refractory ABC-DLBCL,
but not patients with relapsed/refractory GCB-DLBCL,
to chemotherapy (including (R-)CHOP and DA-EPOCH)
[263]. Bortezomib alone as single agent had no significant
activity in relapsed/refractory DLBCL [263–265], but when
combined with chemotherapy, it showed a significantly
higher response (83 % vs. 13 %) and median overall survival
(10.8 vs. 3.4 months) in ABC compared with GCB-DLBCL,
respectively [263] (Additional file 1: Table S5). A subse-
quent phase I/II study of patients with previously untreated
DLBCL investigating bortezomib in combination with R-
CHOP demonstrated that the efficacy of bortezomib plus
R-CHOP was similar in patients with non-GCB- and GCB-
DLBCL, consistent with the concept that the unfavorable
non-GCB-DLBCL subgroup with constitutive NF-κB over-
expression derives benefit from bortezomib sensitization
with chemotherapy [266] (Additional file 1: Table S3). A
phase II study and a randomized phase III study evaluating
the use of R-CHOP with or without bortezomib in unse-
lected patients with newly diagnosed DLBCL (Additional
file 1: Table S4) as well as a randomized phase II/III
study of R-DHAP with and without bortezomib in patients
with relapsed/refractory DLBCL are currently ongoing
(NCT00931918, NCT01324596 and NCT01805557)
(Table 9). Unfortunately, not all ABC-DLBCL are
bortezomib-sensitive, and patients may eventually de-
velop bortezomib-resistant disease. Preclinical studies
showed that proteasome inhibitors not only trigger the
accumulation of proapoptotic proteins, but can also up-
regulate antiapoptotic proteins, particularly MCL1 [267]
and HSP90 [268], which are implicated in bortezomib
resistance [267–269].
Surprisingly, a recent preclinical study uncovered an un-
expected profound regulatory role for the bromodomain and
extraterminal domain (BET) proteins BRD2 and BRD4 in
cytoplasmic signaling through IKK in ABC-DLBCL [239].
Inhibition BET proteins by small molecules inhibitors
CPI203 and JQ1 as well as siRNA-mediated depletion of
BRD2 and BRD4 expression, attenuated oncogenic IKKβ
signaling, thereby inhibiting downstream oncogenic NF-
κB-driven transcriptional programs and killing ABC-
DLBCL cells in vitro and in an ABC-DLBCL xenograft
model [239].
Inhibition of MALT1 in the BCR-subtype of ABC-DLBCL
Recent studies demonstrated that the proteolytic activity of
mucosa-associated lymphoid tissue lymphoma translocation
(MALT) protein-1 is required for the survival and pathogen-
esis of ABC- DLBCL with chronic active BCR signaling [270,
271] and therefore, represents another new potential thera-
peutic target in relapsed/refractory cases of the BCR-subtype
of ABC-DLBCL [270]. MALT1 is an enzymatically active
signaling component essential for upstream activation of
NF-κB upon antigen stimulation of BCR [270]. MALT1-
dependent cleavage of the non-canonical and tumor sup-
pressive NF-κB family member RELB promotes canonical
NF-κB activation in DLBCL [272]. Recent preclinical stud-
ies demonstrated that selective inhibition of the proteo-
lytic activity of MALT1 with small-molecule inhibitors
Table 9 Novel agents in clinical trial phase III studies for first-line and second-line treatment of DLBCL-NOS
Drug Agent mechanism or target Pathway Manufacturer Status Studies

























Lenalidomide (Revlimid) IRF4 Immuno modulatory
drug





































mAB monoclonal antibody, PKCβ protein kinase Cβ, BCR B cell receptor, NF-κB, nuclear factor-kappa B, IRF4 interferon-regulatory factor 4, STAT2 signal transducer
and activator, of transcription 2, IFNα/β interferon alpha/beta, BTK Bruton’s tyrosine kinase, mTORC1, mammalian target of rapamycin (mTOR) complex 1, PI3K
phosphoinositide 3-kinase
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blocks the anti-apoptotic NF-κB signaling pathway and
elicits toxic effects selectively on MALT1-dependent sub-
sets of ABC-DLBCL cells in vitro and in vivo with very lit-
tle toxicity towards primary B cells [273, 274].
Inhibition of TLR-mediated canonical NF-κB signaling
pathways in ABC-DLBCL
As mentioned above, a recent clinical phase II study dem-
onstrated that ibrutinib does not inhibit the growth and
survival of BCR wild-type ABC-DLBCL tumors with
MyD88 mutations [235, 239, 240]. MyD88 is an initial
adapter linker protein in the canonical NF-κB signaling
pathway activated by Toll-like receptors (TLRs), including
the endosomal TLRs 7, 8, and 9 [275]. In the presence of
the most common MyD88 mutant L265P, ligand activation
of those TLRs results in markedly increased signaling with
subsequent increased cell activation, cell survival, and cell
proliferation in DLBCL [103]. Thus, direct inhibition of
TLR/MyD88 signaling pathways by TLR antagonists might
circumvent the resistance of BCR wild-type ABC-DLBCL
tumors withMyD88 mutations against ibrutinib. A dose es-
calation phase I/II study evaluating the efficacy and safety
of the TLR antagonist IMO-8400 in patients with relapsed
or refractory DLBCL bearing a MyD88-L265P mutation
has been recently started (NCT02252146). IMO-8400 is
an antagonistic oligonucleotide specifically designed to in-
hibit ligand activation of TLRs 7, 8 and 9 [276]. The scien-
tific rationale for assessing the use of IMO-8400 to treat
patients with DLBCL and the L265P mutation is based
on the observations that IMO-8400 inhibits ligand-
based activation of DLBCL cell lines with the L265P
mutation and decreases the survival and proliferation of
DLBCL cells (unpublished data of preclinical studies per-
formed by Idera Pharmaceuticals, Inc.).
Inhibition of non-canonical NF-κB signaling pathways in
TRAF3-negative ABC-DLBCL
Several recent studies provided strong evidence for an
important role of the non-canonical NF-κB signaling
pathway in DLBCL, particularly in ABC-DLBCL [160].
Non-canonical NF-κB signaling appears to be activated by
a restricted number of ligands in DLBCL, such as CD30 lig-
and (CD30L), CD40 ligand (CD40L) and B cell activating
factor BAFF, belonging to the TNF superfamily. Binding to
the corresponding receptors (CD30, CD40 or BAFF-R/
BR3) results in activation and accumulation NF-κB-
inducing kinase (NIK), which in turn activates IKKα, the
kinase that promotes the processing of p100 into the active
p52 isoform, thereby resulting in continuous activation of
p52/p50, RelB/p50 or RelB/p52 heterodimers in the nucleus
[27, 160, 161]. Pham L.V. et al. recently reported that NIK
kinase is overexpressed and accumulates in both GCB-like
and ABC-like DLBCL cell lines [160]. NIK activation is
usually tightly controlled through negative feedback
mechanisms involving negative regulation by the adaptor/
regulator proteins TNF receptor-associated factor 2 and 3
(TRAF2/3) and the cellular inhibitors of apoptosis ubiquitin
ligases (c-IAP1/2) [27, 160, 161]. CD30, CD40 and BR3 re-
ceptors have been suggested to form a multimeric complex
with TRAF3, TRAF2, TRAF5 c-IAP1, and c-IAP2 in
DLBCL cells [27, 160, 161]. Both TRAF2 and TRAF3 serve
as negative regulators of non-canonical NF-κB signaling
pathways and target NIK for constant ubiquitination and
degradation [161]. Loss of this quaternary inhibitory
complex can lead to increased NIK protein accumulation
and constitutive activation of the non-canonical NF-κB
signaling pathway [161]. Indeed, 10 % of DLBCL cases
demonstrate nuclear NF-κB activity exclusively for the non-
canonical pathway (indicated by nuclear staining of p52 but
not p50) while 20 % of DLBCLs display nuclear staining for
both p50 and p52 [18], strongly indicating that the concur-
rent activation of both canonical and non-canonical NF-κB
pathways occurs in a large fraction of DLBCL [18, 27, 160].
In line with these observation, recurrent loss of function
mutations and deletions were recently revealed in genes en-
coding TRAF2 and/or TRAF3 in DLBCL [12, 15, 16, 19,
26, 27, 161]. Zhang B. et al. demonstrated that biallelic or
monoallelic deletions/mutations of TRAF3 occur recur-
rently in roughly 15 % of ABC-DLBCL and GCB-DLBCL
(in similar fractions) and correlate with non-canonical NF-
κB activity in ABC-DLBCL cases [27]. Modeling these gen-
etic events in mice, Zhang B. et al. demonstrated a key
oncogenic role for the non-canonical NF-κB pathways in
DLBCL pathogenesis [27]. Most DLBCL tumors developed
in their mice model resembled ABC-DLBCL [27]. Thus,
NIK appears to be an attractive new therapeutic target for
ABC-DLBCL treatment, particularly for patients with
ABC-DLBCL that are refractory to bortezomib or to the
BCR pathway inhibitor ibrutinib. Of interest, proteasome
inhibitors such as bortezomib or carfilzomib, can also block
the constant ubiquitination and degradation of NIK,
thereby upregulating the non-canonical NF-κB signaling
pathways. In addition, targeting both arms of NF-κB signal-
ing may also improve the therapeutic outcome in patients
with newly diagnosed high-risk DLBCL displaying muta-
tions in both canonical and non-canonical NF-κB pathways
[12, 18, 19, 27, 161]. Dual targeting of NF-κB pathways has
been successfully demonstrated for multiple myeloma in
vitro and in a xenograft model [277, 278].
Combination therapy simultaneously targeting NIK and
IKKβ (as a main kinase of the canonical NF-κB pathway),
either using the selective NIK inhibitors (AM-0216 or
AM-0561) and a small molecule IKKβ inhibitor (MLX)
[278] or the promising dual inhibitor of NIK and IKKβ,
PBS-1086 [277], showed significant anti-multiple mye-
loma activity, associated with apoptosis and inhibition of
both NF-κB pathways in tumor cells in vitro [277, 278]
and in a mouse xenograft model of human multiple
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myeloma [277]. To our best knowledge, there are no clin-
ical trial studies ongoing, which evaluate the safety and ef-
ficacy of NIK inhibitors in patients with newly diagnosed
or relapsed/refractory DLBCL.
Inhibition of NF-κB signaling and reactivation of a lethal
type I interferon response in the BCR-subtype of GCB and
ABC-DLBCL by targeting cereblon
Recent preclinical study demonstrated that the thalido-
mide-like drug lenalidomide is preferentially suppressing
the proliferation and survival of ABC-DLBCL subtypes
with minimal effects on non- ABC-DLBCL [90, 91].
Thalidomide-like immunomodulatory agents such as
lenalidomide or pomalidomide, are clinically important
drugs for multiple myeloma and other B-cell malignancies
[279–281]. The activity of lenalidomide in ABC-DLBCL
has at least two postulated mechanisms: inhibition of
BCR-mediated NF-κB-dependent pro-survival signaling
pathways in and expression of trancription factor IRF4,
which in turn leads to the upregulation of the STAT2/
type I interferon death pathway [90, 91]. IRF4 overexpression
has been shown to enhance NF-κB activation and BCR
signaling [90, 91]. The lenalidomide-mediated reduction of
IRF4 requires the E3 ubiquitin ligase complex coreceptor
protein cereblon (CRBN) [90, 91]. CRBN a substrate recep-
tor of the Cul4-Rbx1-DDB1-CRBN E3 ubiquitin ligase com-
plex, is a direct target of the immunomodulatory drugs
thalidomide, lenalidomide and pomalidomide [282, 283].
Thalidomide-like drugs directly bind to CRBN and pro-
mote the recruitment of its common substrates such as
transcription factors Aiolos and Ikaros to the E3 ubiquitin
ligase complex, thus leading to substrate ubiquitinylation
and degradation [284] and subsequent repression of IRF4
and SPIB [90, 91]. Repression of IRF4 and SPIB by lenali-
domide induces a lethal type I interferon response in
ABC-DLBCL by augmenting interferon β (IFNβ) produc-
tion [90]. IRF4 and its regulatory partner SPIB prevent
IFNβ production by repressing IRF7 in ABC-DLBCLs
[90]. The STAT2/type I interferon (IFNα/β) axis is well
known to have a tumor suppressor function in B-cell
lymphoma in vitro [285, 286] and inhibits tumor growth
in vivo [287]. Loss of the STAT2-IFNα/β axis confers re-
sistance to apoptosis induced by chemotherapeutic drugs
in B-cell lymphoma cell lines [285, 286]. However, due to
their high toxicities, IFNα and -β have not yet been
accepted as clinically useful agents in patients with aggres-
sive B-cell lymphoma.
Multiple phase I/II and phase II clinical trial studies
revealed that lenalidomide is well tolerated and produces
already as single agent durable responses in patients
with aggressive relapsed/refractory ABC-DLBCL, leading
to an overall response rate (ORR) of up to 53 % and a
complete response rate (CR) of up to 23 % in non-GCB-
DLBCL (including ABC-DLBCL cases) (Additional file 1:
Table S2) [288–293]. In line with the reported efficacy of
bortezomide and ibrutinib for non-GCB-DLBCL, pa-
tients with non-GCB-DLBCL showed a higher response
to lenalidomide in relapsed/refractory DLBCL (ORR
52.9 %) when compared to patients with GCB-DLBCL
(ORR 8.7 %) (Additional file 1: Table S2) [288]. In an
additional separate ongoing multicenter, randomized
clinical phase II/III study, patients with refractory ABC-
DLBCL treated with lenalidomide, when compared to
GCB patients, showed greater improvements in ORR
(45.5 % vs. 21.4 %), PFS (82 weeks vs. 13.2 weeks) and
OS (108.4 weeks vs. 30 weeks) [294] (Additional file
1: Table S2). Recent phase I/II clinical trial studies have
demonstrated that the combination of lenalidomide with R-
CHOP is safe and efficacious, particularly in elderly patients
[291, 295–299] (Additional file 1: Table S5). Several random-
ized phase III studies evaluating the use of lenalidomide with
or without R-CHOP in patients with newly diagnosed
DLBCL as well as in patients with relapsed/refractory
DLBCL are currently ongoing (NCT01122472 (REMARC),
NCT02285062 (ROBUST), NCT02128061, NCT01197560)
[281] (Table 9 and Additional file 1: Table S2).
A recent study performed by Hagner P.R. et al. dem-
onstrated that CC-122, a novel immunomodulatory
agent-like thalidomide analog, directly binds to CRBN
and promotes ubiquitinylation and degradation of Aiolos
and Ikaros in DLBCL in vitro, in vivo and in patients
with relapsed/refractory DLBCL, resulting in a mimicry
of lethal IFN type I signaling through direct de-
repression of interferon-stimulated gene (ISGs) tran-
scription and induction of interferon inducible proteins,
and ultimately leading to apoptosis in DLBCL [300]. Sur-
prisingly, CC-122 emerges with features that differenti-
ate it from family member of thalidomide analogs. The
anti-lymphoma activity of CC-122 was independent of
the cell of origin and observed in both ABC- and GCB-
DLBCL cell lines, in contrast to the ABC-subtype selective
activity of lenalidomide [300]. CC-122 has therefore been sug-
gested to belong to a new class of drugs: pleiotropic pathway
modifiers [300, 301]. These novel properties make CC-122 po-
tentially clinically active in the GCB- subtype of DLBCL in
which its predecessor, lenalidomide, has only limited or even
no activity [300].
At least three possibilities have been suggested to explain
the differential activity of CC-122 and lenalidomide [300,
301]. First, CC-122 may promote the recruitment, ubiquitina-
tion and degradation of specific and unique substrates to me-
diate some of its biological effects distinct from lenalidomide
[300]. Secondly, Aiolos and Ikarus, both known co-repressors
of ISG transcription may act independently of IRF4 and inter-
feron secretion in GCB- and type-3 DLBCL [300]. Thirdly,
CC-122 may promote the upregulation of the STAT2/type I
interferon death pathway independently of IRF4 in GCB-
DLBCL [301]. Moreover, other potential immunomodulatory
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mechanisms for its activity in (GCB)-DLBCL likely do exist
and may impact the nonimmune environment in vivo, in pa-
tients as well [301]. CC-122 has already demonstrated clinical
activity as single-agent in DLBCL [300–302, 303]. CC-122 is
currently in phase I trials in patients with newly diagnosed
DLBCL or relapsed/refractory DLBCL, either as a single-
agent (NCT01421524) [300–302, 303] (Additional file 1:
Table S2) or in combination with the novel dual mTORC1/
mTORC2 inhibitor CC-223 [304], the novel BTK inhibitor
CC-293 [305] and/or rituximab (NCT02031419) as well as in
combination with obinutuzumab, (NCT02417285) [303]
(Additional file 1: Tables S5 and S14).
Of interest, Shi C.X. et al. recently demonstrated that
proteasome inhibitors such as bortezomib and carfilzomib
can block Ikaros degradation by lenalidomide in multiple
myeloma, when concomitantly added to the lenalidomide
treatment [306]. These data suggest that administration of
thalidomide-like agents concurrent with or shortly after
proteasome inhibitor administration might be ineffective or
at least strongly reduce the efficacy of thalidomide-like
agents in DLBCL.
Inhibition of JAK2/STAT3 in ABC-DLBCL
The JAK/STAT3 signaling pathway represents another po-
tential therapeutic drug target for relapsed or refractory
ABC-DLBCL. Constitutive STAT3 activation has been re-
cently correlated with poor overall survival in patients with
ABC-DLBCL subtype treated with R-CHOP [307–310].
Inhibition of constitutive STAT3 activity sensitizes resistant
B-cell NHL cells to chemotherapeutic cytotoxic drugs,
including CHOP, cisplatin, fludarabine, adriamycin, and
vinblastine [164, 171]. STAT3 is persistently phosphorylated
(pSTAT3-Y705) in most ABC-DLBCL in an autocrine and
paracrine manner (from the tumor microenvironment)
[311–313]. Inactivating STAT3 in ABC-DLBCL cells inhibits
cell proliferation and triggers apoptosis in vitro [312–314].
Small molecule inhibitors of STAT3 signaling (inhibitors of
nuclear translocation or JAKs) are currently under investiga-
tion whether they could serve as drugs for relapsed and/or
refractory ABC-DLBCL [171, 311, 315] (Additional file 1:
Table S6). A phase I/II is currently being performed in
patients with advanced tumors, including refractory DLBCL,
evaluating the clinical efficacy and safety of ISIS-
STAT3Rx, an antisense oligonucleotide, which inhibits nu-
clear translocation of STAT3 (NCT01563302). Clinical
grade oral inhibitors of JAK1 and JAK2, such as fedratinib
(SAR302503/TG101348) or ruxolitinib, which blocks
phosphorylation of STAT1 and STAT3 [60] have been re-
cently proposed for clinical evaluation for the treatment of
ABC-DLBCL [60, 316, 317]. A multicentre phase II study
of ruxolitinib in patients with relapsed/refractory DLBCL
is ongoing (NCT01431209) [109].
Moreover, a phase I study evaluating the safety and efficacy
of the novel JAK1 inhibitor INCB039110 [318] has been
recently started in relapsed/refractory B-cell lymphoma, in-
cluding DLBCL (NCT01905813) (Additional file 1: Table S6).
In addition, the novel macrocyclic pyrimidine-based selective
oral inhibitor of JAK2/JAK2(V617F) and FLT3 kinases, pacriti-
nib (SB1518), which blocks phosphorylation of STAT1,
STAT3 and STAT5 has also been suggested for further inves-
tigations in clinical studies of patients with relapsed/refrac-
tory DLBCL [317, 319, 320] (Additional file 1: Table S6).
A phase I dose-finding and pharmacokinetic/pharmacody-
namic study of pacritinib (SB1518) has shown safety and
early clinical activity in patients with relapsed B-cell
lymphoma, providing the first proof of principle of the po-
tential clinical value of targeting JAK/STAT pathway in
B-cell lymphoma [317, 321]. Unfortunately, no responses
were observed in the five patients with relapsed/refractory
DLBCL, which was explained by the small number of pa-
tients [317, 321] (Additional file 1: Table S6). To date,
pacritinib (SB1518) is the first and only JAK2 inhibitor
that has been already evaluated in patients with relapsed/
refractory DLBCL [317].
HDAC inhibitors can also enhance dephosphorylation
of STAT3 and are evaluated in ongoing clinical trials in
DLBCL, including relapsed/refractory DLBCL (see next
sections). Moreover, a recent study provided evidence
that STAT3 mediated proliferation and survival of
DLBCLs also depends on IL10/IL10-receptor signaling
[322, 323], suggesting IL10-receptor (IL10R) as a novel
JAK2/STAT3 pathway-specific therapeutic target in
DLBCLs [322]. Inhibition of IL10R signaling with an
anti-IL10R-blocking antibody induced dose-dependent
cell death in all tested ABC-DLBCL cell lines and
primary DLBCLs [322, 323]. Anti-IL10R treatment
resulted in interruption of the IL10/IL10R-STAT3 auto-
stimulatory loop [322].
Inhibition of PI3K/AKT/mTORC1 and PI3K/mTORC2/PKC/AKT
pathways in GCB-DLBCL and BCR-subtype of ABC-DLBCL
The constitutive activation of the PI3K/AKT/mTORC1
pathway in GCB-DLBCL plays a central role in promoting
survival and chemotherapy-resistance and represents a ra-
tional therapeutic target in relapsed or refractory GCB-
DLBCL [324]. Deregulation of the PI3K/AKT/mTORC1
pathway by the inactivation of PTEN, an inhibitor of the
PI3K/AKT/mTORC1 pathway, is found in 55 % of GCB-
DLBCL cases, but only in 14 % of non-GCB-DLBCL and
worsens prognosis [324]. In preclinical in vitro studies, inhib-
itors of PI3K, such as LY294002 selectively targeted PTEN-
deficient GCB-DLBCL cells [324, 325]. In addition, inhibition
of target of rapamycin complex 1 (mTORC1) or PI3K blocks
proliferation and induces cell death in BCR-subtype of ABC-
DLBCL [133, 232, 233]. Idelalisib (formerly GS-1101 and
CAL-101), a selective oral reversible inhibitor of the p110δ
isoform of PI3K, is currently evaluated in an ongoing early
phase I study as a single-agent in patients with relapsed/
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refractory DLBCL. Moreover, an ongoing early dose escal-
ation and dose expansion phase I study is evaluating the
safety and efficacy of idelalisib in combination with the novel
BTK inhibitor ONO-4059 in patients with relapsed/refrac-
tory ABC-DLBCL (Additional file 1: Table S14). In addition,
MK-2206, an AKT inhibitor and BKM-120, a pan-class I
PI3K inhibitor, are currently being tested in early clinical
phase I trials in DLBCL, including relapsed/refractory
DLBCLs (Additional file 1: Table S2).
However, new drugs targeting the PI3K/AKT/mTORC1
pathway appears to have only modest activities as a single-
agent in treating patients with relapsed/refractory DLBCL
and many patients experience severe side effects [326–328].
For instance, recent phase II trial studies of the oral mTORC1
inhibitors everolimus (RAD001) and temsirolimus, two ana-
logues of the parental compound rapamycin, showed a very
modest ORR of 30 to 38 % and CR of only 12 % for DLBCL
[326–328] (Additional file 1: Tables S2 and S5). An ongoing
randomized clinical phase III study is further evaluating
everolimus in patients with relapsed/refractory DLBCL (NCT
00790036) (Table 9). The modest activity observed in these
clinical studies has been explained in two ways: First, block-
ade of PI3K/AKT/mTORC1 pathway induces autophagy
[329, 330], which can serve as a protective mechanism to
mitigate the cytotoxicity of drugs targeting the PI3K/AKT/
mTORC1 pathway in DLBCL cells [329]. Autophagy can also
serve as a protective mechanism to survive from
chemotherapeutic-induced genotoxic stress [331]. Inhibition
of autophagy has been shown to enhance chemotherapy-
induced cell death [331] and enhance the toxic activity of
drugs targeting the PI3K/AKT/mTORC1 pathway in DLBCL
cells [329]. Secondly, the weak activity of rapamycin ana-
logues can also be explained by their mTORC1-selective in-
hibitor activity. Both everolimus and temsirolimus target only
the mTORC1 but not mTORC2. mTORC2 is generally con-
sidered to be unaffected by rapamycin and produces resist-
ance at least partly via the induction of upstream receptor
tyrosine kinase signaling and phosphorylation of AKT on
S473, a critical regulatory site that stimulates maximal activity
of this important survival kinase [332–334]. Thus, it is hy-
pothesized that dual mTOR kinase inhibitors, blocking both
PI3K/AKT/mTORC1 and PI3K/TORC2/PKC/AKT signaling
pathways to prevent feedback loops, may have expanded
therapeutic potential [304]. Pre-clinical studies have already
demonstrated that dual inhibition of mTORC1/2 can over-
come rapamycin and/or temsirolimus resistance in solid can-
cer types [335]. An ongoing phase I/II, multi-center study
evaluating the safety and efficacy of the novel dual mTORC1/
mTORC2 inhibitor CC-223 [304] in patients with relapsed/
refractory tumors, including DLBCLs, is currently testing this
hypothesis (NCT01177397) [304]. A preclinical study per-
formed by Mortensen D.S. et al. provided preliminary evi-
dence that CC-223 can strongly inhibit the growth of GCB-,
ABC- and type-3 DLBCL cell lines associated with high
mTORC1 and mTORC2 activity in vitro [304]. Of interest,
these data suggest that ABC-DLBCL with high IRF4 tend to
be less sensitive towards CC-223 [304]. In addition, a phase I
study evaluating the efficacy and safety of the dual mTORC1/
2 inhibitor OSI-027 in patients with solid cancer and B-cell
lymphoma, including DLBCL has been recently completed
and is pending announcement of the results (NCT00698243)
[336]. OSI-027 is a novel, highly selective, dual mTORC1/2
inhibitor that inhibits the phosphorylation of mTORC1 and
mTORC2 [336]. A previous preclinical study showed that
OSI-027 markedly diminished proliferation and induced
apoptosis in a variety of lymphoid cell lines and induced
tumor regressions in B-cell lymphoma xenograft models
[336]. Moreover, using in vitro screening, Ezell S.A. et al. re-
cently demonstrated that the combination of ibrutinib and
AZD2014, a novel dual catalytic inhibitor of mTORC1/
mTORC2, is highly synergistic in killing ABC-subtype
DLBCL cell lines, weakly expressing IRF4 [232]. Simultaneous
inhibition of BTK and mTORC1/2 caused apoptosis both in
vitro and in vivo and resulted in tumor regression in a xeno-
graft model [232].
Taken together, despite their modest activity as single-
agents both everolimus and temsirolimus might be targeted
as a clinical strategy for re-sensitization to (R-)CHOP based
chemotherapy [329, 337, 338]. Ongoing clinical phase I/II
studies are evaluating the safety and activity of salvage therapy
consisting of the oral mTORC1 inhibitors everolimus and
temsirolimus, added to standard therapy of rituximab or R-
CHOP, respectively, in patients with newly diagnosed or re-
lapsed/refractory DLBCL (Additional file 1: Tables S4 and S5).
Inhibition of programmed death-1 (PD-1) signaling in
(HR-like)-subtypes of ABC-DLBCL
Programmed death 1 (PD-1) is an inhibitory receptor
expressed on the surface of T cells that functions in conjunc-
tion with receptor ligands, PD-L1 and PD-L2 to physiologic-
ally limit T-cell activation and proliferation [339]. Its ligands,
PD-L1 and PD-L2, are expressed on antigen-presenting cells
[339]. Binding of PD-L1 or PD-L2 to its receptor inhibits T-
cell activation and counterbalances T-cell stimulatory signals,
thus primarily limits the T-cell response in peripheral tissues
[339]. The sustained expression of PD-1 and the receptor li-
gands result in T-cell exhaustion and immune escape [339,
340]. This mechanism has been adopted by tumors to pre-
vent antitumor activity in tumor-infiltrating lymphocytes that
are present in the tumor microenvironment [340].
The PD-1/PD-L1 pathway plays an important role in tumor
immune evasion [340]. PD-L1 expression is either driven by
direct oncogenic signaling or upregulated on the tumor cell
surface via induction by IFNγ or other inflammatory cyto-
kines, as occurs in the course of the normal immune response
[340]. IFNγ/cytokine induced expression of PD-L1 is mainly
mediated through JAK2-STAT1 and/or STAT3 respectively
[341–343]. PD-L1 is aberrantly overexpressed in subsets of
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aggressive GCB- and ABC-DLBCL (10–14 % of DLBCL-
NOS) with worse prognosis, most likely belonging to the HR-
subtype of ABC-DLBCL [344–348]. A recent phase II study
of the anti-PD-1 antibody pidilizumab (NCT00532259), ad-
ministered to patients after ASCT for relapsed/refractory
DLBCL demonstrated an overall response rate of 51 % in pa-
tients with DLBCL [349] (Additional file 1: Table S2). 34 % of
patients who had residual disease after ASCT experienced a
complete response [349]. The 16-month progression-free sur-
vival was 72 % in the population as a whole and 70 % in high-
risk patients [349]. These data suggest that PD-1 is a very
promising target in the treatment and management of re-
lapsed/refractory DLBCL. A phase II clinical trial is currently
ongoing to evaluate the role of the anti-PD-1 antibody nivolu-
mab in relapsed/refractory DLBCL [344] (Additional file 1:
Table S2). There are also efforts to combine anti-PD1 agents
with other drugs [344] (Additional file 1: Table S2). For in-
stance, a phase I/II clinical trial evaluating the efficacy and
safety of the anti-PD-1 antibody MEDI4736 in combination
with ibrutinib in patients with relapsed/refractory DLBCL is
currently ongoing (Additional file 1: Table S2).
Inhibition of EZH2 in GCB-DLBCL
The polycomb-group oncogene product enhancer of zeste
homologue 2 (EZH2) is a histone methyltransferase and plays
a key role in transcriptional repression through chromatin
remodeling [350]. The EZH2Y641F has now been reported
as a gain-of-function mutation in > 21 % of GCB-DLBCL
and is essentially absent from ABC-DLBCL [29]. The Y641F
mutation in EZH2 results in altered histone-lysine methyl-
transferase activity [351, 352]. The EZH2Y641F mutation can
cooperate with c-MYC to accelerate lymphomagenesis in
animal models and is implicated in drug resistance [353]. In
addition, EZH2 cooperates with BCL2 and BCL6 to create
the GCB phenotype and induce B-cell lymphomas through
formation and repression of bivalent chromatin domains [77,
79]. Several recent preclinical studies demonstrated that po-
tent and selective S-adenosyl-methionine-competitive small
molecule inhibitors of EZH2 such as E7438 (EPZ-6438),
GSK-126 or CPI-360 eliminate tumor growth in GCB-
DLBCL models with activating EZH2 mutations [77,
354–356]. GSK-126 is selectively targeting the activating
oncogenic mutant form of EHZ2 [355]. GSK-126 af-
fected the viability of mutant EZH2-containing GCB-
DLBCL cells in vitro and in mouse xenograft models
with EZH2 mutations in vivo but not of wild-type (WT)
EZH2-containing GCB-DLBCL cells or in mouse WT-
EZH2 xenograft models [355]. On the other hand
inhibitors such as CPI-360 are broadly efficacious also
in GCB-DLBCL models with wild-type EZH2 [356].
Thus pharmacological inhibition of EZH2 activity may
provide a promising treatment for relapsed or refractory
GCB-DLBCL overexpressing EZH2 wild-type and/or
mutants. Moreover, a recent preclinical study provided
evidence for synergistic anti-tumor activity of the EZH2
inhibitor E7438 (EPZ-6438) and glucocorticoid receptor
agonists in models of GCB-DLBCL in vitro [357]. A
phase I/II clinical trial study of E7438 (EPZ-6438) in
NHL including newly diagnosed DLBCL is currently
ongoing (NCT01897571) [354, 357].
Inhibition of BCL2, BFL-1 and MCL1 in GCB- and
ABC-DLBCL
Deregulation of members of the B-cell lymphoma (BCL)-2
family of pro- and anti-apoptotic proteins are associated with
rituximab and/or chemotherapy resistance in DLBCL-NOS
[358–363]. BCL2, BCL2-related factor (BFL)-1 and myeloid
leukemia cell differentiation protein (MCL)-1 represent novel
therapeutic targets for relapsed or refractory GCB- and/or
ABC-DLBCL, respectively [360–364]. BCL2 is overexpressed
in approximately 40–65 % of DLBCL tumors, owing to
t(14;18)(q32;q21) translocations found in 15–30 % of cases,
and through additional mechanisms that are not well defined
[75, 107, 144, 145, 360, 362, 365, 366]. BCL2 is frequently
overexpressed in both GCB- and ABC-DLBCL, albeit the
mechanisms of BCL2 upregulation are different between
GCB- and ABC-DLBCL [75, 362, 365]. ABC-DLBCLs overex-
press MCL1 at significantly higher levels compared with
GCB-DLBCL, showing IHC positivity in 50 % of ABC and
30 % of GCB tumors [363]. Recent studies have suggested that
overexpression of BCL2 remains a negative predictor of
outcome after rituximab-based chemotherapy mainly
in GCB-DLBCL [360, 361] while MCL1 mainly contrib-
utes to chemotherapy resistance in ABC-DLBCL [363]. On
the other hand, in presence of c-MYC overexpression,
BCL2 overexpression also contributes to a decreased
survival of ABC-DLBCL after rituximab-based chemother-
apy [107].
Structure-based design was used for the development of
small-molecule BH3 mimetics that bind to the BH3
hydrophobic-binding groove of the anti-apoptotic proteins
BCL2, B-cell lymphoma-extra large (BCL-XL), BCL2-related
protein A1 (BCL2A1/A1) and MCL1 and promote apoptosis
[367]. Small-molecule BH3 mimetics include the clinically
relevant agents ABT-737, ABT-263 (navitoclax), ABT-199
and GX15-070 (obatoclax) [367–370]. ABT-737 and its oral
derivative A263 bind to BCL2, BCL-W and BCL-XL, but not
to MCL1, BFL1 or A1 [367, 369, 370], whereas GX15-070, a
pan-BCL2 inhibitor also binds to and inactivates MCL1 [367,
368]. Preclinical studies indicate that ABT-737, ABT-263 and
GX15-070 are effective against GCB- and/or ABC-DLBCL
cells in vitro, including bortezomib-resistant DLBCL cells
and substantially suppressed tumor growth in vivo [363,
371–373]. ABT-263 and GX15-070 have been suggested to
be effective in patients with relapsed/refractory DLBCL
[363, 371]. However, on-target BCL-XL inhibition by
ABT-263 and GX15-070 led to dose-dependent
thrombocytopenia and posed a barrier to maximizing the
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activity of these agents [374]. Moreover, a recent preclin-
ical study suggests that patients may eventually develop
ABT-737-resistant disease by up-regulating the expression
of MCL1 and BFL1 [364]. ABT-199 (venetoclax), a
second-generation orally available derivative of ABT-737
that selectively targets BCL2 is currently under evaluation
in clinical trials of B-cell NHL [367, 374, 375]. ABT-199
has greater than 100-fold selectivity for BCL2 over BCL-
XL [375, 376].
Preclinical and early clinical studies demonstrated that
ABT-199 inhibits the growth of aggressive c-MYC-driven
mouse B-cell lymphomas and human BCL2-dependent
B-cell lymphoma tumors in vivo without causing
thrombocytopenia [375, 377]. Of interest, a recent study
provided preliminary evidence that normal, untransformed
mature B cells may also be sensitive to ABT-199, both in
vitro and in vivo [378]. A preclinical study showed that
single-agent ABT-199 had only modest antitumor activity
against most DLBCL lines and resulted in compensatory up-
regulation of MCL1 expression [379]. Moreover, in a phase I
clinical trial study, used as a single-agent, ABT-199 has
shown a modest overall response rate of up to 33 % in
DLBCL, with a complete response rate of only up to 11 %
[380–382]. On the other hand, treatment of high-risk
DLBCL with ABT-199 combined with the potent new
cyclin-dependent kinase inhibitor dinaciclib [383], which
knocks down MCL1 by inhibiting CDK9 [379, 383],
synergistically induced tumor regression, in xenografts and
in a genetically accurate murine model of c-MYC/BCL2
double-hit B-cell lymphoma [379]. A phase II study is
currently ongoing combining ABT-199 with bendamustine
and rituximab in relapsed/refractory NHL including
relapsed/refractory DLBCL (NCT01594229) (Additional file 1:
Table S5).
Inhibition of BCL6 in the BCR-subtype of GCB- and
ABC-DLBCL
B-cell lymphoma protein BCL6 overexpression inhibits
apoptosis induced by chemotherapeutic agents in DLBCL
[32]. BCL6 is overexpressed in both GCB- and ABC-
DLBCL, albeit through different mechanisms [32]. Recent
studies demonstrated that HSP90 forms a complex with
BCL6 and inhibition of HSP90 with the drug PU-H71, a
purine scaffold HSP90 inhibitor destabilizes BCL6 and
selectively kills BCL6-positive DLBCL cells in vitro and
in vivo [384]. Subsequent studies demonstrated that small
molecule inhibitors, including the retro-inverted BCL6
peptide inhibitor (RI-BPI, 79–6) that directly antagonize
BLC6 function by disrupting the BCL6-corepressor
complexes via binding in the lateral groove of the BCL6
BTB domain and thereby selectively inhibiting the
interaction with nuclear receptor co-repressor BCOR,
NCOR1 and NCOR2 proteins [123, 385, 386]. The
small-molecule inhibitor mediated disruption of the
activity of BCL6, can be selectively toxic towards high-
risk BCL6-dependent BCR-subtypes of GCB and ABC-
DLBCL in vitro and potently suppressed GCB-DLBCL
tumors in a DLBCL xenograft mouse model in vivo
through reactivating pro-apoptotic genes repressed by
BCL6 [123, 385, 386]. RI-BPI mediated inhibition of
BCL6 also induces the expression of EP300, resulting in
acetylation and activation of TP53 and concomitant
acetylation and inactivation of HSP90 [386]. Moreover
the BCL6 activity can also be indirectly blocked in
DLBCLs by pharmacologic inhibition of both HDACs
and SIRT1/2 [387–389], see next sections. Together,
BCL6 represents a novel promising therapeutic target in
relapsed/refractory BCR-subtypes of GCB- and ABC-
DLBCL. To our best knowledge, there are no clinical
trial studies ongoing, which evaluate the safety and
efficacy of HSP90 or BCL6 inhibitors in patients with
newly diagnosed or relapsed/refractory DLBCL.
Inhibition of HDACs and Sirtuins in GCB- and ABC-DLBCL
Several recent studies identified small inhibitory mole-
cules targeting histone deacetylases (HDACs) and sirtuins
as promising potential therapeutic agents in relapsed/
refractory GCB- and ABC-DLBCLs [387]. SIRT1 expres-
sion is associated with poor prognosis in DLBCL [390].
Several HDAC inhibitors (HDACi) are already approved
for clinical use or in clinical trials [391]. HDACi and
sirtuin inhibitors can target both GCB- and ABC-DLBCL,
albeit through different mechanisms [387, 392]. Various
HDACi and sirtuin inhibitors can repress GCB-DLBCL as a
result of their inhibition of the BCL6 oncogene [386–389].
Inhibition of both HDACs and SIRT1 results in the accu-
mulation of acetylated BCL6 [388]. Acetylation of BCL6
inhibits the ability of BCL6 to recruit HDAC-containing
SMRT co-repressor complexes [388]. Thus, inhibition of
HDACs and Sirtuins in BCL6-positive GCB-DLBCLs
(and to a minor extend in ABC-DLBCL) results in the
accumulation of inactive acetylated BCL6 and even-
tually in cell cycle arrest and apoptosis [386, 388].
Moreover a recent preclinical and clinical study dem-
onstrated that combined sirtuin and pan-HDAC inhib-
ition synergistically kills DLBCLs with a preference for
GCB-DLBCL [389]. Combined treatment of DLBCL
cells with HDACi such as vorinostat in combination
with the Sirtuin inhibitor niacinamide produced
synergistic cytotoxicity in vitro and in vivo by inhibiting
BCL6 and activating TP53 [389]. Acetylation of p53
strongly stimulates its pro-apoptotic activity [393]. A
subsequent proof-of-principle phase I clinical pilot
trial in patients with relapsed or refractory NHL, in-
cluding DLBCL led to an ORR of 18 % and CR of
18 % [389]. 46 % of the patients experienced
stabilization of their aggressive disease [389]. In
addition, a study performed by Gupta M. et al.
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demonstrated that HDACi such as LBH589 can ef-
fectively suppress STAT3 in ABC-DLBCL [392]. In-
hibition of HDACs leads to increased acetylation of
STAT3, dephosphorylation of pSTAT3(Y705), nuclear
export of STAT3 to the cytoplasm and blocks sur-
vival of ABC-DLBCL cells [392]. Inhibition of SIRT1
has also been shown to induce dephosphorylation of
pSTAT3(Y705), nuclear export of STAT3 to the cyto-
plasm and thereby inactivation of STAT3 [394]. Prelim-
inary data from a clinical phase II trial study indicate
that HDACi might not work as single-agents in re-
lapsed/refractory GCB and ABC-DLBCL [395]. Despite
an encouraging activity of the HDACi vorinostat in
DLBCL was noted in a phase I trial study [396], subse-
quent clinical phase II trial studies of oral vorinostat in
relapsed DLBCL showed only limited activity against re-
lapsed DLBCL [395]. Although vorinostat seems not to
be very effective as a single-agent, other more potent pan-
HDACi such as romidepsin, panobinostat, MGCD-0103,
LBH589 have been suggested as rational therapeutic op-
tions for clinical trials in relapsed/refractory DLBCL when
combined with other agents [1, 397].
Inhibition of BRD4 (and BRD2) in the c-MYC-driven
subtype of DLBCL-NOS
High c-MYC expression correlates with inferior clinical
outcome in R-CHOP-treated DLBCL patients [107, 138,
366]. C-MYC-driven gene (over)expression has been sug-
gested to confer resistance to rituximab immunotherapy
[107, 138, 366, 398]. Recent preclinical studies demon-
strated that the transcriptional coactivator and bromodo-
main and extra terminal (BET) protein BRD4 is required
for transcriptional amplification of the c-MYC oncogene
[398–402]. BRD4 occupies a small set of exceptionally
large super-enhancers associated with genes including the
c-MYC oncogene [399, 403]. Inhibition of BRD4 (and
other BRD family members) by small molecule inhibitors
of the BET family, such as the BET-bromodomain inhibi-
tor JQ1, leads to preferential inhibition of c-MYC onco-
gene expression, growth arrest and extensive apoptosis in
a variety of B-cell leukemia and lymphoma cell lines,
including c-MYC/BCL2-double-hit DLBCLs and AML
cells that overexpress c-MYC in association with BCL2
[398–401, 404]. I-BET151, another novel highly selective
inhibitor of both BRD2 and BRD4 causes transcriptional
silencing of the c-MYC gene and c-MYC-dependent pro-
grams in myeloma cells by inhibition of BRD2 and BRD4
binding to the promoter of the c-MYC gene and failure to
recruit P-TEFb and PAFc1 complexes to the IGH/c-MYC
enhancer by BRD2 and BRD4, and lack of subsequent
RNA-Pol-II recruitment [405]. Both JQ1 and PFI-1,
another highly selective inhibitor of BRD4 and BRD2, also
displayed significant antitumor activities in vivo in xeno-
graft models of DLBCL, Burkitt’s lymphoma or acute
myeloid leukemia and thereby improved survival of
engrafted mice [399–402, 406]. Another preclinical study
recently demonstrated that the new BET bromodomain
inhibitor OTX015 affects pathogenetic pathways in
preclinical B-cell tumor models, including GCB-,
ABC-and type-3 DLBCL-NOS [407]. OTX015 showed
strong anti-proliferative activity in a large panel of cell
lines derived from mature B-cell lymphoid tumors [407].
Interestingly, in addition to its broad cytostatic activity,
OTX015 selectively induced apoptosis in a genetically de-
fined subgroup of cells, derived from ABC-DLBCL, bear-
ing wild-type TP53 and mutations in MYD88, CD79B
and/or CARD11 [407]. OTX015 targets and inhibits ca-
nonical NF-κB, TLR and JAK/STAT3 signaling pathways,
as well as c-MYC- and E2F1-regulated genes in DLBCL in
vitro and in vivo [407]. As already mentioned above, inhib-
ition of BRD2 and BRD4 by CPI203 and JQ1 could also
inhibit the oncogenic NF-κB activity and kill ABC-DLBCL
cells [239]. Surprisingly, this effect seems to be independ-
ent of c-MYC since ectopic provision of c-MYC did not
rescue ABC-DLBCL cells from JQ1 toxicity [239]. Re-
markably, Eμ-Brd2 transgenic mice developed predom-
inately ABC-like DLBCLs [408]. Confirming previous
preclinical studies [398, 399], Boi M. et al. also showed
that BET bromodomain inhibition by OTX015 in-
creases rituximab sensitivity in DLBCL cells [407]. At
least four small-molecule bromodomain inhibitors of
BET are in ongoing oncology/hematology early phase I
clinical studies (CPI-0610, NCT01949883; GSK525762,
NCT01587703; OTX015, NCT01713582 and TEN-010,
NCT01987362), which include relapsed/refractory
DLBCL (CPI-0610; NCT01949883) (Additional file 1:
Table S2). The first results from a phase I study with the
orally available BET bromodomain inhibitor OTX015
have been reported with clinical responses in both
leukemia and B-cell lymphoma patients in the absence of
major toxicities [409, 410].
Of interest, a recent study performed by Lu J. et al.
showed that JQ1 and OTX015 can lead to BRD4 protein
accumulation over time in Burkitt lymphoma (BL) cells
and incomplete c-MYC suppression in vitro [411].
Whether these effects may also occur in DLBCL remain
to be investigated. Remarkably, three recent studies
provided a novel strategy, which can circumvent these
limitations by generating bifunctional phthalimide or
VHL-ligand-conjugated versions of JQ1 and OTX015
[411–413]. Lu J. and colleagues designed a hetero-
bifunctional proteolysis targeting chimera (PROTAC),
ARV-825, by connecting the small-molecule BRD4
binding moiety OTX015 to the E3 ligase cereblon
binding moiety of pomalidomide that recruits BRD4
and BRD2 to the E3 ubiquitin ligase cereblon, leading
to fast, efficient, and prolonged degradation of BRD4
and BRD2, effective suppression of c-MYC signaling,
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inhibition of cell proliferation and apoptosis induction
in BL in vitro [411]. In the second study, Winter G.E.
et al. generated a bifunctional thalidomide-conjugated
version of JQ1, termed dBET [412]. Treatment of acute
myeloid leukemia (AML) cells with dBET1 induced
highly selective cereblon-dependent protein degrad-
ation of BET family members in vitro and in vivo,
resulted in transcriptional downregulation of MYC,
induction of antiproliferative responses in leukemia
cells in vitro and delayed proliferation and leukemia
progression in mice, without toxicity, thus underscoring
the potential clinical utility of this approach [412].
Moreover, treatment with dBET1 or ARV-825 induced
a superior apoptotic response compared with JQ1 or
OTX015, respectively in primary AML or BL cells
[412]. Pharmacologic destabilization of BRD4 in vivo
also resulted in improved anti-tumor efficacy in a hu-
man leukemia xenograft compared to JQ1, highlighting
the potential superiority of BET degradation over BET
bromodomain inhibition [412]. Moreover a third study
using a BET-specific PROTAC, termed MZ1, that
tether JQ1 to a ligand for the E3 ubiquitin ligase VHL,
demonstrated preferential degradation of BRD4 over
BRD2 and BRD3 at low concentrations and did not
observe any degradation of JQ1-specific off-targets by
MZ1, thus point to a more BRD4-selective pharmaco-
logical profile of BET specific PROTACs compared
with pan-selective BET inhibitors JQ1 or OTX015
[413]. Taken together, cereblon-based PROTACs may
therefore provide a better and more efficient strategy
in targeting BRD4 and BRD2 than traditional small-
molecule inhibitors [411, 412]. This chemical strategy for
controlling target protein stability of BRD proteins may
also have broad implications for therapeutically targeting
previously intractable proteins in DLBCL [412].
Inhibition of PRPS2 in the c-MYC-driven subtype of
DLBCL-NOS
Using a mouse model of c-MYC-driven B-cell lympho-
magenesis, a recent study uncovered the mechanism by
which c-MYC coordinates the nexus between nucleotide
metabolism and protein biosynthesis. The authors found
that the single rate-limiting enzyme, phosphoribosyl-
pyrophosphate synthetase 2 (PRPS2), promotes in-
creased nucleotide biosynthesis in c-MYC-transformed
cells [414]. Remarkably the levels of PRPS2 are specif-
ically increased in c-MYC-driven lymphomagenesis
and this upregulation tightly correlates with eukaryotic
translation initiation factor 4E (eIF4E) expression, which
was also directly induced by c-MYC [414]. Moreover, the
authors also demonstrated that loss of PRPS2 in the Prps2
knockout mouse background is synthetically lethal in c-
MYC-transformed human and mouse cell lines, but
knockout of Prps2 did not affect wild-type cells or mice
[414]. Depletion of PRPS2 levels by siRNA in c-MYC-
driven B-cell lymphomas improved survival and induced
complete tumor regression in 30 % of mice, strongly
indicating that protein and nucleotide biosynthesis con-
trolled by PRPS2 is crucial for c-MYC-driven tumorigen-
esis [414]. Together, PRPS2 might be a promising and
effective druggable target in c-MYC-driven subtype of
DLBCL-NOS.
Reactivation of the pro-apoptotic TGF-β-SMAD pathway
through inhibition of DMNTs in relapsed/refractory GCB
and ABC-DLBCL-NOS
Several recent studies identified the transforming growth
factor-β (TGF-β)-SMAD pathway as a critical target in re-
lapsed/refractory DLBCL [415–418]. By profiling genome-
wide DNA methylation at single-base pair resolution in
thirteen DLBCL diagnosis-relapse sample pairs and in a
GCB-DLBCL cell line, Pan H. et al. identified a relapse-
associated DNA methylation signature based on consist-
ently differentially methylated regulatory elements be-
tween diagnosis and relapsed pairs [418]. This signature
was linked with specific genes and pathways, including the
pro-apoptotic TGF-β-receptor-SMAD pathway suggested
to play an important role in relapse of DLBCL [418].
These data confirm a previous study indicating that
methylation aberrations of TGF-β receptor activity
pathway-associated genes might be involved in relapse
and chemoresistance in DLBCL [417]. Pan H. et al.
demonstrated that prolonged exposure to low-dose DNMT
inhibitors (DNMTi) reprogrammed chemoresistant GCB-
and ABC-DLBCL cells to become doxorubicin sensitive
in vivo [417]. Recurrent hypermethylation of the promoter
region and reactivation of SMAD1 was a critical
contributor and required for chemosensitization [417].
A subsequent phase I clinical pilot study evaluating
the priming by DNMT inhibitor azacytidine (AZA)
followed by standard R-CHOP in high-risk patients
with DLBCL showed a very high rate of complete re-
mission (92 %) and confirmed SMAD1 demethylation
and chemosensitization [417]. AZA and 5-aza-2′-deoxycy-
tidine/decitabine (5-AZA/DAC) mainly inhibit DNA
methyltransferases DMNT1 and DMNT3 resulting in
the re-expression of tumor-suppressor genes [419, 420].
Both studies are in line with a previous report demon-
strating that escaping from TGF-β-SMAD5-mediated
growth inhibition through microRNA-155-mediated
inhibition of SMAD5 is critical to relapse of DLBCL
[415, 416]. Together these studies delineate a personal-
ized therapeutic strategy for the clinical use of
DNMT inhibitors as activator of the pro-apoptotic
TGF-β receptor-SMAD pathway in relapsed/refrac-
tory GCB- and ABC-DLBCL. Two recent phase I
studies evaluating the efficacy and safety of decita-
bine in combination with the HDACi vorinostat or
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valproic acid in patients with relapsed/refractory B-
cell lymphoma, including DLBCL has been recently
completed and are pending announcement of the
results (NCT00109824, NCT00275080) (Additional file 1:
Table S14).
Treatment of relapsed/refractory DLBCL-NOS with
antibody drug-conjugates targeting CD19, CD22, CD30 or
CD79B positve tumors
Antibody drug-conjugates (ADCs), in which cytotoxic
drugs are linked to antibodies targeting antigens on
tumor cells, represent promising novel agents for the
treatment of malignant B-cell lymphomas. ADCs use
antibodies to deliver a potent cytotoxic compound se-
lectively to specific antigen expressing malignant cells,
thereby maximizing drug delivery while limiting by-
stander effects of traditional cytotoxic agents, thus im-
proving the specificity and efficacy of chemotherapeutic
agents. Over the past several years, the use of ADCs as
targeted chemotherapies has successfully entered clinical
practice. Most of ADC developed for B-cell malignancies
target CD19 or CD22 [421, 422]. CD19 is the earliest
differentiation antigen of the B-cell lineage and uni-
formly expressed on all types of B-lymphocytes and the
vast majority of B-cell malignancies but not on other
normal cells, thereby representing an attractive target in
B-cell malignancies, including DLBCL [423, 424]. CD19
is a transmembrane protein that forms a signaling
complex together with CD21, CD81 and CD225, which
decreases the threshold for the activation of B cells me-
diated by the BCR [425]. There are already at least seven
distinct ADCs in preclinical and clinical studies, evaluat-
ing their efficacy in DLBCL, including relapsed/refrac-
tory DLBCL: SAR3419 [426, 427], MEDI-551 [421],
inotuzumab-ozogamicin (INO/CMC-544) [428–430],
moxetumomab-pasudotox (HA22, CAT-8015) [421, 431],
brentuximab-vedotin (ADCETRIS) [432], pinatuzumab-
vedotin (DCDT2980S) [432] and polatuzumab-vedotin
(DCDS4501A) [433] (Additional file 1: Table S7).
SAR3419 is an anti-CD19 antibody conjugated to the
cytotoxine Maytansine DM4, a potent inhibitor of tubu-
lin polymerization and microtubule assembly [421, 422].
Two recent early phase I multi-dose-escalation safety
and pharmacokinetic studies evaluating SAR3419 in pa-
tients with relapsed/refractory DLBCL provided prelim-
inary evidence for promising clinical activity in relapsed/
refractory DLBCL and demonstrated that SAR3419 can
be safely administered to patients with relapsed/refrac-
tory DLBCL (Additional file 1: Table S7) [426, 427].
Another CD19-specific ADC currently evaluated in an
ongoing phase I study in relapsed/refractory DLBCL is
SGN-CD19A (NCT01786135, Additional file 1: Table
S7). SGN-CD19A is an affinity-optimized monoclonal
anti-CD19 antibody linked to the microtubule disrupting
agent monomethyl auristatin E (MMAE) [434]. An in-
terim analysis of this phase I study showed promising
activities in patients with relapsed or refractory DLBCL;
with an ORR of 35 % a CR of 20 % and a PR of 16 %
[434, 435]. Antitumor activity appeared to be higher in
relapsed DLBCL with an ORR of 55 %, a CR of 32 % and a
PR of 23 % [434, 435]. MEDI-551, an affinity-optimized
and afucosylated monoclonal anti-CD19 antibody with
enhanced antibody-dependent cellular cytotoxicity
(Additional file 1: Table S7). Inotuzumab-ozogamicin is an
affinity-optimized monoclonal anti-CD22 antibody linked
to the DNA damaging toxin N-acetyl-γ-calicheamicin
dimethyl hydrazide (CalichDMH) [430]. Calicheamicin
binds to DNA in the minor groove and introduces
double-strand DNA breaks, leading to G2/M arrest and
subsequent cell death [430]. Promising anti-tumor re-
sponses were observed in early stage clinical trials,
where inotuzumab ozogamicin was administered ei-
ther as single-agent or in combination with rituximab
[430]. However, subsequent phase II studies evaluating
inotuzumab-ozogamicin with rituximab in patients
with high-risk relapsed/refractory DLBCL showed
mixed results in patients with high-risk relapsed/
refractory DLBCL [428, 429]. The observed activities
were in one study less than that seen with other stand-
ard salvage regimens for transplant eligible patients
with DLBCL [428, 429]. In the first phase II study
inotuzumab-ozogamicin has shown an ORR of up to
74 % and a CR of up to 50 % [429], while in the second
phase II study, the observed activity of inotuzumab-
ozogamicin was rather modest with an ORR of 40 %
and CR of 21 % (Additional file 1: Table S7) [428].
Ongoing phase II trials in CD22 expressing DLBCLs
are examining inotuzumab-ozogamicin as part of
chemotherapy combination regimens (Additional file
1: Table S7). An additional CD22-specific ADC under
investigation is moxetumomab-pasudotox (HA22/BL22),
an affinity-optimized monoclonal anti-CD22 antibody
linked to a synthetic ADP-ribosylating Pseudomonas
exotoxin (PE38) [421, 422]. PE38 exerts its cytotoxic effect
on cells by mono-ADP-ribosylating elongation factor 2,
thereby inhibiting protein synthesis and leading to cell
death [422]. A recent phase II study evaluating the efficacy
and safety of moxetumomab pasudotox in patients with
relapsed/refractory B-cell lymphoma, including DLBCL
has been recently completed and is pending announce-
ment of the results (NCT01030536). Another promising
ADC currently being tested in clinical trials in re-
lapsed/refractory B-cell lymphoma, including DLBCL
is brentuximab-vedotin (ADCETRIS). Brentuximab-
vedotin is a human CD30-specific antibody-drug
conjugate, which consists of the chimeric monoclonal
anti-CD30 antibody SGN-30 conjugated to the synthetic
microtubule disrupting agent monomethyl auristatin E
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(MMAE) [421]. After binding to CD30 on the tumor cell
surface, brentuximab-vedotin internalizes leading to re-
lease of MMAE via proteolytic cleavage and induction of
cell-cycle arrest and apoptosis [421]. CD30, part of the
tumor necrosis factor (TNF) receptor family, is an ideal
target for ADC-based therapy in DLBCL. CD30 is variably
expressed in approximately 20-30 % of DLBCL, with a
higher frequency in non-GCB-DLBCL [436–438]. A phase
II study, evaluating the efficacy of brentuximab-vedotin in
relapsed/refractory CD30- expressing NHL, showed sig-
nificant activity as single-agent in relapsed/refractory
DLBCL with an ORR of 44 %, CR of 17 % and with a
median duration of 16.6 months thus far [432] (Additional
file 1: Table S7). Ongoing phase I and phase II trials in
CD30 expressing DLBCLs are examining brentuximab-
vedotin after autologous stem cell transplantation, as
part of chemotherapy combination regimens (Additional
file 1: Table S7).
In two recent clinical phase I studies, Pfeifer M. et
al. demonstrated that pinatuzumab-vedotin and
polatuzumab-vedotin are active agents for the treatment
of patients with GCB, ABC and/or type-3 subtypes of re-
lapsed/refractory DLBCL, respectively (Additional file 1:
Table S7) [433]. Pinatuzumab-vedotin is an anti-CD22
ADC and polatuzumab-vedotin an anti-CD79B ADC that
are both conjugated to the microtubule-disrupting agent
MMAE [421]. Preclinical experiments unexpectedly
showed that both pinatuzumab-vedotin and polatuzumab-
vedotin are highly active and induced cell death in the vast
majority of ABC- and GCB-DLBCL cell lines [433],
suggesting that both can be used effectively in DLBCL
subtypes without the need for sophisticated molecular
testing [433, 439]. In a subsequent phase Ib study evaluat-
ing escalating doses of polatuzumab-vedotin in combin-
ation with rituximab in patients with relapsed/refractory
DLBCL, Palanca-Wessels M.C. et al. demonstrated that
polatuzumab-vedotin has an acceptable safety and toler-
ability profile in patients with relapsed/refractory DLBCL
[439]. Polatuzumab-vedotin showed significant activity in
relapsed/refractory DLBCL with an ORR of 56 % and
CR of 14.8 % [433, 439] (Additional file 1: Table S7).
Polatuzumab-vedotin is currently being studied in a
phase I trial as a replacement for vincristine in combin-
ation with immuno-chemotherapy (R-CHOP) in patients
with newly diagnosed DLBCL (NCT01992653) [439] as
well as in a phase II study in combination with rituximab
or obinutuzumab plus bendamustine in patients with
relapsed/refractory DLBCL NCT02257567 (Additional
file 1: Table S7).
Treatment of relapsed/refractory DLBCL-NOS with
anti-CD19 or anti-CD20 chimeric antigen receptor T cells
Another potential approach to target chemotherapy re-
fractory DLBCLs are chimeric antigen receptor-modified
autologous T cells (CAR T cells) targeted specifically to
antigens expressed by B-cell malignancies. T cells that
are genetically modified to express chimeric antigen re-
ceptors (CARs) recognizing the B cell-associated CD19
or CD20 molecules have emerged as a clinically feasible,
potentially potent therapeutic modality and appears to
be safe [440–446]. CARs are fusion proteins made up of
antigen recognition moieties and T-cell activation do-
mains [440, 447–450]. T cells expressing anti-CD19 CARs
are activated in a CD19-specific manner and recognize
and kill CD19+ primary malignant B cells [440, 441, 443,
451–453]. The CAR T cell based immunotherapy ap-
proach serves as a form of adoptive T-cell immunotherapy
[440, 454]. For a detailed description of CAR T-cell based
therapies, the readers are referred to the recent excellent
reviews [440, 441, 443].
Studies of CAR T cells have mainly been performed in
multiple myeloma, chronic lymphocytic leukemia and
acute lymphocytic leukemias [440–446]. Initial studies
on patients with relapsed DLBCL treated with anti-
CD20 or anti-CD19 CAR T cells were not very success-
ful, most likely due to a cellular anti-transgene immune
response in some of the patients [443, 455]. Moreover
previous studies of anti-CD19 CAR T cells showed that
multiple patients with indolent B-cell malignancies had
specific depletion of normal B cells and lengthy remis-
sions [456–458]. However, interim results of an ongoing
study performed by Kochenderfer J.N. et al. on heavily
pre-treated patients showed the first patients, which
obtained complete remissions (CRs) in chemotherapy-
refractory DLBCL after receiving anti-CD19 CAR T cells
[459, 460]. Using a significantly changed anti-CD19
CAR T cell production process and modified clinical
treatment protocol four of the seven evaluable patients
with DLBCL obtained CRs, two obtained PRs, and one
had stable disease (SD) after infusion of CAR T cells
[460] (Additional file 1: Table S8). Infusion of anti-CD19
CAR T cells was associated with significant but only
transient toxicity [460]. In addition, preliminary findings
from an ongoing phase IIb study (NCT02030834) evalu-
ating the safety and efficacy of the anti-CD19 CAR-T
cells in patients with relapsed or refractory DLBCL and
follicular lymphoma showed an ORR of 50 %, a CR of
45 % and a PFS of 37 % at median follow up 6 months
with acceptable toxicity in the 12 evaluable patients
with relapsed or refractory DLBCL (Additional file 1:
Table S8) [461].
Several additional phase I/II studies with CAR T cells
directed against CD19+ B cells are currently being per-
formed in patients with advanced relapsed/refractory
DLBCL after autologous stem cell transplant (NCT
01865617, NCT01475058, NCT02431988, NCT02348216,
NCT01840566 and NCT02445248) (Additional file 1:
Table S8). Moreover, a preliminary report of an ongoing
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pilot study (NCT01735604) evaluating the efficacy and
safety of anti-CD20 CAR T cells in patients with chemo-
therapy refractory advanced DLBCL showed that five out
of six evaluable patients experienced objective responses
in this pilot trial [446] (Additional file 1: Table S8). Thus,
CAR T cell based immunotherapy approaches represent a
promising novel strategy in the treatment of patients with
relapsed/refractory DLBCL.
Acquired (secondary) resistance to novel experimental
drugs
Unfortunately, several reports already demonstrated that
a small proportion of patients with B-cell malignancies
had a relapse during therapies with novel experimental
agents, such as ibrutinib, lenalidomide or bortezomib
[280, 462–464]. However, the molecular mechanisms of
resistance are poorly understood. For instance, recent
studies showed that up to 10 to 15 % of patients with
chronic lymphocytic leukemia (CLL) [462] or mantle cell
lymphoma (MCL) [463] treated with ibrutinib have had
a partial response (relapse) due to acquired (secondary)
drug resistance to ibrutinib during therapy. A subse-
quent study demonstrated that the observed acquired
resistance to ibrutinib in CLL was due at least in part
to recurrent mutations in BTK and phospholipase Cγ2
(PLCγ2) genes [465].
A cysteine-to-serine mutation in BTK at the binding
site of ibrutinib was identified in five patients and three
distinct mutations in PLCγ2 were identified in two pa-
tients [465]. Functional analysis showed that the C481S
mutation of BTK confers resistance to ibrutinib by
preventing irreversible drug binding. The R665W, and
L845F mutations in PLCγ2 are all potentially gain-of-
function mutations that allow autonomous B-cell-
receptor activity that is independent of BTK [465].
PLCγ2 is one of the key regulators of the B-cell receptor
signaling pathway [110]. Thus, the investigation of the
molecular mechanisms underlying the observed secondary
resistance to novel agents is of great importance. The
identification of novel drug targets that may lead to novel
alternative therapeutic strategies for patients with drug
resistant relapsed/refractory DLBCL is urgently needed to
overcome the arising resistance to novel experimental
agents. Molecular profiling of advanced cancer patients
participating in targeted therapy trials will be import-
ant to identify mutational signatures that may predict
for drug sensitivity and guide rational patient specific
drug combinations.
Tumor microenvironment (TME)/cell adhesion–mediated
drug resistance
It is increasingly apparent that differences in the local
tumor microenvironment (TME) affect survival of pa-
tients with DLBCL after treatment with chemotherapeutic
regimens [217, 218, 466]. The local TME seems to be an
essential player for the development and disease
progression of DLBCL and to dictate lymphoma cell
growth, response to therapy, as well as resistance of
residual lymphoma cells to chemotherapeutic agents [217,
466]. It is thought that specific niches within the DLBCL
tumor microenvironment provide sanctuary for subpopu-
lations of DLBCL cells through dynamic stromal cell-
tumor cell interactions [217, 466]. Adaptive, reciprocal
signaling circuits between tumor cells and supportive
fibroblast-like stromal cells of TME via positive feed-
back/feed-forward loops have been suggested to be
essential for the observed TME or environmental-
mediated drug resistance (EMDR) [217, 218]. EMDR
in resident DLBCL cells has been suggested to result
in small foci of residual disease that subsequently
develop complex genetic or epigenetic means of ac-
quired resistance in response to the selective pressure
of therapy [217, 466]. However, the exact molecular mech-
anisms involved in EMDR are not yet fully understood in
DLBCL and remain to be elucidated.
The dynamic interplay between tumor cells and sup-
portive fibroblast-like stromal cells, mediated through
consists of extrinsic signals, which are generated by
the lymphoma microenvironment and intrinsic factors
encompassing signaling determinants of cell cycle and
pro-survival pathways [217, 218, 466]. For instance, it
has been recently suggested that chronic and tonic
BCR signaling is a central hub for the integration be-
tween the extrinsic B cell microenvironment and the
intrinsic signaling pathways in B-cell lymphomas [218].
For a detailed review about TME induced chronic BCR
signaling in B-cell lymphomas the readers are referred to
the recent excellent review [218]. In addition, autocrine
and/or paracrine IL6 and IL10, two putative DLBCL
survival cytokines, have also been proposed to play an
important role in EMDR [217, 218]. Several studies
documented that higher levels of serum IL6 and/or IL10
in patients with more aggressive disease correlated with
unfavorable prognostic factors included in the inter-
national prognostic index (IPI) [323, 467]. As already dis-
cussed, IL10 has been recently shown to enhance survival
of primary DLBCL cell lines in vitro [322, 323]. Signaling
downstream of IL6 and IL10 in B-cell lymphoma involves
primarily activation of JAK1/JAK2-STAT3 axis and to a
lesser extend the JAK1/JAK2-STAT1 or TYK2-MAPK-
STAT1 axis [313, 322, 323, 468]. Activation of the JAK1/
JAK2-STAT3 and JAK1/JAK2-STAT1 signaling cascades
often results in upregulation of survival factors such as
BCL2 family members [313, 322, 323, 468], IFN/NF-κB
signaling-related immune modulatory factors such as PD-
1/PD-L1 [341–343], and/or drug resistance related factors
such as DTX3L or ARTD9 [116, 469–471]. Both DTX3L
and ARTD9 have been shown to be involved in drug
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resistance in HR- DLBCL associated with a R-CHOP
chemotherapy-induced microenvironment gene expres-
sion signature [469, 470, 472], see next sections. For a
detailed review about TME or environmental-mediated
drug resistance the readers are referred to the recent
excellent reviews [217, 218, 466].
Novel potential drug targets in relapsed and/or chemo-
refractory HR-subtypes of GCB-, ABC- and type-3-DLBCL-NOS
Except for the antibodies pidilizumab and nivolumab, both
targeting PD-1, no small molecule inhibitors, which specific-
ally target relapsed/refractory HR-subtypes of DLBCLs are
yet under investigations. However, several recent studies
from different labs identified several candidates, including
STAT1, the E3 ubiquitin ligase DTX3L (also known as
B-lymphoma and BAL-associated protein (BBAP)) and
the B-aggressive lymphoma protein and mono-ADP-
ribosyltransferase ARTD9 (also known as BAL1 or
PARP9), which may be essentially required for the ob-
served chemotherapy resistance in HR-DLBCL and also
play a role in editing or inhibiting the host immune
response against HR-DLBCL [469, 470, 473]. These studies
strongly suggest that STAT1, ARTD9 and DTX3L might
serve as novel druggable targets in HR-subtype DLBCL
[469, 470, 473]. Moreover, a recent study using an Eμ-c-Myc
driven B-cell lymphoma tumor mice model, demonstrated
that the ARTD9-related ARTD8 (also known as B-
aggressive lymphoma protein BAL2 or PARP14) is over-
expressed in mouse B-lymphoma cells and can facilitate
c-MYC driven B-lymphoid oncogenesis [474].
Both ARTD9 and the closely related ARTD8 belong to
the intracellular Diphteria toxin-like glutamate/aspartate-
specific mono- and polymerizing-ADP-ribosyltransferase
(ARTD) superfamily (also known as PARPs) [475–477] that
also includes the ARTD9-related B-aggressive lymphoma
protein and active mono-ADP-ribosyltransferase ARTD7 (also
known as BAL3 or PARP15) [475, 476, 478–480], ARTD7,
ARTD8 and ARTD9 contain several evolutionary conserved
macrodomains [475, 476, 478–480], which have been recently
shown to act as binding modules for free and protein-linked
mono- or poly-ADP-ribose [475, 481–483]. A schematic
comparison of the domain architecture of the macrodomain
containing ARTD (PARP) family members ARTD7-9 is
presented in Fig. 4. Both, ARTD8 and ARTD9 have been
shown to interact with ARTD1 [471].
ARTD1, also known as PARP1, is the founding member of
the ARTD/PARP family and has been suggested to act as a
crucial oncogenic factor in various solid cancer types [484–
488]. Numerous preclinical and clinical studies provided pre-
liminary evidence that potent ARTD/PARP inhibitors with a
high specificity towards ARTD1 and ARTD2, such as ola-
parib and veliparib (ABT-888) are promising drugs in the
treatment of various solid cancer types [484, 485]. ARTD1/
2-specific inhibitors are not only effective as single-agents to
selectively kill DNA repair deficient solid cancer tumors (i.e.,
BRCAness tumors) but also as radio- and chemosensitizers
of DNA repair proficient solid cancer tumors [484, 485].
Recent preclinical studies provided preliminary evidence that
the ARTD1/2 inhibitors may also target DNA DSB repair
deficient B- and T-lymphoid cells [489]. Several clinical trial
phase I/II studies investigating the roles of ARDT1 and
ARTD1/2 inhibitors in DLBCL are currently ongoing
(Additional file 1: Table S9). For a detailed description of the
oncogenic functions of ARTD1 and ARTD2, the readers are
referred to the recent excellent reviews [488, 490, 491].
Inhibition of STAT1 in the HR-subtype of GCB-, ABC- and
type-3-DLBCL
STAT1 signaling is mainly activated by IFNγ and mediated
through activation of IFNγ receptor and receptor-associated
kinases JAK1 and JAK2 [492]. However, STAT1 can also be
activated by other stimuli such as IL6 and IL10, which play
crucial roles in tumor survival and progression [493–496].
Ligand-mediated activation of JAK1, JAK2 or tyrosine
kinase 2 (Tyk2) lead to tyrosine phosphorylation of STAT1
on Y701, homodimerization and translocation of STAT1 to
the nucleus [497–501]. JAK1/2-mediated phosphorylation
of STAT1 phosphorylation on Y701 enhances the nuclear
shuttling by triggering the nuclear retention of the shuttling
STAT1α and STAT1β, which are kept in the nucleus until
tyrosine dephosphorylation occurs [498, 501, 502]. STAT1
exists in two mayor isoforms, the full-length isoform
STAT1α, which mainly acts as a sequence specific tran-
scriptional activator of gene expression and STAT1β, lack-
ing a complete transactivation domain [503]. STAT1β can act
both as a transcriptional activator and repressor or antagonist
of STAT1α, depending on the stimuli and cell type [504–508].
Subsequent nuclear phosphorylation on S727 in the transacti-
vation domain of STAT1α can also occur independent of
STAT1 tyrosine phosphorylation [509]. For instance, BCR sig-
naling enhances S727 phosphorylation through calcium
mobilization and activation of multiple serine kinase pathways,
resulting in increased transcriptional activation of STAT1 tar-
get genes [510].
STAT1 has been initially considered to act exclusively as
tumor suppressor and key regulator of the surveillance of
developing tumors, primarily by activating growth-inhibitory
and pro-apoptotic signaling in tumor cells, mainly mediated
by IRF1 [511–514]. However, recent studies identified STAT1
as a proto-oncogene product in a variety of cancers [468, 470,
471, 515–518]. The oncogenic activity strongly correlated with
abnormal expression of STAT1 and pSTAT1(pY701 and/or
pS727) in these tumors [468, 470, 471, 515–518].
Constitutively active STAT1 promotes cell survival, invasion,
metastasis, chemotherapy and/or radiation resistance in
multiple types of solid cancers [468, 470, 471, 515–523]. Sev-
eral studies have demonstrated that chemotherapeutic agents,
such as doxorubicin or other anthracyclines enhance the
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expression of STAT1, its activation and the nuclear
localization of phosphorylated STAT1 in chemotherapy-
resistant solid cancer cells [516–518, 520, 524]. STAT1 has
therefore been suggested as a potential target for radio- and
chemosensitization of aggressive solid tumors that constitu-
tively overexpress IFNγ/STAT1-dependent pathways [518].
Previous reports provided first evidence that a subset of
STAT1- dependent antiviral gene products can simultaneously
have radio- and chemo-protective pro-survival functions and
are associated with oncogenesis in solid cancers [518].
Recent studies indicate that STAT1 can also act as a
proto-oncogene product in hematopoietic cells and acceler-
ate the development of T- and B-lymphoid malignancies
[468, 470, 525]. Constitutive activation of STAT1 has been
demonstrated in both acute and chronic leukemia [468,
470, 525]. For instance STAT1 promotes B-lymphoid
leukemia development, at least in part by maintaining high
MHC class I expression independently of IFN signaling
[525]. Upregulation of MHC class I molecules has been
suggested to represent a general mechanism to escape
tumor surveillance [525]. A subsequent study identified an
oncogenic TYK2-STAT1 pathway in T-cell acute lympho-
blastic leukemia (T-ALL) cell lines, mediated through
gain-of-function TYK2 mutations or activation of IL10 re-
ceptor signaling, that leads to the upregulation of BCL2
and T-ALL cell survival [468]. IFNγ/STAT1 signaling has
therefore been suggested to exhibit both pro- and antitu-
mor properties, depending on the context and cancer type
[497]. Initially, IFNγ/STAT1 signaling helps protecting the
host from tumor formation and development (immune
surveillance), but subsequently IFNγ can also promote the
tumors to resist attack (immunoediting) and escape by
Darwinian evolution [473, 497, 526].
Our own recent study implies that STAT1 might also acts
as an oncogene in DLBCLs and be required for proliferation,
survival and chemoresistance of HR-subtypes of GCB- and
ABC-DLBCL [470]. We observed increased constitutive
phosphorylation of STAT1 on Y701 and S727 in the HR-like
GCB-DLBCL cell line SUDHL7 and to a minor extend in
the pSTAT3(Y705) positive BCR-subtype ABC-DLBCL
cell lines OCI-Ly3 and OCI-Ly10 [470]. SUDHL7 has
been suggested to represent a bona fide model cell line
for HR-subtype GCB-DLBCL [470]. Analysis of primary
DLBCL samples revealed positive nuclear co-staining for
the oncogene product IRF2, STAT1-pY701 and STAT1-
pS727 in 18 % of the primary DLBCL tumor samples
analyzed, while benign tissue did not show this pattern in
any case [470]. Our siRNA-STAT1-knockdown studies
revealed that STAT1 is required for growth, survival and
chemoresistance of HR-subtype GCB-DLBCL cells in
vitro. STAT1β together with ARTD9 synergistically down
regulated the transcriptional expression of tumor suppres-
sor IRF1, while STAT1α together with ARTD9 up-
regulated the expression of the proto-oncogene IRF2
[470]. IRF2, an antagonist of IRF1 is known to act as an
oncogene in various types of cancer [527]. Recent stud-
ies showed that overexpression of STAT1β, the antagon-
istic isoform of STAT1α increases the growth rate of
cells and their resistance to drug-induced apoptosis and
cell cycle arrest by repressing STAT1α target genes such
as p21 and IRF1 in human B cells [505]. Our study
provides first evidence that STAT1β, together with
ARTD9 may negatively regulate a tumor suppressor
network (see also next section). Moreover, in line with
the observed activity in B-cell leukemia STAT1 might also










Fig. 4 Schematic comparison of the domain architecture of the macrodomain-containing ARTD family members ARTD7, ARTD8 and ARTD9 Domain
architecture of the human diptheria toxin-like macro-domain containing mono-ADP-ribosyltransferases and ARTD family members ARTD7, ARTD8 and ARTD9.
The following domains are indicated: The diptheria toxin-like ART(D) domain is the catalytic core required for basal (mono-)ADP-ribosyltransferae (ART) activity.
The WWE domain is named after three conserved residues (W-W-E) and is predicted to mediate specific protein-protein interactions in ubiquitin- and
ADP-ribose conjugation systems [555, 636, 637]. The macro or A1pp domains are structurally related to the catalytic domain of enzymes that process
ADP-ribose-1-phosphate, a reaction product derived from ADP-ribose 1-2′cyclic phosphate generated by TpT [638]. The macrodomain can serve
as ADP-ribose or O-acetyl-ADP-ribose binding module [638]. RRM is an RNA and poly-ADP-ribose-binding/recognition motif [639]
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immunogenicity (immunoediting). Future knockdown or
ectopic (co)-overexpression xenograft studies need to be
carried out in order to determine whether absence or
overexpression of STAT1α and/or STAT1β negatively or
positively affects chemoresistance and tumor growth of
HR-DLBCL in vivo.
Together, STAT1 may serve as a novel potential drug
target for treatment of high-risk relapsed and/or refrac-
tory DLBCLs with a brisk, but ineffective, host immune/
inflammatory response and IFNγ signature. It remains to
be investigated whether constitutive overexpression and/
or phosphorylation of STAT1 alone, independent of
ARTD9 or DTX3L, may also serve as novel useful prog-
nostic biomarker for poor survival of fatal high-risk re-
lapsed/refractory DLBCL. A model for the postulated
functions of STAT1 in DLBCLs is shown in Fig. 5. Sev-
eral clinical phase I/II studies, evaluating the safety and ef-
ficacy of JAK1 and JAK2 inhibitors in patients with
relapsed/refractory B-cell lymphoma, including DLBCL
are ongoing (NCT01905813, NCT01431209) (Additional
file 1: Table S6) or in planning [109, 317, 318].
Inhibition of ARTD9 in HR- and BCR-subtype of GCB-,
ABC- and type-3-DLBCL-NOS
The inactive mono-ADP-ribosyltransferase ARTD9 is a
nucleocytoplasmic shuttling protein that has been iden-
tified as a potential risk-related gene product in fatal
high-risk DLBCLs [469, 472]. ARTD9 is constitutively
overexpressed in high-risk chemoresistant subsets of
DLBCL tumors associated with a brisk, but ineffect-
ive IFNγ-mediated host inflammatory response [469,
472, 473]. The large majority of ARTD9-positive HR-
subtypes were classified as ABC-DLBCL [469, 472].
Recent studies demonstrated that overexpression of
ARTD9 is mainly mediated by (IFNγ)-JAK1/STAT1
and/or autocrine (IL6)-JAK1/STAT3 signaling [469–471,
528]. In line with these observations and with the
expression pattern in DLBCL tumors in vivo, ARTD9
is mainly overexpressed in pSTAT1(Y701/S727)-posi-
tive HR-subtype GCB-DLBCL cells and pSTAT3(Y705/
S727)-positive BCR-subtype ABC-DLBCL cells weekly
expressing pSTAT1(Y701/S727) [470]. Thus, overex-
pression of ARTD9 in high-risk tumors might also be
modulated by differences in tumor microenvironment
or relevant signaling pathways. Interestingly, overex-
pression of ARTD9 could not be observed so far in
other pSTAT1(Y701/S727)-positive or pSTAT3(Y705/
S727)-positive subgroups of DLBCLs such as T/
HRLBCL or PMLBCL, which molecular profiles resem-
ble (at least in part) those of HR-subtype DLBCL tu-
mors [46, 53–55, 116].
ARTD9 has been proposed to be associated with
lymphocyte migration and may promote the dissemin-
ation of malignant B cells in high-risk DLBCL in vivo
[469]. Moreover, doxocyclin-induced overexpression of
ARTD9 in an ARTD9-negative low-risk GCB-DLBCL
cell line led to the induction of a small subset of
IFN(γ)-related genes [469], thus provided preliminary
evidence that ARTD9 might play a direct role in IFN
signaling pathways [469]. Indeed, our own subsequent
study identified ARTD9 as a novel oncogenic survival
factor, which acts as a crucial negative and positive co-
regulator of IFNγ/STAT1 signaling and mediates prolif-
eration, survival and chemoresistance in HR-subtype
DLBCL cells [470]. Inactivation of ARTD9 through
siRNA- mediated depletion of ARTD9 not only inhib-
ited cell proliferation and survival but also reversed
chemoresistance in high-risk HR-subtype DLBCL cells
[470]. Our study showed that ARTD9 can inhibit the
IFNγ/STAT1-dependent anti-proliferative and pro-
apoptotic activities of tumor suppressor IRF1 while
simultaneously activating the STAT1/IRF2-mediated
anti-apoptotic-pro-survival pathways in HR-subtype
DLBCL cells [470]. ARTD9 acts as a repressor of the
transcriptional activation of IRF1 and TP53 expression
and thereby counteracts the IFNγ-dependent anti-
proliferative and pro-apoptotic IFNγ-STAT1-IRF1-
TP53 axis and induces an oncogenic switch in STAT1
from a tumor suppressor to an oncogene [470]. This
may explain why constitutive IFNγ-STAT1 signaling does
not lead to apoptosis but rather to survival and chemoresis-
tance in HR-subtype DLBCL cells. The observed ARTD9-
mediated down-regulation of tumor-suppressors IRF1 and
TP53 may also represent a novel molecular mechanism
inactivating the TP53/IRF1 pro- apoptotic pathway in high-
risk DLBCL expressing wild-type TP53 [470]. In addition,
ARTD9 simultaneously up-regulates the expression of
BCL2 and BCL6 and thereby activates additional anti-
apoptotic-pro-survival pathways [470]. The observed con-
comitant overexpression of BCL2 and BCL6 in the ARTD9
positive HR-subtype DLBCL cells also indicates that
ARTD9 blocks the BCL6-mediated repression of BCL2
[470], which is frequently disrupted in DLBCL [365].
Thus, our study provided first evidence that ARTD9
together with STAT1β may negatively regulate a
tumor suppressor network, while ARTD9 may con-
comitantly positively regulate a STAT1- dependent
and independent proto-oncogene network in HR-
subtype DLBCL [470]. It will be important to confirm
these in vitro observations in vivo through ectopic
overexpression of ARTD9 in xenograft DLBCL tu-
mors, alone or in combination with STAT1α and/or
STAT1β, respectively.
ARTD9 physically interacts with both isoforms of
STAT1, STAT1α and STAT1β through its macrodo-
mains in an ADP-ribosylation dependent manner
[470, 471]. Co-immunoprecipitation of endogenous BAL1
and STAT1 in presence of increasing concentration of
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ADP-ribose and subsequent immunoblot analysis for BAL1
and STAT1 revealed that free ADP-ribose could disrupt the
interaction between ARTD9 and STAT1 in a dose
dependent manner [470, 471]. Thus, the observed inter-
action of ARTD9 with STAT1α or STAT1β, respectively,
might be modulated in vivo through the levels of mono-
ADP-ribosylation on the corresponding STAT1 isoforms.
Our ADP-ribosylation analyses revealed that both STAT1α
and STAT1β isoforms could be mono-ADP-ribosylated in
vitro by ARTD8 and ARTD10 (unpublished observations).
However, we cannot exclude the possibility that the ob-
served interaction might be indirect and mediated through
a mono-ADP-ribosylated bridging factor. Thus, the exact
molecular mechanisms underlying the observed interaction
between STAT1 and ARTD9 as well as the exact functional
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Fig. 5 Proposed model for the postulated functions of STAT1 in HR-DLBCL-NOS. Chronic exposure to IFNs and chemotherapeutic
agents such as alkylating agents, topoisomerase inhibitors, HDAC inhibitors, or proteasome inhibitors, can lead to constitutive oncogenic
upregulation of STAT1 and interferon signaling genes (ISGs) during tumor development [515–518, 524, 640–643] and select tumor
clones resistant to a cytotoxic microenvironment and concurrently to genotoxic therapy [518]. The overall population of tumor cells
is sensitive to cytotoxic factors of microenvironment and committed to death because of the secretion of cytotoxic ligands by host
cells (T lymphocytes, B lymphocytes, tumor-associated macrophages, dendritic cells etc.) [518]. The majority of tumor cells are relatively
sensitive to radio- and/or chemotherapy. However, a small fraction of tumor cells (HR-DLBCL cells) constitutively express STAT1/ISGs and are resistant
to the cytotoxic microenvironment and genotoxic therapy. Oncogenic constitutive expression of STAT1 can activate the prosurvival secretome,
including the interleukines IL6 and IL10 [322, 468, 644] and in turn, can enhance selective advantages of surrounding tumor cells [518]. Moreover,
STAT1 pathway can be also activated in the context of IL6 and IL10 [322, 645], thereby generating auto-stimulatory feedback loops (IL6-IL16R-STAT1
and IL10-IL10R-STAT1). Thus, IFN/JAK pathway and chemotherapeutic agents may act in concert with other HR-DLBCL specific intrinsic signaling
pathways such as IL10/IL10R-JAK1-TYK2 and or IL6/IL6R-gp130-JAK1/2-TYK2 to induce chemotherapy resistance. In addition, oncogenic JAK/STAT1α-
autocrine signaling in HR-DLBCL causes enhanced expression of STAT1α dependent proto-oncogenes (i.e., DTX3L ARTD9, IRF2, MCL1, BCL2, BCL6),
thereby stimulating proliferation and survival pathways [470]. In addition, oncogenic STAT1α signaling helps the tumors to escape the attack by the
immune system (immunoediting) [473, 497, 526]. Conversely, STAT1β repress the transcriptional activation of anti-proliferative and pro-apoptotic genes
(including tumor the suppressors IRF1 and TP53) [470, 471] as well as genes involved in immune surveillance [473, 497, 526]. Adapted from REF: [470,
471, 518]. Abbreviations: HR-DLBCL host response DLBCL, ARTD ADP-ribosyltransferase Diphteria toxin-like, STAT signal transducer and activator of
transcription, ISG interferon stimulated gene, IL interleukin, JAK Janus kinase, TYK2 tyrosine kinase 2, IRF interferon response factor, BCL6 B cell
lymphoma protein 6, BCL2 B cell lymphoma protein 2
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remain to be investigated. The recent development of dis-
tinct ARDT7-, ARTD8- and ARTD10-specific ARTD inhib-
itors may help us in future to elucidate the ARDT
enzyme(s) required for the exact functional roles of the pro-
posed mono-ADP-ribosylation activity in DLBCL [529,
530]. In this regard, it will also be important to investigate
whether ectopic overexpression of ARTD9 wild-type or
ADP-ribose-binding mutant forms of ARTD9 in xenograft
DLBCL tumors may positively or negatively affect tumor
growth and metastasis in vivo. ARTD9 also interacted with
the IFNGR-receptor complex and thereby stimulated
directly or indirectly the kinase activity of JAK1/2 and
phosphorylation of STAT1 on Y701 [470, 471]. However,
the exact molecular mechanisms underlying these observa-
tions remain to be investigated.
ARTD9 may also be directly involved in editing or
inhibiting the IFNγ-dependent host immune response
against HR-subtype DLBCL either through its transcrip-
tional co-repressor activity and termination of IFNγ-
mediated gene expression and inhibition of the extrinsic
IFNγ-induced anti-proliferative and pro-apoptotic
STAT1-IRF1-TP53 axes or through its transcriptional
co-activator activity and induction of expression of the
NK/T-cell inhibitory molecules i.e., PD-1L and increasing
the resistance of IFNγ-treated tumor cells towards NK
cell- or lymphokine activated killer-mediated lysis [470].
IFNγ is typically secreted by activated, tumor-infiltrating
cytotoxic T lymphocytes and NK and NK/T cells [531,
532]. A proposed model for the postulated functions of
ARTD9 in DLBCL is presented in Fig. 6. Remarkably, our
study strongly suggests that ARTD9 (may be together with
DTX3L) acts both as a negative and positive co-factor in
transcription in HR-DLBCL. The observed antagonistic
transcriptional activities might be explained by the forma-
tion of different ARTD9-containing promoter-specific
co-repressor and co-activator complexes. In analogy to
other chromatin remodeling and transcriptional cofactors
such as the ARTD members ARTD1 or ARTD8, respect-
ively [533–536], and depending on the methylation status
of the corresponding promoters and/or enhancers,
ARTD9 might differentially interact either with STAT1α/
β- or other unknown factor-X-containing transcriptional
coactivator complexes (i.e., containing the co-activators
CBP/EP300, NCOA and/or BRG1 [537–539]) or with
STAT1β-homodimer- or other unknown factor-Y-containing
corepressor complexes (i.e., containing the co-repressors
MeCP, and NCORs [540, 541]). Promoters and/or enhancers
of genes involved in survival, proliferation, chemoresistance,
autocrine signaling as well as immunoediting are considered
as being hypomethylated in HR-DLBCL under these
conditions while the corresponding promoters and/or
enhancers of pro-apoptotic and anti-proliferative genes are
considered as being hypermethylated. Future studies are
required to decipher the composition of these distinct
ARTD9-STAT1 or ARTD9-X-factor co-repressor and co-
activator complexes.
Taken together, aberrant constitutive overexpression of
ARTD9 may not only serve as a novel useful prognostic
biomarker for poor survival of fatal high-risk relapsed/
refractory DLBCL but also as a novel rational future
drug target for treatment of high-risk relapsed/refractory
HR- (and BCR-) subtypes of DLBCL-NOS. The observed
macrodomain and mono-ADP-ribosylation-mediated inter-
action between ARTD9 and STAT1 not only indicates a
regulatory cross-talk between ARTD9 and other active
members of the ARTD family but also provide the rational
base for the development of macrodomain-specific small
molecules that can selectively disrupt ARTD9 complex for-
mations in ARTD9-positive relapsed/refractory HR-subtype
DLBCLs.
Inhibition of DTX3L in HR- and BCR-subtype of GCB-,
ABC- and type-3-DLBCL-NOS
The Deltex (DTX)-3-like E3 ubiquitin ligase DTX3L is
an active E3 ubiquitin ligase with C-terminal identity to
the Deltex (DTX) family member DTX3 [542, 543]. The
human DTX family of E3 ubiquitin ligases encompasses
six E3 ubiquitin ligases [542–546]. A schematic compari-
son of the domain architecture of the DTX family is
shown in Fig. 7. DTX3L was originally identified as a
binding partner of ARTD9 and as a novel risk-related
gene product in high-risk chemotherapy-resistant ag-
gressive forms of DLBCL [469, 542]. DTX3L is also
overexpressed in HR- and BCR- subtype DLBCLs and
at least in part associated with intrinsic IFNγ signal-
ing and constitutive activity of STAT1 [469, 470].
Similar to ARTD9, no overexpression of DTX3L
could be observed so far in T/HRLBCL or PMLBCL
[46, 53–55, 116]. In line with the observation that the
DTX3L and ARTD9 genes are located in a head-to-
head orientation on chromosome 3q21, sharing the
same bidirectional STAT1/IRF1 and STAT3-responsive
promoter [469–471], DTX3L is mainly overexpressed
in pSTAT1(Y701/S727)-positive HR-subtype GCB-DLBCL
cells and pSTAT3(Y705/S727)-positive BCR-subtype ABC-
DLBCL cells weekly expressing pSTAT1(Y701/S727) [470].
Several recent studies provided evidence that DTX3L
acts tightly together with ARTD9 in proliferation, che-
moresistance and survival of solid tumor cells, albeit
through different mechanisms [471, 547, 548]. For
instance, we could recently demonstrate that DTX3L to-
gether with ARTD9 forms a complex with STAT1 and
mediates together with ARTD8 and ARTD9 prolifera-
tion, chemoresistance and survival of CRPC-like meta-
static prostate cancer (mPCa) cells [471]. DTX3L and
ARTD9 act together as repressors of the tumor suppressor
IRF1 in mPCa cells [471]. Remarkably, DTX3L together
with STAT1 and STAT3 enhanced cell migration of mPCa
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cells in an ARTD9-independent manner [471] and has
been suggested to function in a non-canonical STAT1:
STAT3 heterodimer-mediated signaling pathway in mi-
gration of mPCa cells in vitro [471]. Thus, it is very
likely that DTX3L act also together with ARTD9 in the
same proliferation, cell survival and chemotherapy re-
sistance pathways in DLBCL. In analogy to the sug-
gested roles of ARTD9, DTX3L may also be directly
involved in editing or inhibiting the IFNγ-dependent
host immune response against HR-subtype DLBCL. It
will therefore be important to investigate whether ec-
topic overexpression of DTX3L xenograft tumors (alone
or simultaneously in combination with ARTD9 and/or
STAT1) may positively or negatively affect chemoresis-
tance, enhanced growth and/or metastasis of HR-


































































































Fig. 6 Proposed model for the postulated functions of ARTD9 and DTX3L in DLBCLs. ARTD9 and DTX3L act as novel oncogenic survival factors
in relapsed or refractory DLBCL. Constitutively active IL6/IL6R-JAK1-STAT3, oncogenic IFN/IFNGR-JAK1/2-STAT1 and/or IL10/IL10R-JAK1-TYK2-
autocrine signaling in HR-DLBCL causes overexpression of ARTD9 and DTX3L, which in turn, further stimulates the phosphorylation of STAT1
on Y701 and subsequently the enhanced expression of STAT1α dependent proto-oncogenes (i.e., ARTD8, ARTD9, DTX3L, IRF2, BCL6, BCL2).
Both ARTD9 and DTX3L might also enhance the transcription of DNA damage repair/response genes upon treatment of tumors with genotoxic
chemotherapeutic agents [548]. Conversely, ARTD9 and DTX3L repress together with STAT1β the transcriptional activation of tumor suppressor
IRF1 and TP53 [470, 471]. Overexpression of ARTD9 inhibits intrinsic and extrinsic IFNγ-STAT1-IRF1/p53-mediated cell death pathways while
simultaneously enhancing the STAT1-dependent IRF2-mediated proliferation and BCL6-BCL2 mediated survival pathways. As a consequence
ARTD9 induces an oncogenic switch in STAT1 from a tumor suppressor to an oncogene and mediates proliferation, survival and chemo-
resistance in HR-DLBCL. Pharmaceutical inhibition of ARTD9 in HR-DLBCL associated with constitutively active STAT1 signaling might
therefore reactivate the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1/p53 axes and reverses chemo-resistance in HR-DLBCL.
In addition, endogenous overexpression of DTX3L and/or ARTD9 might also be associated with lymphocytes migration and may promote
the dissemination of malignant B cells in high-risk DLBCL in vivo, potentially dependent on STAT3 or PI3K/AKT/mTORC1 signaling [471].
DTX3L and/or ARTD9 might form specific complexes with non-canonical STAT1:STAT3 heterodimers and activate a migration-specific
signaling and gene expression program in HR-DLBCL. Finally, oncogenic. ARTD9/DTX3L-STAT1α signaling might upregulate immunomodulatory
genes and may help the tumors to escape the attack by the immune system (immunoediting) [470, 471, 473]. Conversely, ARTD9 and DTX3L
together with STAT1β might repress the transcriptional activation of genes involved in immune surveillance [470, 471, 473]. Adapted from
REF: [470, 471]. Abbreviations: ARTD ADP-ribosyltransferase Diphteria toxin-like, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, STAT signal
transducer and activator of transcription, ISG interferon stimulated gene, IL interleukin, JAK Janus kinase, TYK2 tyrosine kinase 2, IRF
interferon-regulatory factor, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2
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Several DTX3L studies in solid cancer cell lines strongly
indicate that DTX3L might also act in a STAT1/IFNγ in-
dependent manner [547, 548]. The first studies performed
by Yan Q. et al. suggested that DTX3L is implicated in the
DNA damage response pathway via monoubiquitinylation
of histone H4K91 [547, 548]. Ectopically overexpressed
GFP-tagged DTX3L and ARTD9 were recruited to sites of
DNA damage in solid cancer cells [547, 548]. This activity
was dependent on ARTD1/PARP1-mediated (n)ADP-
ribosylation [548], see also next sections.
DTX3L together with ARTD9 protected solid can-
cer cells exposed to DNA-damaging agents and have
been therefore suggested to limit the efficacy of
chemotherapy-induced DNA damage responses [547,
548]. More importantly, a recent in vivo study per-
formed by Thang N.D. et al. provided first evidence
that DTX3L mediates invasion and metastasis in
melanoma through stimulation of the FAK/PI3K/
AKT signaling pathway [549]. Depletion of DTX3L
in murine and human melanoma cells resulted in
decreased activity of FAK/PI3K/AKT signaling and
reduced invasion and metastasis of murine and human
melanoma cells [549]. It is therefore important to investi-
gate whether DTX3L may cooperate with the PI3K/AKT/
mTORC1 or PI3K/AKT/NF-κB signaling pathways in
DLBCL.
Besides forming homodimers, DTX3L can also form het-
erodimers with DTX1 via their respective N- termini in a
manner that enhance the E3 ubiquitin ligase activity of
DTX3L [542]. DTX1 is thought to act as a signal repressor
or as a mediator of negative feedback for canonical
NOTCH1 signaling pathways [550]. On the other hand,
DTX1 can also positively regulate cell context-dependent
non-canonical NOTCH1/2 signaling pathways and
NOTCH1/2-independent signaling pathways in cancer
[551, 552]. DTX1 has been shown to enhance the aggres-
siveness and survival of cancer cells through the activation
of the RTK/PI3K/AKT and the MAPK/ERK mitotic path-
ways and induction of anti-apoptotic MCL1 [551]. DTX1
is frequently mutated in GCB- and ABC-DLBCL [21, 22].
A recent exome sequencing study found DTX1 mutated at
high frequency (9–12 %) in a DLBCL cohort derived from
Chinese patients [21]. The Non-silent (gain or loss of
function) mutations in DTX1 have been postulated to im-
pair its function as a negative regulator of Notch pathway
[21]. Functionally relevant gain-of-function mutations of
NOTCH1 and NOTCH2 were identified in up to 8 % of

































Fig. 7 Schematic comparison of the domain architecture of the DTX family. Domain architecture of the human Deltex-like E3 ubiquitin ligases
and DTX family members DTX1, DTX2A, DTX2B, DTX3, DTX3L and DTX4. The domain organization is based on analogous functional motifs in
murine DTX family members DTX1, DTX2, DTX2deltaE and DTX3 [589], human DTX1 [544, 646], and human DTX3L [542, 543]. DTX1, DTX2 and
DTX4 have well-conserved domains I, II and III. DTX1, DTX2A, DTX2B and DTX4 contain two conserved tandem WWE modules in their domain I
[646]. The N-terminal domains I of DTX1, DTX2A and DTX2B bind through their tandem WWE modules to the ankyrin repeat region of intracellular
NOTCH1 [646]. The WWE domain is named after three conserved residues (W-W-E)and is predicted to mediate specific protein-protein interactions
in ubiquitin- and ADP-ribose conjugation systems [555, 636, 637]. DTX3 lacks most of the site corresponding to the binding site for the ankyrin
repeats of human NOTCH1. Of interest, the WWE domain of DTX1 serves also as a bona fide poly-ADP-ribose binding module [555]. Domains II of
DTX1, DTX2A, DTX3 and DTX4 contain a proline-rich region (black boxes) that is not found in DTX3L. DTX2B is an alternatively spliced form of
DTX2A, DTX2B lack a proline-rich motif (PRM), the fourth of nine predicted DTX2 exons. The most conserved region of all human DTX family
members (DTX1, DTX2A, DTX2B, DTX3, DTX3L and DTX4) is their C-terminal part, domain III. The C-terminal domain III of DTX1, DTX2A, DTX2B
and DTX4 contain a classic RING finger E3 ubiquitin ligase domain (RING-H2 finger motif; red box); while domain III of DTX3 and DTX3L contain a
RING-C3HC4 finger motif found in many E3 ubiquitin ligases (indicated by an orange box). Human DTX3 has a short unique N-terminal domain
(yellow box), and DTX3L contains a longer unique N-terminal region (grey box). Abbreviations: RING really interesting new gene, DTX deltex, DTC
Deltex C-terminal domain
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DLBCL pathogenesis [16, 553, 554]. NOTCH2 mutations
mainly occur in ABC- and type-3-DLBCL-NOS [16]. HR-
subtype-DLBCL has been shown to overexpress NOTCH2
[116]. Future studies are required to investigate whether
DTX3L might also act independently of ARTD9 to-
gether with DTX1 in non-canonical NOTCH1/2-Del-
tex1-dependent PI3K/AKT signaling pathways in HR
subtype DLBCL. Of interest, the WWE domain of DTX1
(Fig. 7) serves also as a bona fide poly-ADP-ribose-binding
module [555] and might therefore be also involved in the
observed ARTD1 dependent recruitment of DTX3L to
sites of DNA damage in solid cancer cells.
Taken together, DTX3L might serve as a novel useful
prognostic biomarker for poor survival and as a rational
drug target for treatment of high-risk relapsed/refractory
HR- (and BCR-) subtypes of DLBCL-NOS.
ARTD8, a novel drug target in HR-, BCR- and MYC-driven
DLBCL subtypes?
We have recently shown that both DTX3L and ARTD9
can form nuclear complexes with the closely related
macrodomain-containing and enzymatically active ARTD8
[471]. Although no functional or clinical studies providing
evidence for a direct role of ARTD8 in DLBCL have yet
been published, we recently showed that ARTD8 is overex-
pressed in HR-subtype GCB-DLBCL and BCR-subtype
ABC-DLBCL cell lines [470]. We recently demonstrated
that ARTD8 mediates in cooperation with DTX3L and
ARTD9 survival and proliferation of high-risk metastatic
castration resistant prostate cancer (CRPC) cells [471]. Our
study also provided first evidence that the enzymatic activ-
ity of ARTD8 is required for survival of metastatic CRPC
cells [471]. These observations imply that ARDT8 might
also cooperate with DTX3L and ARTD9 in DLBCL.
Several recent studies by the Boothby lab demon-
strated that ARTD8 interacts with STAT6 and amplifies
STAT6-mediated gene expression pathways in B and T
cells [479, 480]. ARTD8 has been suggested to functions
as STAT6-specific coregulator of IL4-mediated gene ex-
pression and to enhance IL4-induced proliferation and
protection of B cells against apoptosis following irradi-
ation or growth factor withdrawal [479, 480, 556]. How-
ever, STAT6 may only play a significant role in a small
subset of DLBCL-NOS. For instance, STAT6 has been
suggested to be inactive in ABC-DLBCL cells due to the
overexpression of protein tyrosine phosphatase 1B (PTP1B)
in this subtype [557, 558]. Thus other DLBCL related
factors might be a target of ARTD8. Indeed, it has been
suggested that ARTD8 could influence c-MYC-induced B-
lymphoid oncogenesis by increasing the cellular metabolic
rates [474]. A recent study using an Eμ-c-Myc driven B-cell
lymphoma mice model, demonstrated that ARTD8 is over-
expressed in mouse B-cell lymphoma and can facilitate B-
lymphoid oncogenesis and alterations in developmental
progression driven by c-MYC [474]. Conversely, ARTD8-
deficient mice showed a reduced susceptibility to c-MYC-
induced B-cell lymphoma [474]. Interestingly, ARTD8 also
enhance the expression of MCL1 or PIM1, which are both
implicated in chemotherapy resistance in DLBCL [556].
A recent study showed that ARTD8 was overexpressed
in over 80 % of primary multiple myeloma (MM) sam-
ples tested in this study [559]. More importantly, this
study demonstrated that ARTD8 promotes c-Jun N-
terminal kinase (JNK)-2-dependent survival in MM in
vitro by binding and inhibiting the kinase activity of
JNK1 [559]. Depletion of ARTD8, or inhibition of the
catalytic activities of ARTD8 enhanced the sensitization
of MM cells to anti-myeloma agents [559]. Preclinical
studies in DLBCL and MM indicate that obatoclax/
bortezomib- or obatoclax/carfilzomib- as well as ricoli-
nostat/carfilzomib mediated lethality in DLBCL cells in
vitro and in vivo includes activation of the stress-related
JNK1 signaling pathway [371, 560–562]. It is therefore
important to test whether ARTD8 might also function
as a druggable oncogenic factor in relapsed or refractory
c-MYC-driven double-hit or triple-hit DLBCL, HR- and/
or BCR-subtype DLBCLs.
Are the proposed ARTD9-DTX3L-dependent pathways
involved in chemotherapy-resistance in DLBCL connected
to ARTD1?
Recent studies provided first evidence that ARTD9 and
DTX3L might act in a (poly or) mono-ADP-ribosylation-
dependent DNA damage response pathway and together
with ARTD1 enhance tumor cell survival [547, 548]. As
already mentioned above, both DTX3L and ARTD9 were
recruited to sites of DNA damage in solid cancer cells
[547, 548]. Moreover, both ARTD9-related macrodomain-
containing ARTD family members and ARTD7 and
ARTD8 were also localized to sites of DNA damage in a
(poly-)ADP-ribosylation and macrodomain-dependent
manner [548, 563]. Both ARTD8 and ARTD9 have been
suggested to act as novel modulators of homologous
recombination (HR) required for mitigating replication
stress and promoting and genomic stability [548, 563],
albeit their exact functions in this process remain to be
defined [548, 563]. These studies indicate that combined
inhibition of the enzymatic activities of ARTD1 and
ARTD8 inhibitors might potentiate genotoxic chemother-
apy by blocking HR-DNA repair and rendering solid
cancer cells hypersensitive to DNA damage. We have
recently demonstrated that DTX3L forms complexes
with ARTD8 and ARTD9 independent of mono-ADP-
ribosylation, where as ARTD9 interacts with ARTD8
and other ARTD family members, such as ARTD1 in a
(mono-)ADP-ribosylation dependent manner [471].
Thus ARTD1 might indeed function together with
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DTX3L and macro-domain-containing macroARTD7-
9 in chemotherapy resistance in solid cancer.
However, it remains to be further investigated
whether this proposed ARTD1 connected macro-
ARTD(7–9)-DTX3L pathways and mechanisms do also
exists in DNA-DSB repair proficient DLBCL, or may be
restricted to DNA-DSB repair deficient solid cancer
types and certain DNA-DSB repair deficient B and T
lymphoid tumor types. Indeed, a recent study provided
preliminary evidence that the ARTD1/2 inhibitor ola-
parib selectively targets ATM mutant (DNA-DSB repair
deficient) but not wild-type (DNA-DSB repair profi-
cient) B-lymphoid cells, including proliferating primary
CLL cells in vitro and in vivo [489]. Moreover, one has
to be also very cautious because several recent studies
provided preliminary evidence that ARTD1 might not
act as an oncogenic factor but rather as a tumor sup-
pressor in DNA DSB repair proficient DLBCL and other
B-cell lymphoma [23, 564, 565]. For instance, a recent
study demonstrated that endogenously overexpressed
BCL2 localizes in the nucleus in B-lymphoid tumors
and suppresses ARTD1 function and non-apoptotic
ARTD1 dependent necrotic cell death in ATM wild-
type DLBCL cells [564]. BCL2 directly interacts with
ARTD1 and blocks the enzymatic activity of ARDT1 in
CLL and DLBCL cells [564]. Remarkably, ABT-737 can
disrupt the BCL2-ARTD1 interaction and promotes
ARTD1 and poly-ADP-ribosylation dependent necrotic
cell death in primary ATM wild-type CLL cells [564].
Thus, ARTD1 might therefore act as a tumor suppres-
sor in absence of BCL2 in ATM wild-type DLBCL.
Along this line, ARTD1 activation has been recently
shown to be associated with NOTCH1 ligand-mediated
apoptosis in B-cell acute lymphoblastic leukemia (B-
ALL) where NOTCH1 activation leads to growth arrest
and cell death [566]. The NOTCH1 target Hairy/Enhan-
cer of Split1 (HES1) interacts with ARTD1, activates the
enzymatic activity of ARTD1, which then in turn results
in ARTD1 overactivation, NAD depletion and necrotic
cell death [566]. Another cautionary study provided pre-
liminary evidence that ARTD1 acts as a transcriptional
co-repressor of the BCL6 gene in DLBCL [565]. ARTD1
binds to the enhancer/promoter region of the BCL6
gene and inhibits the transcriptional activation of BCL6
in a poly-ADP-ribosylation-dependent manner [565]. In
line with these observations, it has been recently shown
that a subset of primary DLBCL samples presents loss-
of-function mutations in ARDT1 and/or lower expres-
sion levels of ARDT1 [23]. Targeting and inactivation of
ARTRD1 by some DLBCL tumors has been suggested
to represent a survival adaptation strategy to high de-
grees of genomic instability in B-cell lymphoma [23].
These observations strongly indicate that the proposed
cancer promoting ARTD1-DTX3L/ARTD9 connection
might only exist in solid cancers and support the idea
that ARTD1 acts as an ARTD9 and DTX3L independ-
ent tumor suppressor in DLBCL. Interestingly, it has
been recently shown that macrodomain-containing
macroH2A1.1 can inhibit the enzymatic activity of
ARTD1 [567, 568]. Thus one cannot exclude the
possibility that the macrodomain-containing ARTD9,
ARTD8 or ARTD7 may indeed functionally interact
with ARTD1 in DLBCL and even block the enzymatic
and potential tumor suppressor activity of ARTD1
through their macrodomains.
Several preclinical and clinical trial phase I/II studies,
which include B-cell lymphoma patients, are currently
ongoing to test the efficacy of ARTD/PARP inhibitors
as therapeutic agents 7 (NCT00810966, NCT01326702,
NCT00740805) [488, 569, 570] (Additional file 1: Table
S9). Thus the ongoing preclinical and clinical trial
phase I/II studies and future phase II studies investigat-
ing the role of ARDT1/2 specific inhibitors in ARTD9
or BCL2-positive and -negative DLBCL-NOS subtypes
will certainly clarify whether the proposed functional
crosstalk of ARTD1 and ARTD7-9 may also exist in
DLBCL.
Status quo of drugs targeting the STAT1, ARTD8, ARTD9
and DTX3L-mediated pathways
Although the combination of classical therapeutic drugs
with highly ARTD8 or DTX3L-specific inhibitors and
drugs specifically targeting STAT1 or the macrodomains
of ARTD9 might provide a novel therapeutic strategy to
increase the sensitivity of relapsed/refractory DLBCL tu-
mors towards classical therapy, the specificity and tox-
icity of novel agents selectively targeting STAT1, DTX3l,
ARTD9 or ARTD8 have to be carefully analyzed to avoid
toxic off target effects in the surrounding benign cells/
tissues and counter activity of drug-target related pro-
teins (i.e., antagonistic activities of ARTD or DTX family
members). Highly selective and potent inhibitors specif-
ically targeting STAT1, DTX3L or ARTD9, respectively
are not yet available.
Selective STAT1 inhibitors
Selective STAT1 inhibitors are not yet available due to
the observed STAT cross-binding specificity of SH2-
domain-based competitive small inhibitors of STAT1
and STAT3 [571]. STAT1/3 selective SH2-domain-based
competitive small inhibitors act through the prevention
of the recruitment of STAT1 or STAT3 to the receptor
complex and inhibition of their homo- (or hetero-)
dimerization, which is critical for nuclear transloca-
tion and DNA binding [572, 573]. Thus, the SH2-
domain-based competitive small inhibitors of STAT3
might therefore not only target the pSTAT3 positive
HR-subtype ABC-DLBCL but also pSTAT3 negative
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HR-subtype GCB-DLBCL. In addition, inhibition of JAK2
does not only block the activation of STAT3 but also the
activity of STAT1 in B-cell lymphoma [60]. Despite clear
anti-cancer efficacy in vitro and in vivo [574–577], SH2-
domain-based competitive small inhibitors of STAT3 have
not yet reached the clinic.
JAK1/JAK2 inhibitors, such as fedratinib (TG101348)
[60, 317], which strongly reduce the phosphorylation of
both STAT1 and STAT3 [60], have been shown to inhibit
ABC-DLBCL growth in vitro and in vivo [313, 316].
JAK1/JAK2 inhibitors, such as INCB039110 [318] or
ruxolitinib (INCB18424), are currently in clinical phase I
and II trials in B-cell lymphoma, including relapsed/refrac-
tory DLBCL (NCT01905813, NCT01431209), or have
been suggested for further clinical evaluation in DLBCL
(pacritinib, SB1518), including relapsed or refractory
DLBCL [109, 317, 318] (Additional file 1: Table S6).
Drugs targeting the activity of JAK1/2 mainly block
the phosphorylation of STAT1 on Y701 but do only
affect the phosphorylation of STAT1 on S727 to a minor
extend. Moreover, the activity of uSTAT1, an unpho-
sphorylated form of STAT1 also involved in oncogenesis
[578, 579], is not inhibited by JAK1/2 inhibitors. In
contrast, SH2-domain-based competitive small inhibi-
tors selectively targeting STAT1 will inhibit all iso-
forms and phosphorylated forms of STAT1.
However partial inhibition of STAT1 or selective
inhibition of STAT1:STAT3 signaling pathways could be
more beneficial than complete inhibition of STAT1. A
recent mice study provided evidence that complete
inhibition of STAT1 might affect B-lymphoid develop-
ment before differentiation to pre-B cells, and particu-
larly blocks the recovery phase from doxorubicin-
(chemotherapy) induced hematopoietic toxicity [580].
STAT1 is required for the efficient B lymphocyte re-
population in the recovery phase in mice and thus
particularly the B cell immune function might be dis-
turbed or delayed after hematopoietic reconstitution in a
situation of chemotherapy, combined with complete
STAT1 inhibition [580]. On the other hand it is not
yet clear whether all STAT1 isoforms (STAT1α and
STAT1β) or phosphorylated forms (uSTAT1, pSTAT1(Y701),
pSTAT1(S727) or pSTAT1(Y701/S727)) are involved in
these process. Thus, small molecule inhibitors that only
partially inhibit STAT1, such as of JAK1/JAK2 inhibitors,
or indirectly inhibit STAT1 by targeting a subset of
STAT1-dependent oncogenic signaling pathways, such as
small molecule inhibitors of ARTD9 and DTX3L, might
be the more suitable drugs for targeting the oncogenic
functions of STAT1 in DLBCL.
Remarkably, recent studies provided evidence that
pan-HDACi may not only inhibit the phosphorylation
of STAT3 (on Y705) but also the phosphorylation of
STAT1 (on Y701). For instance, HDAC4 positively
regulates STAT1 activation and mediates STAT1-dependent
platinum resistance in ovarian cancer [522]. HDAC4 dea-
cetylates STAT1, thereby enhancing phosphorylation and
nuclear translocation of STAT1 upon cisplatin-treatment
in platinum resistant ovarian cancer cells (exposure to
chemotherapy) [522]. Conversely silencing of HDAC4
increased acetyl-STAT1 levels and dephosphorylation of
STAT1, thereby prevented platinum induced STAT1
activation and restored cisplatin sensitivity [522].
Inhibitors targeting the macro-domains of ARTD8 and ARTD9
Since ARTD9 is an inactive enzyme ARTD inhibitors
targeting the enzymatic activity of ARTD family members
cannot be applied for blocking the function of ARTD9.
On the other hand the selective mono-ADP-ribose-spe-
cific ADP-ribose-binding activity of the macro-domains of
ARTD7, ARTD8 and ARTD9 [482] presents rational
drug targets for the selective inhibition of the onco-
genic functions of macro-domain-containing ARTDs.
A recent study provided first evidence that the ARTD
macrodomains have highly selective binding activities
[482], which makes them even more attractive as
druggable targets. The high-resolution crystal struc-
ture of the macro-domains of ARTD7 and 8 have
already been recently published [481, 482, 581] or de-
posited in the protein data bank PDBe, allowing now
the design of small molecule inhibitors selectively tar-








ARTD inhibitors selectively targeting the enzymatic
activities of ARTD8
Although developed as selective ARTD1/PARP1 inhib-
itors, family-wide chemical profiling and structural
analysis of ARTD/PARP inhibitors demonstrated that
many of the best-known inhibitor compounds, which
are widely used as so called ARTD1/2-specific research
tools as well as in experimental clinical studies, includ-
ing olaparib, veliparib (ABT-888) and rucaparib, lack
clear selectivity towards ARTD1 and ARTD2 and have
additional low promiscuous inhibitory activity across
the ARTD family, thus exhibiting polypharmacology
[582]. Moreover, recent studies found diverse ARTD-
independent mechanisms of action associated with
the ARTD1/2-specific clinically relevant inhibitors
such as rucaparib, veliparib, and olaparib [583–585].
They have both “beneficial” and detrimental off target
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effects: For instance rucaparib and to a lesser extend
veliparib inhibit PIM1/2 and CDK9 [584], which are
important kinases and signaling factors regulating cell
survival and can mediate chemotherapy resistance to
available agents, such as rapamycin or BCL2 inhibi-
tors [379, 586, 587]. In addition rucaparib has the
capacity to inhibit the phosphorylation of STAT3
most-likely through its inhibition of the STAT3 phos-
phorylating kinases DYRK1A and/or CDK1 [584].
Moreover, treatment of BRCA1-deficient cancer cells
with olaparib leads to the induction of an IFN-related
gene expression signature and activation of IFN-
dependent pro-apoptotic signaling pathways in solid
cancer cells [588].
Thus, the development of 4th and 5th generation of
ARTD inhibitors selectively targeting single ARTD
family members without having off target activity is of
extraordinary importance for the therapeutic use of
ARTD inhibitors. The high-resolution crystal structure
of the catalytic domains of ARTD7 and 8 have been re-
cently published [529, 582] or deposited in the protein
data bank PDBe, allowing now the design of small mol-
ecule inhibitors selectively targeting the enzymatic ac-
tivity of ARTD8: http://www.ebi.ac.uk/pdbe/entry/pdb/
4f1q, http://www.ebi.ac.uk/pdbe/entry/pdb/4f1l, http://
www.ebi.ac.uk/pdbe/entry/pdb/4py4. Indeed, using a
virtual screening approach, including structural model-
ing, a set of more than 16 small molecule inhibitors
has been recently discovered that bind to ARTD7,
ARTD8 and/or ARTD10 [529, 530]. The molecules
belonged to eight different structural classes, and two of
the molecules with good water solubility displayed a
promising selectivity for ARTD8 in the low micromolar
range [529].
Inhibitors targeting the DTX-like E3 ubiquitin ligase
activity of DTX3L
Drugs selectively inhibiting the E3 ubiquitin ligase activ-
ity of the Deltex family members are not yet available.
Unfortunately, there are no high-resolution crystal struc-
tures of the C-terminal catalytic RING E3 ligase domain
of DTX family members published so far. The only
reported high-resolution structure of the conserved C-
terminal region of DTX proteins is the so called Deltex
C-terminal (DTC) domain of human DTX3L [543].
DTC is of unknown function but has been suggested
to be involved in the catalytic process or required for
the substrate specificity of DTX family members [542,
543, 589]. The design of small molecule inhibitors
selectively targeting the E3 ubiquitin ligase of DTX3L
remains therefore dependent on the published RING
E3 structures of other E3 ligases. RING E3 ligases do
not possess intrinsic catalytic activity and act by simul-
taneously binding to the charged E2, ubiquitin and the
protein substrate [279, 590]. Thus the most advanced
ligase-based drug discovery strategy to date for targeting
RING E3 ligases has been the development of allosteric
antagonists or protein-protein inhibitors of E3-substrate
binding, that is considered more difficult to target than a
catalytic site [279, 590]. In contrast to the ARTD inhibi-
tors, the selectivity might not be a crucial prerequisite for
drugs blocking DTX3 functions.
Non-selective drugs simultaneously targeting DTX3
and DTX1 might be even more efficient and beneficial
for DLBCL patients since DTX1 may also have onco-
genic functions in DLBCL and forms distinct hetero-
dimers with DTX3L.
Multi-targeted mechanism-based combinatorial
experimental therapies for relapsed/refractory DLBCLs
Since most patients with relapsed/refractory DLBCL
show activation of multiple pathways including activa-
tion of feedback signaling pathways that can circumvent
the drug target, most targeted therapies may not
succeed as molecularly targeted single-agent mono-
therapy. Given the genetic diversity of relapsed/
refractory DLBCL subtypes, and given that cells in
different functional or anatomical compartments will
have differing phenotypes, overcoming drug resistance
to conventional and novel experimental immuno-
chemotherapeutic regimens is highly reliant on multi-
targeted mechanism-based subtype- and signature-specific
combinatorial therapies concomitantly targeting multiple
signaling pathways to restore apoptotic pathways in tumor
cells and to inhibit pro-survival signaling from the stroma
environment. Next-generation of multi-targeted combina-
torial experimental therapies composed of new targets and
conventional (immuno-)chemotherapeutic regimens may
thus provide more immediate hope for relapsed/refractory
patients who have failed current (immuno-)chemothera-
peutic regimens. Ideally, one hopes to exploit synthetic
lethality with multi-targeted mechanism-based combinator-
ial therapies that target the oncogenic rewiring of malignant
cells [591, 592]. For instance, there is strong evidence for
an oncogenic cooperation of the c-MYC and BCL2
signaling pathways in c-MYC-driven c-MYC/BCL2-double
hit DLBCL subtypes in vivo [107, 366, 375, 377]. In mouse
models, inhibiting BCL2 using ABT-199 prolongs the
survival of mice with c-MYC-driven c-MYC/BCL2-double
hit DLBCL tumors [375, 377]. In addition, several recent
genetic and pharmacological studies in vitro and/or in vivo
provided evidence for a functional cooperation between
EZH2, BCL2 and BCL6 [77, 79], c-MYC and the PI3K/
AKT/mTORC1 pathway [324, 593, 594], between NF-
κB, STAT3, PI3K and c-MYC [233, 594, 595] as well as
between non-canonical NF-κB signaling and BCL6 [27].
A scheme of mechanism-based combinatorial experi-
mental regimens aimed at disrupting known oncogenic
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cooperation pathways in GCB-DLBCL and ABC-DLBCL
are presented in Figs. 8 and 9.
Various mechanism-based experimental drug combina-
tions are currently investigated in preclinical models and are
already demonstrating promising activities in vitro and in
vivo. For instance, combination studies in vitro suggest that
the biological crosstalks between the c-MYC, PI3K/AKT/
mTORC1, STAT3, IRF4 and/or BCR/NF-κB-dependent
signaling pathways represent promising targets in a subset of
ABC-DLBCL that may be exploited for a combination
therapy of relapsed/refractory DLBCL together with cyto-
toxic (immuno-)chemotherapeutic agents, that are currently
used to treat ABC-DLBCL [313, 595, 596]. Preclinical studies
demonstrated that co-administration of the BCR inhibitor
ibrutinib with the proteasome inhibitor bortezomib synergis-
tically increased mitochondrial injury and apoptosis in highly
bortezomib-resistant GCB and ABC-DLBCL in vitro [561].
Another recent preclinical study showed that the combin-
ation of ibrutinib and lenalidomide is synthetic lethal in
blocking IRF4 expression, increasing IFNβ production, and
killing ABC-DLBCL cells in vitro and in vivo [90]. Preclinical
studies have also documented synergistic interactions be-
tween pan-HDACi (i.e., vorinostat, SNDX-275, or SBHA)
and the novel proteasome inhibitor carfilzomib (CFZ) in
GCB- and ABC-DLBCL cells sensitive or resistant to borte-
zomib [560]. A recent preclinical study showed that com-
binatorial multilevel inhibition of PI3K/AKT/mTORC1 and
CDK1 cell-cycle pathways is very effective in inhibiting
DLBCL proliferation and overcoming drug resistance and
has been suggested as an effective strategy in treating drug
resistant DLBCLs with overactive AKT and CDK1 [338].
Moreover, a large matrix-based high-throughput screening
platform for the rapid and systematic identification of syner-
gistic, additive, and antagonistic drug combinations has been
recently established for DLBCL [233]. This matrix-based
strategy was used to screen ABC-DLBCL cell lines for sensi-
tivity to the BCR inhibitor ibrutinib in combination with
nearly 500 established or investigational anti-cancer com-
pounds [233]. This study identified a wide range of com-
pounds, including inhibitors of the PI3K/AKT/mTORC1
signaling pathway (i.e., idelalisib, everolimus, BKM-120),
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Fig. 8 Mechanism-based combinatorial experimental regimens aimed at disrupting known oncogenic cooperation pathways in GCB-DLBCLs. Targets
for rational mechanism-based combinatorial experimental regimens are shown for GCB-DLBCL (a and b). The black thick lines connecting the different
drug targets pathways depict established biological interactions and/or dependencies. The single drugs listed in (a) have either proven clinical activity
in patients with DLBCL or are currently in clinical trials for patients with B-cell lymphoma, including DLBCL. Pathways in GCB-DLBCL targeted by rational
drug combinations using drugs tested as single agent in preclinical studies or clinical trials are shown in (b). Silvestrol inhibits RNA helicase and
translation initiationfactor eIF4A thereby blocking translation (i.e., of oncogenic factors) [647]. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine
(DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting in the re-expression of tumor-suppressor genes [419, 420]. Adapted
from REF: [601, 602]. Information for this figure was gleaned from the following references: [2, 3, 13, 15–17, 20, 29, 31, 66, 75–84, 87, 93, 107, 123, 148,
233, 255, 257, 324, 325, 352, 354–356, 360–367, 374, 375, 377, 380–382, 384–386, 388, 393, 407, 415–417, 594, 595, 601, 602, 612, 648–650]. See also
additional tables 2 and 5–9. Abbreviations: Gα13 (GNA13) heterotrimeric G protein alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1,
PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma
protein 6, EZH2 enhancer of zeste homologue 2, PD-1 programmed cell death, PD-L1 programmed cell death ligand, TGFβR transforming growth factor
beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases, BCL6i inhibitors of BCL6, AZA azacytidine, DAC decitabin
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pathway inhibitors that cooperate with ibrutinib to kill ABC-
DLBCL cell lines [233]. In addition, using a similar high-
throughput screening platform, a more recent report
demonstrated that ibrutinib strongly synergized with BET in-
hibitors CPI203 and JQ1 in killing ABC-DLBCL cells in vitro
and in a xenograft mouse model in vivo [239]. Moreover, an-
other in vitro screen using a panel of different drugs and
DLBCL cell lines showed synergistic or additive effects of the
BET inhibitor OTX015 when combined with several anti-
lymphoma agents [407]. In line with previous studies, the
combination of OTX015 and ibrutinib was strongly synergis-
tic in ABC-DLBCL cells [407]. Besides ibrutinib, OTX015
acted also synergistically when combined with clinically
achievable doses of other anti-lymphoma drugs such as ri-
tuximab, lenalidomide, the PI3Kδ inhibitor idelalisib, the
mTORC1 inhibitor everolimus, the demethylating agent dec-
itabine and the HDACi vorinostat [407]. The strongest syn-
ergism was obtained with the mTORC1 inhibitor everolimus
[407]. The combination OTX015/rituximab appeared more
active in ABC-DLBCL cell lines [407], which was explained
by the common targeting of the IL10 and STAT3 pathway by
both OTX015 and rituximab [165, 407]. A detailed list of pre-
clinical multi-targeted combinatorial experimental treatments
for DLBCL-NOS is shown in Additional file 1: Table S10.
Another elegant and efficient way to further circum-
vent chemotherapy resistance might be the application
of rationally designed highly selective dual inhibitors
simultaneously blocking two or more molecular targets
in DLBCL. The combination of highly selective dual in-
hibitors may strongly increase the number of concomi-
tantly targeted signaling pathways without leading to
severe side effects. As already mentioned before, the dual
mTORC1/2 catalytic inhibitor AZD2014 acts highly syn-
ergistically in combination with the BTK inhibitor ibruti-
nib and causes apoptosis both in vitro and in vivo and
resulted in tumor regression in an ABC-type DLBCL
xenograft model [232]. A recent high-throughput screen-
ing study performed by Griner M. et al. confirmed these
results demonstrating that the combination of NVP-
BEZ235 and the BTK inhibitor ibrutinib is highly synergis-
tic in killing ABC-subtype DLBCL cell lines in vitro [233].
NVP-BEZ235 is an ATP-competitive dual panPI3K/
mTORC1/2 with retained activity against cells harboring
PI3K-activating mutations [597–599]. Moreover, Rahmani
and colleagues, recently demonstrated that NVP-BEZ235 in
combination with the HDACi panobinostat markedly poten-
tiates HDAC inhibitor activity in DLBCL cells, including in
poor-prognosis ABC- and double-hit subtype in vitro and
induced tumor regressions in DLBCL xenograft models
[597]. When combined, BEZ235 and panobinostat appeared
well tolerated by mice in in vivo studies [597]. A list of dual
inhibitors currently evaluated in preclinical and/or clinical
studies in DLBCL is shown in Additional file 1: Table S11.
Remarkably, several recent clinical studies of multi-
targeted combinatorial experimental therapies composed
of new targets and conventional (immuno-)chemother-
apeutic regimens showed already promising effects
and at least in part, could confirm the preclinical ob-
servations. For instance, novel agents such as lenali-
domide in combination with rituximab were very
effective in relapsed/refractory DLBCL, showing ORR
of up to 70 % and CR of up to 60 % [289, 429]
(See figure on previous page.)
Fig. 9 Mechanism-based combinatorial experimental regimens aimed at disrupting known oncogenic cooperation pathways in ABC-DLBCLs.
Targets for rational mechanism-based combinatorial experimental regimens are shown for ABC-DLBCL (a and b). The black thick lines connecting
the different drug targets pathways depict established biological interactions and/or dependencies. The single drugs listed in (a) have either
proven clinical activity in patients with DLBCL or are currently in clinical trials for patients with B-cell lymphoma, including DLBCL. Pathways in
ABC-DLBCL targeted by rational drug combinations using drugs tested as single agent in preclinical studies or clinical trials are shown in (b).
Bortezomib and carfilzomib inhibit the 26S proteasome complex thereby blocking the degradation of negative regulators of cell cycle progression
as well as of NF-κB inhibitory protein IκBα. Lenalidomide is an immunomodulatory agent directly binding to the E3 ubiquitin ligase substrate
receptor CRBN and promoting the recruitment of its common substrates to the E3 ubiquitin ligase complex, thus leading to substrate ubiquitinylation
and degradation [284] and subsequent repression of IRF4, a hallmark of ABC-DLBCL cells, thereby inhibiting the BCR-mediated canonical NF-κB-
dependent pro-survival signaling pathways [90, 91]. Silvestrol inhibits RNA helicase and translation initiationfactor eIF4A thereby blocking translation
(i.e., of oncogenic factors) [647]. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine (DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1
and DMNT3) resulting in the re-expression of tumor-suppressor genes [419, 420]. Mechanism-based drug combinations targeting the biological
interaction between MYC and BCL2 as well as MYC and the PI3K/AKT/mTORC1 pathway are aimed for both GCB- and ABC-DLBCL. Adapted from REF:
[590, 591]. Information for this figure was gleaned from the following references: [2, 3, 13, 16–18, 20, 29, 31, 54, 57, 60, 65, 66, 75–81, 87, 90, 91, 93,
96–100, 103, 104, 107, 123, 133, 148, 171, 232, 233, 242, 247–250, 255, 257, 266, 270, 271, 285, 286, 289, 296, 297, 307–311, 313–317, 319, 323, 324, 326,
327, 360–365, 367, 374, 375, 377, 380–382, 384–386, 388, 393, 394, 398–402, 407, 415–417, 601, 602, 612, 620, 648–652]. See also Additional file 1: Table
S2 and S5–S9. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine kinase, CD40L CD40 ligand, JAK Janus kinase, CRBN cereblon, IRF4
interferon-regulatory factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1, BCL10 B cell lymphoma protein 10,
TLR Toll-like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein kinase
Cβ, IKK inhibitor kappa B (IκB) kinase, NF-κB nuclear factor-kappa B, NIK NF-κB inducing kinase, STAT signal transducer and activator of transcription, PI3K
phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL2 B-cell lymphoma protein 2, BCL6 B-cell
lymphoma protein 6, TGFβR transforming growth factor beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases, BCL6i inhibitors of
BCL6, PD-1 programmed cell death, PD-L1 programmed cell death ligand, AZA azacytidine, DAC decitabine
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whereas combinations with other novel agents such
as mTORC inhibitors were less effective [328]. Clinical
trials with ibrutinib combinations are still ongoing. More-
over, combinations of R-CHOP with lenalidomide or epra-
tuzumab in experimental clinical studies showed
promising effects in first-line treatment of DLBCL [296,
297, 600]. A detailed list of ongoing experimental clinical
multi-targeted studies combining novel experimental
agents with or without conventional (immuno-)chemo-
therapy in newly diagnosed or relapsed/refractory DLBCL
is shown in Additional file 1: Tables S12-14.
Mechanism based multi-targeted combinatorial therapies
combining multiple novel agents with rituximab and/or
conventional chemotherapy might represent much more
effective treatment regimens with less toxicity for individu-
alized molecular precision therapy in relapsed/refractory
DLBCL. These novel multi-targeted drug combinations
may be eventually already incorporated as part of a person-
alized first-line precision therapy, where the impact on
preventing relapse will hopefully lead to a significantly im-
proved overall survival for patients with aggressive subtypes
of DLBCL. However it is important to note that one has to
be cautious regarding the side effects of multi-targeted
mechanism-based combinatorial therapies. As more tar-
geted agents are developed, the timing of administration
with other agents and dose of each single drug in clinical
trials will become increasingly important to define
mechanism-based synergistic combinations associated with
minimal toxicities rather than simply adding new precision
medicines to existing chemotherapeutic regimens, thus en-
sure maximal efficacy while minimizing side effects.
Unexpected and/or synergistic toxicities can represent a
practical limitation to clinical development. Given the syn-
ergy between drugs such as ibrutinib or lenalidomide and
multiple agents uncovered thus far, it may eventually be
possible to combine in a personalized manner conven-
tional immuno-chemotherapeutic regimes with three,
four or more novel single-agent drugs simultaneously
inhibiting the most important oncogenic signaling path-
ways to overcome the aggressive nature of HR-and
BCR-subtype ABC-DLBCL or other subtypes of re-
lapsed/refractory DLBCLs and thereby ensure maximal
efficacy while minimizing side effects. Thus, subtype
and subset-specific personalized multi-targeted combi-
nations of novel highly selective therapeutic drugs (i.e.,
BCL2-, BCL6-, NF-κB- or STAT3-specific small mol-
ecule inhibitors) together with or without ADC and/or
standard (immuno-)chemotherapy (i.e., R-CHOP or
DA-EPOCH-R) might provide a novel therapeutic strategy
to increase the sensitivity of relapsed/refractory DLBCLs
towards conventional immuno-chemotherapeutic regi-
mens and thus pave the way to develop novel personalized
therapeutic strategies for patients suffering from highly
aggressive relapsed/refractory DLBCLs.
Concluding remarks
Although the clinical outcome in DLBCL has tremendously
improved over the last decades and will likely improve
further with the introduction of novel specific anti-cancer
agents and therapeutic approaches, relapsed/refractory
DLBCL remains a major cause of morbidity and mortality.
Unfortunately, the ongoing efforts exploring novel
conditioning regimens and maintenance approaches for
relapsed/refractory DLBCL will have limited impact for
most of the current patients with relapsed/refractory
DLBCL, because only a minority of patients proceed to
this second line treatment. On the other hand the im-
proved understanding of DLBCL subtypes and etiology
of relapsed/refractory DLBCL is leading to the identifica-
tion of targeted drugs that not only may allow for
subtype-specific and molecularly targeted combinational
therapy in the management of patients with relapsed/
refractory DLBCL who are not cured in the rituximab
era but also to development of very efficient personal-
ized first-line therapeutic regimens. Due to the extensive
intra-patient and intra-tumor genetic heterogeneity in
DLBCL and the efficiency of single-agent therapies it is
evident that rational personalized therapeutic regimens
using novel agents directed at distinct cellular pathways
and properly tested in well-designed (personalized) clinical
trials are needed for optimal therapy for relapsed or refrac-
tory DLBCL. Such rational personalized therapeutic regi-
mens will also require both, positive selection strategies to
identify patients most likely to respond to therapy as well
as a negative selection approach to determine which pa-
tients may be resistant to a given therapy [601, 602], thus,
taking the molecular subtypes and molecular signatures of
DLBCL into account. The most suitable strategy to achieve
this is to identify the patient specific mutational and gene
expression profiles either via a combinatorial analysis using
mass-spectrometry (protein expression analysis), next gen-
eration sequencing (RNA expression analysis) and candi-
date gene sequencing (mutation analysis) or alternatively,
using combinations of thoroughly validated clinical bio-
markers highly specific for each molecular subtype and
gene expression signature.
There is preliminary evidence that novel agents such as
lenalidomide or epratuzumab could be very effective in re-
lapsed/refractory DLBCL when used as novel agent in com-
bination with rituximab or R-CHOP. Conversely, many
other novel agents such as enzastaurin alisertib, or
everolimus were less effective when used as novel agent
in combinations with rituximab or R-CHOP. Thus, large
multicenter non-randomized and personalized long
term clinical phase III trials combining 2, 3 or more novel
agents with or without standard immunochemotherapy
(i.e., R-CHOP21 or DA-ECHOP-R) are required to inves-
tigate whether (personalized) multi-targeted combinations
of novel experimental agents together with rituximab or
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CHOP21 regimens have a superior efficacy when com-
pared with optimized R-CHOP21 or DA-ECHOP-R regi-
mens in relapsed/refractory DLBCL or as first line
treatments for newly diagnosed high-risk DLBCL.
A better understanding of the functions of novel po-
tential drug targets such as PLCγ2, PRPS2, NOTCH1/2,
STAT1, DTX3L, or ARTD9 and the generation of novel
highly selective small molecule inhibitors with negligible
off target activity are also required to give us the oppor-
tunity to develop novel personalized therapeutic strat-
egies targeting novel subtype-specific pathways, thereby
also minimizing toxicities by limiting exposure of pa-
tients to agents to which their disease would be unlikely
to respond. Moreover, acquired drug resistance is very
likely mediated by a finite set of pathways whose relative
contributions will vary in individual patients which
would allow genomic and proteomic analyses to be per-
formed on primary samples from patients with relapsed/
refractory DLBCL to determine which targets need to be
suppressed or activated to restore sensitivity to drugs
that were used successfully in a prior line of therapy, or
to optimize the efficiency of the available therapeutic
personalized regimens. In addition the interactions be-
tween relapsed/refractory DLBCL tumors and their
microenvironment are biologically and clinically crucial.
Thus, an understanding of how novel potential drug tar-
gets such as STAT1, ARTD9 and/or DTX3L may modu-
late the interaction between (relapsed or refractory)
DLBCL tumors and their microenvironment should also
provide new therapeutic options.
Together, multi-targeted combinatorial personalized
precision therapies composed of multiple novel agents
highly selectively targeting at distinct cellular pathways
and DLBCL subtypes (i.e., ABC, GCB) or subsets (i.e.,
BCR, OxPhos, MD or HR) combined with ADC or con-
ventional rituximab based chemotherapy will most likely
represent the future mainstay of treatment for patients
with newly diagnosed high-risk DLBCL or relapsed/
refractory DLBCL and thus may provide hope for re-
lapsed patients who have failed current chemotherapies
in the rituximab era.
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